NextPlat (NXPL) S-4 18 Jun 24 2024 Q1 Registration of securities issued in business combination transactions Financial data

Document And Entity Information

Document And Entity Information	3 Months Ended
	Mar. 31, 2024
Document Information [Line Items]
Entity Central Index Key	0001058307
Entity Registrant Name	NextPlat Corp
Amendment Flag	false
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Document Type	S-4
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	65-0783722
Entity Address, Address Line One	3250 Mary Street, Suite 410
Entity Address, City or Town	Coconut Grove
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33133
City Area Code	305
Local Phone Number	560-5355
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Current Assets
Cash	$ 23,526,000	$ 26,307,000		$ 18,891,000
Accounts receivable, net	12,928,000	8,923,000		384,000
Receivables - other, net	2,068,000	1,846,000		0
Inventory, net	5,610,000	5,135,000		1,287,000
Unbilled revenue	185,000	189,000		142,000
VAT receivable	357,000	342,000		433,000
Prepaid expenses	404,000	640,000		46,000
Notes receivable due from related party	260,000	256,000		0
Total Current Assets	45,338,000	43,638,000		21,183,000
Property and equipment, net	3,846,000	3,989,000		1,246,000
Goodwill	731,000	731,000		0	$ 0
Intangible assets, net	13,725,000	14,423,000		50,000
Operating right of use assets, net	1,303,000	1,566,000		855,000
Finance lease right-of-use assets, net	18,000	22,000		0
Deposits	39,000	39,000		0
Prepaid expenses, net of current portion	61,000	61,000		49,000
Total Other Assets	15,877,000	16,842,000		6,215,000
Total Assets	65,061,000	64,469,000		28,644,000
Current Liabilities
Accounts payable and accrued expenses	14,893,000	13,176,000		1,523,000
Contract liabilities	140,000	42,000		36,000
Notes payable	233,000	312,000		60,000
Due to related party	42,000	18,000		28,000
Operating lease liabilities	532,000	532,000		209,000
Current portion, Finance Lease Liability	20,000	18,000		0
Income taxes payable	90,000	139,000		94,000
Total Current Liabilities	15,950,000	14,237,000		2,062,000
Long Term Liabilities:
Long-term portion of notes payable	1,165,000	1,211,000		156,000
Long-term portion of lease liabilities, operating lease	853,000	929,000		650,000
Long-term portion of lease liabilities, finance lease	0	5,000		0
Total Liabilities	17,968,000	16,382,000		2,868,000
Commitments and Contingencies
Equity
Preferred stock ($0.0001 par value; 3,333,333 shares authorized)	0	0		0
Common stock ($0.0001 par value; 50,000,000 shares authorized, 18,724,596 and 18,724,596 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively)	2,000	2,000		1,000
Additional paid-in capital	67,717,000	67,170,000		56,963,000
Accumulated deficit	(36,406,000)	(34,925,000)		(31,147,000)
Accumulated other comprehensive loss	(90,000)	(63,000)		(41,000)
Equity attributable to NextPlat Corp stockholders	31,223,000	32,184,000		25,776,000
Equity attributable to non-controlling interests	15,870,000	15,903,000		0
Total Equity	47,093,000	48,087,000	$ 24,627,000	25,776,000	$ 17,531,000
Total Liabilities and Equity	$ 65,061,000	$ 64,469,000		$ 28,644,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	3,333,333	3,333,333	3,333,333
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	50,000,000	50,000,000	50,000,000
Common stock, shares issued (in shares)	18,724,596	18,724,596	14,402,025
Common stock, shares outstanding (in shares)	18,724,596	18,724,596	14,402,025

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Revenue	$ 17,493	$ 2,876	$ 37,756	$ 11,710
Cost of revenue	12,683	2,255	26,445	9,221
Gross profit	4,810	621	11,311	2,489
Operating expenses:
Selling, general and administrative	2,005	788	9,910	5,085
Salaries, wages and payroll taxes	2,624	588	6,643	2,565
Impairment loss	132	0	28	0
Professional fees	985	321	1,981	1,552
Depreciation and amortization	906	162	2,110	490
Total operating expenses	6,652	1,859	34,539	9,692
Loss before other (income) expense	(1,842)	(1,238)	(23,228)	(7,203)
Other (income) expense:
Interest expense	21	5	79	24
Interest earned	(215)	(10)	(620)	(21)
Other income	0	(50)	(317)	0
Foreign currency exchange rate variance	26	(28)	(107)	129
Total other income	(168)	(83)	(937)	132
Loss before income taxes and equity in net loss of affiliate	(1,674)	(1,155)	(22,291)	(7,335)
Income taxes	(27)	0	(28)	(87)
Loss before equity in net loss of affiliate	(1,701)	(1,155)	(22,319)	(7,422)
Equity in net loss of affiliate	0	(32)	(1,440)	(1,739)
Net loss	(1,701)	(1,187)	(12,407)	(9,161)
Net loss attributable to non-controlling interest	220	0	8,629	0
Net loss attributable to NextPlat Corp	(1,481)	(1,187)	(3,778)	(9,161)
Comprehensive income (loss):
Net loss	(1,701)	(1,187)	(12,407)	(9,161)
Foreign currency loss	(27)	(23)	(22)	(44)
Comprehensive loss	(1,728)	(1,210)	(12,429)	(9,205)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (1,481)	$ (1,187)	$ (3,778)	$ (9,161)
Basic weighted average common shares outstanding (in shares)	18,725	14,415	17,494	9,592
Weighted average loss per common share - basic and diluted (in dollars per share)	$ (0.08)	$ (0.08)	$ (0.22)	$ (0.96)
Product [Member]
Revenue	$ 14,120	$ 2,876	$ 32,389	$ 11,710
Cost of revenue	12,620	2,255	26,313	9,221
Service [Member]
Revenue	3,373	0	5,367	0
Cost of revenue	$ 63	$ 0	$ 132	$ 0

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Parent [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2021	7,053
Balance at Dec. 31, 2021	$ 1	$ 39,513	$ (21,986)	$ 3	$ 17,531	$ 0	$ 17,531
Stock-based compensation in connection with options granted	$ 0	822	0	0	822	0	822
Stock-based compensation in connection with restricted stock awards (in shares)	544
Stock-based compensation in connection with restricted stock awards	$ 0	2,151	0	0	2,151	0	2,151
Comprehensive loss	0	0	0	(44)	(44)	0	(44)
Net income (loss)	$ 0	0	(9,161)	0	(9,161)	0	(9,161)
Balance (in shares) at Dec. 31, 2022	14,402
Balance at Dec. 31, 2022	$ 1	56,963	(31,147)	(41)	25,776	0	25,776
Stock-based compensation in connection with restricted stock awards (in shares)	39
Stock-based compensation in connection with restricted stock awards	$ 0	61	0	0	61	0	61
Comprehensive loss	0	0	0	(23)	(23)	0	(23)
Net income (loss)	$ 0	0	(1,187)	0	(1,187)	0	(1,187)
Balance (in shares) at Mar. 31, 2023	14,441
Balance at Mar. 31, 2023	$ 1	57,024	(32,334)	(64)	24,627	0	24,627
Balance (in shares) at Dec. 31, 2022	14,402
Balance at Dec. 31, 2022	$ 1	56,963	(31,147)	(41)	25,776	0	25,776
Stock-based compensation in connection with options granted	$ 0	1,524	0	0	1,524		2,576
Stock-based compensation in connection with restricted stock awards (in shares)	789
Stock-based compensation in connection with restricted stock awards	$ 0	2,468	0	0	2,468	300	2,768
Comprehensive loss	0	0	0	(22)	(22)	0	(22)
Net income (loss)	$ 0	0	(3,778)	0	(3,778)	(8,629)	(12,407)
Balance (in shares) at Dec. 31, 2023	18,725
Balance at Dec. 31, 2023	$ 2	67,170	(34,925)	(63)	32,184	15,903	48,087
Stock-based compensation in connection with options granted	$ 0	160	0	0	160	0	160
Stock-based compensation in connection with restricted stock awards (in shares)	0
Stock-based compensation in connection with restricted stock awards	$ 0	387	0	0	387	65	452
Capital contribution of non-controlling interests	0	0	0	0	0	122	122
Comprehensive loss	0	0	0	(27)	(27)	0	(27)
Net income (loss)	$ 0	0	(1,481)	0	(1,481)	(220)	(1,701)
Balance (in shares) at Mar. 31, 2024	18,725
Balance at Mar. 31, 2024	$ 2	$ 67,717	$ (36,406)	$ (90)	$ 31,223	$ 15,870	$ 47,093

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,701,000)	$ (1,187,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	203,000	155,000
Change in provision for doubtful accounts	2,000	0
Amortization of intangible assets	698,000	6,000
Amortization of right-of-use assets - operating leases	129,000	49,000
Amortization of right-of-use assets - finance leases	5,000	0
Equity in net loss of affiliate	0	32,000
Stock-based compensation	612,000	243,000
Impairment loss	132,000	0
Gain on sale or disposal of property and equipment	(1,000)	0
Accounts receivable	(4,230,000)	(572,000)
Inventory	(475,000)	(877,000)
Unbilled revenue	4,000	142,000
Prepaid expense	236,000	(32,000)
Notes receivable	(4,000)	0
VAT receivable	(15,000)	(76,000)
Accounts payable and accrued expenses	1,745,000	94,000
Operating lease liabilities	(74,000)	(43,000)
Income taxes payable	(49,000)	2,000
Contract liabilities	98,000	(3,000)
Net cash used in operating activities	(2,685,000)	(2,067,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(64,000)	(69,000)
Proceeds from sale or disposal of property and equipment	1,000	0
Net cash used in investing activities	(63,000)	(69,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments of note payable, related party, net	23,000	(2,000)
Capital contribution	122,000	0
Payments on finance lease liabilities	(5,000)	0
Repayments of notes payable	(141,000)	(11,000)
Net cash used in financing activities	(1,000)	(13,000)
Effect of exchange rate on cash	(32,000)	(23,000)
Net decrease in cash	(2,781,000)	(2,172,000)
Cash beginning of period	26,307,000	18,891,000
Cash end of period	23,526,000	16,719,000
SUPPLEMENTAL CASH FLOW INFORMATION
Interest	170,000	4,000
Income tax	$ 74,000	$ 0

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current Assets
Cash	$ 26,307,000	$ 18,891,000
Accounts receivable, net	8,923,000	384,000
Receivables - other, net	1,846,000	0
Inventory, net	5,135,000	1,287,000
Unbilled revenue	189,000	142,000
VAT receivable	342,000	433,000
Prepaid expenses	640,000	46,000
Notes receivable due from related party	256,000	0
Total Current Assets	43,638,000	21,183,000
Property and equipment, net	3,989,000	1,246,000
Goodwill	731,000	0
Intangible assets, net	14,423,000	50,000
Operating right of use assets, net	1,566,000	855,000
Finance lease right-of-use assets, net	22,000	0
Equity method investment	0	5,261,000
Deposits	39,000	0
Prepaid expenses, net of current portion	61,000	49,000
Total Other Assets	16,842,000	6,215,000
Total Assets	64,469,000	28,644,000
Current Liabilities
Accounts payable and accrued expenses	13,176,000	1,523,000
Contract liabilities	42,000	36,000
Notes payable	312,000	60,000
Due to related party	18,000	28,000
Operating lease liabilities	532,000	209,000
Current portion, Finance Lease Liability	18,000	0
Income taxes payable	139,000	94,000
Liabilities from discontinued operations	0	112,000
Total Current Liabilities	14,237,000	2,062,000
Long Term Liabilities:
Long-term portion of notes payable	1,211,000	156,000
Long-term portion of lease liabilities, operating lease	929,000	650,000
Long-term portion of lease liabilities, finance lease	5,000	0
Total Liabilities	16,382,000	2,868,000
Commitments and Contingencies
Equity
Preferred stock ($0.0001 par value; 3,333,333 shares authorized)	0	0
Common stock ($0.0001 par value; 50,000,000 shares authorized, 18,724,596 and 18,724,596 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively)	2,000	1,000
Additional paid-in capital	67,170,000	56,963,000
Accumulated deficit	(34,925,000)	(31,147,000)
Accumulated other comprehensive loss	(63,000)	(41,000)
Equity attributable to NextPlat Corp stockholders	32,184,000	25,776,000
Equity attributable to non-controlling interests	15,903,000	0
Total Equity	48,087,000	25,776,000
Total Liabilities and Equity	$ 64,469,000	$ 28,644,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	3,333,333	3,333,333	3,333,333
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	50,000,000	50,000,000	50,000,000
Common stock, shares issued (in shares)	18,724,596	18,724,596	14,402,025
Common stock, shares outstanding (in shares)	18,724,596	18,724,596	14,402,025

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Revenue	$ 17,493	$ 2,876	$ 37,756	$ 11,710
Cost of revenue	12,683	2,255	26,445	9,221
Gross profit	4,810	621	11,311	2,489
Operating expenses:
Selling, general and administrative	2,005	788	9,910	5,085
Salaries, wages and payroll taxes	2,624	588	6,643	2,565
Goodwill impairment			13,895	0
Professional fees	985	321	1,981	1,552
Depreciation and amortization	906	162	2,110	490
Total operating expenses	6,652	1,859	34,539	9,692
Loss before other (income) expense	(1,842)	(1,238)	(23,228)	(7,203)
Other (income) expense:
Interest expense	21	5	79	24
Interest earned	(215)	(10)	(620)	(21)
Impairment loss	132	0	28	0
Other income	0	(50)	(317)	0
Foreign currency exchange rate variance	26	(28)	(107)	129
Total other income	(168)	(83)	(937)	132
Loss before income taxes and equity in net loss of affiliate	(1,674)	(1,155)	(22,291)	(7,335)
Income taxes	(27)	0	(28)	(87)
Loss before equity in net loss of affiliate	(1,701)	(1,155)	(22,319)	(7,422)
Gain on remeasurement of fair value of equity interest in affiliate prior to acquisition			11,352	0
Equity in net loss of affiliate	0	(32)	(1,440)	(1,739)
Net loss	(1,701)	(1,187)	(12,407)	(9,161)
Net loss attributable to non-controlling interest	220	0	8,629	0
Net loss attributable to NextPlat Corp	(1,481)	(1,187)	(3,778)	(9,161)
Comprehensive income (loss):
Net loss	(1,701)	(1,187)	(12,407)	(9,161)
Foreign currency loss	(27)	(23)	(22)	(44)
Comprehensive loss	(1,728)	(1,210)	(12,429)	(9,205)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (1,481)	$ (1,187)	$ (3,778)	$ (9,161)
Basic weighted average common shares outstanding (in shares)	18,725	14,415	17,494	9,592
Weighted number of common shares outstanding – diluted (in shares)	18,725	14,415	17,494	9,592
Weighted average loss per common share - basic and diluted (in dollars per share)	$ (0.08)	$ (0.08)	$ (0.22)	$ (0.96)
Diluted weighted average earnings (loss) per common share (in dollars per share)			$ (0.22)	$ (0.96)
Product [Member]
Revenue	$ 14,120	$ 2,876	$ 32,389	$ 11,710
Cost of revenue	12,620	2,255	26,313	9,221
Service [Member]
Revenue	3,373	0	5,367	0
Cost of revenue	$ 63	$ 0	$ 132	$ 0

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) shares in Thousands, $ in Thousands	January 2022 Private Placement [Member] Common Stock [Member]	January 2022 Private Placement [Member] Additional Paid-in Capital [Member]	January 2022 Private Placement [Member] Retained Earnings [Member]	January 2022 Private Placement [Member] AOCI Attributable to Parent [Member]	January 2022 Private Placement [Member] Parent [Member]	January 2022 Private Placement [Member] Noncontrolling Interest [Member]	January 2022 Private Placement [Member]	December 2022 Private Placement [Member] Common Stock [Member]	December 2022 Private Placement [Member] Additional Paid-in Capital [Member]	December 2022 Private Placement [Member] Retained Earnings [Member]	December 2022 Private Placement [Member] AOCI Attributable to Parent [Member]	December 2022 Private Placement [Member] Parent [Member]	December 2022 Private Placement [Member] Noncontrolling Interest [Member]	December 2022 Private Placement [Member]	April 2023 Private Placement [Member] Common Stock [Member]	April 2023 Private Placement [Member] Additional Paid-in Capital [Member]	April 2023 Private Placement [Member] Retained Earnings [Member]	April 2023 Private Placement [Member] AOCI Attributable to Parent [Member]	April 2023 Private Placement [Member] Parent [Member]	April 2023 Private Placement [Member] Noncontrolling Interest [Member]	April 2023 Private Placement [Member]	Stock Based Compensation Warrants [Member] Common Stock [Member]	Stock Based Compensation Warrants [Member] Additional Paid-in Capital [Member]	Stock Based Compensation Warrants [Member] Retained Earnings [Member]	Stock Based Compensation Warrants [Member] AOCI Attributable to Parent [Member]	Stock Based Compensation Warrants [Member] Parent [Member]	Stock Based Compensation Warrants [Member] Noncontrolling Interest [Member]	Stock Based Compensation Warrants [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Parent [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2021																													7,053
Balance at Dec. 31, 2021																													$ 1	$ 39,513	$ (21,986)	$ 3	$ 17,531	$ 0	$ 17,531
Issuance of common stock related offering (in shares)	2,230							4,575
Stock issued, value	$ 0	$ 7,005	$ 0	$ 0	$ 7,005	$ 0	$ 7,005	$ 0	$ 7,472	$ 0	$ 0	$ 7,472	$ 0	$ 7,472
Stock-based compensation in connection with restricted stock awards (in shares)																													544
Stock-based compensation in connection with restricted stock awards																													$ 0	2,151	0	0	2,151	0	2,151
Stock-based compensation in connection with options granted																													0	822	0	0	822	0	822
Comprehensive loss																													0	0	0	(44)	(44)	0	(44)
Net income (loss)																													0	0	(9,161)	0	(9,161)	0	(9,161)
Stock-based compensation																													$ 0	822	0	0	822	0	822
Balance (in shares) at Dec. 31, 2022																													14,402
Balance at Dec. 31, 2022																													$ 1	56,963	(31,147)	(41)	25,776	0	25,776
Stock-based compensation in connection with restricted stock awards (in shares)																													39
Stock-based compensation in connection with restricted stock awards																													$ 0	61	0	0	61	0	61
Comprehensive loss																													0	0	0	(23)	(23)	0	(23)
Net income (loss)																													$ 0	0	(1,187)	0	(1,187)	0	(1,187)
Balance (in shares) at Mar. 31, 2023																													14,441
Balance at Mar. 31, 2023																													$ 1	57,024	(32,334)	(64)	24,627	0	24,627
Balance (in shares) at Dec. 31, 2022																													14,402
Balance at Dec. 31, 2022																													$ 1	56,963	(31,147)	(41)	25,776	0	25,776
Issuance of common stock related offering (in shares)															3,429
Stock issued, value															$ 1	$ 5,999	$ 0	$ 0	$ 6,000	$ 0	$ 6,000
Stock-based compensation in connection with restricted stock awards (in shares)																													789
Stock-based compensation in connection with restricted stock awards																													$ 0	2,468	0	0	2,468	300	2,768
Stock-based compensation in connection with options granted																						$ 0	$ 32	$ 0	$ 0	$ 32	$ 0	$ 32	0	1,524	0	0	1,524		2,576
Comprehensive loss																													0	0	0	(22)	(22)	0	(22)
Net income (loss)																													$ 0	0	(3,778)	0	(3,778)	(8,629)	(12,407)
Issuance of common stock related to exercise of warrants (in shares)																													105
Issuance of common stock related to exercise of warrants																													$ 0	184	0	0	184	0	184
Stock-based compensation																						$ 0	$ 32	$ 0	$ 0	$ 32	$ 0	$ 32	0	1,524	0	0	1,524		2,576
Stock-based compensation, noncontrolling interest																																		1,052
Acquisition of subsidiary and noncontrolling interests																													$ 0	0	0	0	0	23,180	23,180
Balance (in shares) at Dec. 31, 2023																													18,725
Balance at Dec. 31, 2023																													$ 2	67,170	(34,925)	(63)	32,184	15,903	48,087
Stock-based compensation in connection with restricted stock awards (in shares)																													0
Stock-based compensation in connection with restricted stock awards																													$ 0	387	0	0	387	65	452
Stock-based compensation in connection with options granted																													0	160	0	0	160	0	160
Comprehensive loss																													0	0	0	(27)	(27)	0	(27)
Net income (loss)																													0	0	(1,481)	0	(1,481)	(220)	(1,701)
Stock-based compensation																													$ 0	160	0	0	160	0	160
Balance (in shares) at Mar. 31, 2024																													18,725
Balance at Mar. 31, 2024																													$ 2	$ 67,717	$ (36,406)	$ (90)	$ 31,223	$ 15,870	$ 47,093

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (12,407,000)	$ (9,161,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	758,000	465,000
Change in provision for doubtful accounts	47,000	0
Amortization of intangible assets	1,337,000	25,000
Amortization of right-of-use assets - operating leases	417,000	106,000
Amortization of right-of-use assets - finance leases	15,000	0
Write-off of digital assets	28,000	43,000
Goodwill impairment	13,895,000	0
Gain on remeasurement of fair value of equity interest in affiliate prior to acquisition	(11,352,000)	0
Equity in net loss of affiliate	1,440,000	1,739,000
Stock-based compensation	5,376,000	2,974,000
Accounts receivable	(3,449,000)	(34,000)
Inventory	(2,217,000)	(267,000)
Unbilled revenue	(47,000)	(41,000)
Prepaid expense	22,000	52,000
Notes receivable	(256,000)	0
Other assets	0	49,000
VAT receivable	91,000	59,000
Accounts payable and accrued expenses	3,231,000	453,000
Operating lease liabilities	(464,000)	(101,000)
Income taxes payable	45,000	37,000
Contract liabilities	6,000	0
Liabilities from discontinued operations	(112,000)	0
Net cash used in operating activities	(3,596,000)	(3,602,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(647,000)	(716,000)
Cash acquired in acquisition of subsidiary	7,352,000	0
Capital contributions to equity method investee	(1,506,000)	(7,000,000)
Net cash used in investing activities	5,199,000	(7,716,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments of note payable, related party, net	(10,000)	(7,000)
Issuance of common stock for PIPE transaction	6,000,000	13,832,000
Payment of stock issuance costs	0	(754,000)
Proceeds from exercise of warrants	184,000	0
Payments on finance lease liabilities	(15,000)	0
Repayments of notes payable	(299,000)	(60,000)
Net cash used in financing activities	5,860,000	13,011,000
Effect of exchange rate on cash	(47,000)	(70,000)
Net decrease in cash	7,416,000	1,623,000
Cash beginning of period	18,891,000	17,268,000
Cash end of period	26,307,000	18,891,000
SUPPLEMENTAL CASH FLOW INFORMATION
Interest	531,000	11,000
Income tax	0	10,000
Supplemental schedule of non-cash investing and financing activities:
Business combination without transfer of consideration	$ 39,859,000	$ 0

Note 1 - Organization and Natur

Note 1 - Organization and Nature of Operations.	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Nature of Operations [Text Block]	1. The term “Company” refers to NextPlat Corp and its wholly, majority owned and controlled subsidiaries, except where the context requires otherwise or where otherwise indicated. NextPlat Corp: NextPlat Corp, a Nevada corporation (the “Company”, “NextPlat”, “we”), formerly Orbsat Corp was incorporated in 1997. two 25 third Web3 Our wholly-owned subsidiary, Global Telesat Communications Limited (“GTC”), was formed under the laws of England and Wales in 2008. February 19, 2015, Our wholly-owned subsidiary, Orbital Satcom Corp. (“Orbital Satcom”), a Nevada corporation, was formed on November 14, 2014. On June 22, 2022, not Progressive Care Inc.: Progressive Care Inc. (“Progressive Care”) was incorporated under the laws of the state of Delaware on October 31, 2006. Progressive, through its wholly-owned subsidiaries, Pharmco, LLC (“Pharmco 901” 1002, 1002” 1103 1204 1103” 1204” Pharmco 901 November 29, 2005 901 October 21, 2010. 901 not Pharmco 1103 1103 June 1, 2019. Pharmco 1002 1002 July 1, 2018. ClearMetrX was formed on June 10, 2020 third 340B RXMD Therapeutics was formed on October 1, 2019. no Florida Sunshine Brands, LLC: Florida Sunshine Brands, LLC (“Florida Sunshine”) is a Florida limited liability company and incorporated December 6, 2023.	Note 1. Nature of Operations. The term “Company” refers to NextPlat Corp and its wholly, majority owned and controlled subsidiaries, except where the context requires otherwise or where otherwise indicated. NextPlat Corp: NextPlat Corp, a Nevada corporation (the “Company”, “NextPlat”, “we”), formerly Orbsat Corp was incorporated in 1997. two 25 third Our wholly-owned subsidiary, Global Telesat Communications Limited (“GTC”), was formed under the laws of England and Wales in 2008. February 19, 2015, Our wholly-owned subsidiary, Orbital Satcom Corp. (“Orbital Satcom”), a Nevada corporation, was formed on November 14, 2014. On June 22, 2022, not Progressive Care Inc.: Progressive Care Inc. (“Progressive Care”) was incorporated under the laws of the state of Delaware on October 31, 2006. Progressive, through its wholly-owned subsidiaries, Pharmco, LLC (“Pharmco 901” 1002, 1002” 1103 1204 1103” 1204” Pharmco 901 November 29, 2005 901 October 21, 2010. 901 not Pharmco 1103 1103 June 1, 2019. Pharmco 1002 1002 July 1, 2018. ClearMetrX was formed on June 10, 2020 third 340B RXMD Therapeutics was formed on October 1, 2019. no

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation and Principles of Consolidation	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	Note 2. The accompanying Condensed Consolidated Financial Statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”), consistent in all material respects with those applied in the 2023 10 not 2023 10 not Business acquisition of Progressive Care, Inc. On July 1, 2023, July 1, 2023, The exercise of the stock options, along with the entry into the voting agreement, resulted in a change in control of Progressive Care under the voting interest model in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 805, Business Combination, July 1, 2023. The accompanying Unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany transactions and balances have been eliminated in consolidation. Use of Estimates In preparing the Consolidated Financial Statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the statements of financial condition, and revenues and expenses for the years then ended. Actual results may not	Note 2. These consolidated financial statements have been prepared by management in accordance with general accepted accounting principles in the United States of America (“U.S. GAAP”) and this basis assumes that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Business acquisition of Progressive Care, Inc. On July 1, 2023, July 1, 2023, The exercise of the stock options, along with the entry into the voting agreement, resulted in a change in control of Progressive Care under the voting interest model in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 805, Business Combination, July 1, 2023. The accompanying Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany transactions and balances have been eliminated in consolidation. Use of Estimates In preparing the Consolidated Financial Statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the statements of financial condition, and revenues and expenses for the years then ended. Actual results may not Reclassification Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 3. The significant accounting policies of the Company were described in Note 1 10 December 31, 2023 no three March 31, 2024. Cash The Company places its cash with high credit quality financial institutions. The Company’s account at these institutions are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. All cash amounts in excess of $250,000, approximately $1.0 million, are unsecured. The Company has a deposit placement agreement for Insured Cash Sweep Service (“ICS”). This service is a secure, and convenient way to access FDIC protection on large deposits, earn a return, and enjoy flexibility. The Company believes that the ICS agreement will mitigate its credit risk as it relates to uninsured FDIC amounts in excess of $250,000. Foreign Currency Translation The Company’s reporting currency is U.S. Dollars. The accounts of one The relevant translation rates are as follows: for the three March 31, 2024 three March 31, 2023 December 31, 2023 Unearned Revenue Contract liabilities are shown separately in the condensed consolidated balance sheets as current liabilities. At March 31, 2024 December 31, 2023 Direct and Indirect Remuneration ( “ DIR ” ) Progressive Care reports DIR fees as a reduction of revenue on the accompanying Consolidated Statements of Operations. DIR fees are fees charged by PBMs to pharmacies for network participation as well as periodic reimbursement reconciliations. The Company accrues an estimate of PBM fees, including DIR fees, which are assessed or expected to be assessed by payers at some point after adjudication of a claim, as a reduction of prescription revenue at the time revenue is recognized. Changes in the estimate of such fees are recorded as an adjustment to revenue when the change becomes known. Through December 31, 2023, not two two three January – April 20xx July – August 20xx December 31, 2023, not second 2024. may January 1, 2024, Recent Accounting Pronouncements Accounting Pronouncements Issued but not In November 2023, 2023 07, 280 2023 07” 2023 07 December 15, 2023, December 15, 2024, Q1 2025, December 31, 2024. not In December 2023, 2023 09, 740 2023 09” 2023 09 December 15, 2024, January 1, 2025. not Other accounting standards that have been issued or proposed by FASB that do not not Subsequent Events The Company has evaluated subsequent events through May 15, 2024, 21	Note 3. The significant accounting policies of the Company are described below the fiscal year ended December 31, 2023. July 1, 2023 December 31, 2023. Discontinued Operations The Company’s former operations were developing and manufacturing products and services, which reduce fuel costs, save power and energy and protect the environment. The products and services were made available for sale into markets in the public and private sectors. In December 2009, The remaining liabilities for discontinued operations are presented in the consolidated balance sheets under the caption “Liabilities from discontinued operation” and relates to the discontinued operations of developing and manufacturing of energy saving and fuel-efficient products and services. The carrying amounts of the major classes of these liabilities as of December 31, 2023 2022 December 31, 2023 December 31, 2022 Assets of discontinued operations $ — $ — Liabilities Accounts payables and accrued expenses $ — $ (112 ) Liabilities from discontinued operations $ — $ (112 ) Liquidity January 2022 On December 31, 2021, “December “December January 2, 2022, December December 31, 2021. December December 31, 2021. The closing of the December January 5, 2022. December December 2022 On December 9, 2022, three On December 9, 2022, three six The offering closed on December 14, 2022, April 2023 On April 5, 2023, April 4, 2023. April 11, 2023, 4 2 506 As of the date of this report, the Company’s existing cash resources and existing borrowing availability are sufficient to support planned operations for the next 12 one Cash and Cash Equivalents The Company places its cash with high credit quality financial institutions. The Company’s account at this institution is insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. All cash amounts in excess of $250,000, approximately $3.1 million, are unsecured. In April 2023, $250,000. Accounts Receivable and Allowance for Doubtful Accounts The Company has a policy of reserving for questionable accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may may Progressive Care trade accounts receivable are stated at the invoiced amount. Trade accounts receivable primarily include amounts from third no Inventories Inventories are valued at the lower of cost or net realizable value, using the first first not Prepaid Expenses Prepaid expenses current and long term amounted to approximately $640,000 and $61,000, respectively for the year ended December 31, 2023 December 31, 2022 Investments The Company applies the equity method of accounting to investments when it has significant influence, but not 15 The Company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not December 31, 2023 not Foreign Currency Translation The Company’s reporting currency is U.S. Dollars. The accounts of one The relevant translation rates are as follows: for the year ended December 31, 2023 December 31, 2022 Revenue Recognition and Unearned Revenue In accordance with ASU No. 2016 12, Revenue from Contracts with Customers (Topic 606 1 606 10 25 7; 2 3 4 5 6 606 not December 15, 2017, no one e-Commerce Operations: The Company recognizes revenue from satellite services when earned, as services are rendered or delivered to customers. Equipment sales revenue is recognized when the equipment is delivered to and accepted by the customer. Only equipment sales are subject to warranty. Historically, the Company has not The Company’s customers generally purchase a combination of our products and services as part of a multiple element arrangement. The Company’s assessment of which revenue recognition guidance is appropriate to account for each element in an arrangement can involve significant judgment. This assessment has a significant impact on the amount and timing of revenue recognition. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, five five 606, Contract liabilities are shown separately in the consolidated balance sheets as current liabilities. At December 31, 2023 December 31, 2022 Healthcare Operations: The Company provides prescription pharmaceuticals, COVID- 19 340B 340B 340B 340B The Company recognizes product sales from prescriptions dispensed to patients (customers) at the time the drugs are physically delivered to a customer or when a customer picks up their prescription, which is the point in time when control transfers to the customer. 340B 340B third 340B 340B not not The Company accrues an estimate of PBM fees, including direct and indirect remuneration (“DIR”) fees, which are assessed or expected to be assessed by payers at some point after adjudication of a claim, as a reduction of prescription revenue at the time revenue is recognized. Changes in the estimate of such fees are recorded as an adjustment to revenue when the change becomes known. DIR fees are fees charged by PBMs to pharmacies for network participation as well as periodic reimbursement reconciliations. For some PBMs, DIR fees are charged at the time of the settlement of a pharmacy claim. Other PBMs do not two two three January – April 2023 July – August 2023). not may Billings for most prescription orders are with third The Company recognizes revenue from TPA services as it satisfies the performance obligations under the TPA contract with a 340B one may not For each TPA contract, the Company recognizes revenue by measuring the progress toward complete satisfaction of each performance obligation. The Company uses various observable output methods in measuring progress toward satisfaction of each performance obligation, most notably gross billings under each contract. ASC 606 may The Company recognizes COVID- 19 Cost of Product Sales and Services Cost of sales consists primarily of materials, airtime and overhead costs incurred internally and amounts incurred to contract manufacturers to produce our products, airtime and other implementation costs incurred to install our products and train customer personnel, and customer service and third Shipping and handling costs are included as a component of costs of product sales in the Company’s consolidated statements of operations because the Company includes in revenue the related costs that the Company bills its customers. Advertising Costs incurred for producing and communicating advertising for the Company are charged to operations as incurred. Advertising expense was approximately $188,000 and $93,000 for the years ended December 31, 2023 2022 Intangible Assets Acquired intangible assets with finite lives other than goodwill are amortized over their useful lives. For intangible assets acquired in a business combination, the estimated fair values of the assets received are used to establish their recorded values. Acquired intangible assets other than goodwill are amortized over their useful lives unless the lives are determined to be indefinite. Valuation techniques consistent with the market approach, income approach, and/or cost approach are used to measure fair value. Intangible assets subject to amortization represent the fair value of pharmacy records, tradenames and customer contracts acquired, and capitalized software development costs. In valuing these assets, the Company makes assumptions regarding useful lives and projected growth rates, and significant judgment is required. The Company periodically reviews its identifiable intangible assets for impairment as events or changes in circumstances indicate that the carrying amount of such assets may not Pharmacy records and developed software are amortized over 5 years. Tradenames and customer contracts are amortized over 10 years. Useful lives of intangible assets are periodically evaluated for reasonableness and the assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may no Business acquisitions The Company records business acquisitions using the acquisition method of accounting. All of the assets acquired, liabilities assumed, and contractual contingencies are recognized at their fair value on the acquisition date. The application of the acquisition method of accounting for business combinations requires management to make significant estimates and assumptions in the determination of the fair value of assets acquired and liabilities assumed in order to properly allocate purchase price consideration between assets that are depreciated and amortized and goodwill. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Acquisition-related expenses and restructuring costs are recognized separately from the business combination and are expensed as incurred. The Company uses a measurement period following the acquisition date to gather information that existed as of the acquisition date that is needed to determine the fair value of the assets acquired, liabilities assumed and equity interests. The measurement period ends once all information is obtained, but no one Goodwill Goodwill represents the excess of the purchase price over the value assigned to net tangible and identifiable intangible assets. Progressive Care, which is our Healthcare Operations, is considered to be the reporting unit for goodwill. Valuation techniques consistent with the market approach, income approach, and/or cost approach are used to measure fair value. Goodwill and other indefinite-lived intangible assets are assessed annually for impairment in the fourth may Property and Equipment Property and equipment are carried at historical cost less accumulated depreciation. Depreciation is based on the estimated service lives of the depreciable assets and is calculated using the straight-line method. Expenditures that increase the value or productive capacity of assets are capitalized. Fully depreciated assets are retained in the property and equipment, and accumulated depreciation accounts until they are removed from service. When property and equipment are retired, sold or otherwise disposed of, the asset’s carrying amount and related accumulated depreciation are removed from the accounts and any gain or loss is included in operations. Repairs and maintenance are expensed as incurred. The estimated useful lives of property and equipment are generally as follows: Years Building 40 Building improvements Remaining life of the building Leasehold improvements Lessor of the estimated useful life or life of the lease Office furniture and fixtures 4-5 Computer equipment 3-4 Rental equipment 4 Vehicles 3-5 Appliques 10 Website development 2 Depreciation expense for the years ended December 31, 2023 2022 Impairment of Long-lived Assets The Company reviews its long-lived assets, comprised of property and equipment, right-of-use assets, and intangible assets, whenever events or changes in circumstances indicate that the carrying amount of an asset may not 360 10, Accounting for the Impairment or Disposal of Long-Lived Assets the assets to the fair value based on estimated discounted future cash flows. If required, an impairment loss is recorded for that portion of the asset’s carrying value in excess of fair value. As of December 31, 2023, no not December 31, 2023 and December 31, 2022 , respectively. Fair Value of Financial Instruments Derivatives are required to be recorded on the balance sheet at fair value. These derivatives, including embedded derivatives in the Company’s structured borrowings, are separately valued and accounted for on the Company’s balance sheet. Fair values for exchange traded securities and derivatives are based on quoted market prices. Where market prices are not The Company did not Stock-based Compensation Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 The Company estimated the fair value of stock options granted using the Black-Scholes option-pricing formula. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The Company’s determination of the fair value using the option-pricing model is affected by the stock price as well as assumptions regarding the number of highly subjective variables. In June 2018, 2018 07, 718 718, December 15, 2018. January 1, 2019. Income Taxes The Company accounts for income taxes pursuant to the provision of ASC 740 10, 740 10” not not The Company follows the provision of ASC 740 10 may 740 10, not not Tax positions that meet the more likely than not 50 The Company believes its tax positions are all more likely than not not The Company has adopted ASC 740 10 25, not not three Leases Effective January 1, 2019, 842, Leases not In calculating the right of use asset and lease liability, the Company has elected to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 Research and Development The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730 10, 730 10” 730 10, December 31, 2023 2022 no Accumulated Other Comprehensive Income (Loss) Comprehensive income (loss) is comprised of net income (loss) and all changes to the statements of stockholders’ equity. For the Company, comprehensive income (loss) for the years ended December 31, 2023 2022 Earnings per Common Share Net income (loss) per common share is calculated in accordance with ASC Topic 260: 260” not Related Party Transactions A party is considered to be related to the Company if the party directly or indirectly or through one may one one one one 25 Recent Accounting Pronouncements Accounting Pronouncements Recently Adopted In August 2023, 2023 04, 405 No. 121”, No. 121. In July 2023, 2023 03, 205 220 480 505 718 No. 120, no In June 2016, 2016 13, 326 2016 13” November 2018, 2018 19, 326, not April 2019, 2019 04, 326, 815, 825, 2016 13. March 2020, 2020 03, 842 326. 2016 13 December 15, 2022, Any new accounting standards, not not not Accounting Pronouncements Issued but not In December 2023, 2023 09, 740 2023 09” 2023 09 December 15, 2024, January 1, 2025. not In November 2023, 2023 07, 280 2023 07” 2023 07 December 15, 2023, December 15, 2024, January 1, 2024. not Management has evaluated other recently issued accounting pronouncements and does not

Note 4 - Fair Value

Note 4 - Fair Value	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 4. Accounting standards define fair value as the price that would be received from selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards establish a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value and also establishes the following three may Level 1: Level 2: 1 not Level 3: no The following methods and assumptions were used by the Company in estimating fair value disclosures for financial instruments: ● Cash, accounts receivable, and accounts payable and accrued liabilities: ● Notes payable and lease liabilities: 2 Identifiable Intangible Assets The initial recognition of the Progressive Care's identifiable intangible assets, resulting from the acquisition on July 1, 2023 3	Note 5. Accounting standards define fair value as the price that would be received from selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards establish a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value and also establishes the following three may Level 1: Level 2: 1 not Level 3: no The following methods and assumptions were used by the Company in estimating fair value disclosures for financial instruments: ● Cash, accounts receivable, and accounts payable and accrued liabilities: ● Notes payable and lease liabilities: 2

Note 5 - Revenue

Note 5 - Revenue	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	Note 5. e-Commerce r The Company recognizes revenue from satellite services when earned, as services are rendered or delivered to customers. Equipment sales revenue is recognized when the equipment is delivered to and accepted by the customer. Only equipment sales are subject to warranty. Historically, the Company has not Healthcare revenue: The Company recognizes pharmacy revenue and 340B third The Company accrues an estimate of pharmacy benefit manager (“PBM”) fees, including direct and indirect remuneration (“DIR”) fees, which are assessed or expected to be assessed by payers at some point after adjudication of a claim, as a reduction of revenue at the time revenue is recognized. Changes in the estimate of such fees are recorded as an adjustment to revenue when the change becomes known. The Company recognizes COVID- 19 The following table disaggregates net revenues by categories (in thousands): Three Months Ended March 31, 2024 2023 Sales of products, net: Pharmacy prescription and other revenue, net of PBM fees $ 11,324 $ — e-Commerce revenue 2,865 2,876 Sub total 14,189 2,876 Revenues from services: Pharmacy 340B contract revenue 3,304 — Revenues, net $ 17,493 $ 2,876	Note 6. e-Commerce revenue: The Company recognizes revenue from satellite services when earned, as services are rendered or delivered to customers. Equipment sales revenue is recognized when the equipment is delivered to and accepted by the customer. Only equipment sales are subject to warranty. Historically, the Company has not Healthcare revenue: The Company recognizes pharmacy revenue and 340B third The Company accrues an estimate of pharmacy benefit manager (“PBM”) fees, including direct and indirect remuneration (“DIR”) fees, which are assessed or expected to be assessed by payers at some point after adjudication of a claim, as a reduction of revenue at the time revenue is recognized. Changes in the estimate of such fees are recorded as an adjustment to revenue when the change becomes known. The Company recognizes COVID- 19 The following table disaggregates net revenues by categories (in thousands): For the Twelve Months Ended December 31, 2023 e-Commerce Operations Healthcare Operations Total Sales of products, net Prescription revenue, net of PBM fees $ — $ 21,412 $ 21,412 e-Commerce revenue 10,977 — 10,977 Subtotal 10,977 21,412 32,389 Revenues from services: Pharmacy 340B contract revenue — 5,367 5,367 Revenues, net $ 10,977 $ 26,779 $ 37,756 For the Twelve Months Ended December 31, 2022 e-Commerce Operations Healthcare Operations Total Sales of products, net Prescription revenue, net of PBM fees $ — $ — $ — e-Commerce revenue 11,710 — 11,710 Subtotal 11,710 — 11,710 Revenues from services: Pharmacy 340B contract revenue — — — Revenues, net $ 11,710 $ — $ 11,710

Note 6 - Loss Per Share

Note 6 - Loss Per Share	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 6. Net income (loss) per common share is calculated in accordance with Accounting Standards Codification (“ASC”) Topic 260: 260” not The components of basic and diluted EPS were as follows (in thousands, except per share data). Three Months Ended March 31, 2024 2023 Net loss attributable to NextPlat Corp common shareholders $ (1,481 ) $ (1,187 ) Basic weighted average common shares outstanding 18,725 14,415 Potentially dilutive common shares — — Diluted weighted average common shares outstanding 18,725 14,415 Weighted average loss per common share - basic and diluted $ (0.08 ) $ (0.08 ) Potentially dilutive common shares excluded from the calculation of diluted weighted average loss per common share: Stock options 105 100 105 100	Note 7. Net income (loss) per common share is calculated in accordance with Accounting Standards Codification (“ASC”) Topic 260: 260” not Year Ended December 31, 2023 2022 Net loss attributable to NextPlat Corp common shareholders $ (3,778 ) $ (9,161 ) Basic weighted average common shares outstanding 17,494 9,592 Potentially dilutive common shares — — Diluted weighted average common shares outstanding 17,494 9,592 Basic weighted average earnings (loss) per common share $ (0.22 ) $ (0.96 ) Diluted weighted average earnings (loss) per common share $ (0.22 ) $ (0.96 ) Potentially dilutive common shares excluded from the calculation of diluted weighted average loss per common share: Stock options 136 265 Common stock purchase warrants 675 1,403 811 1,668

Note 7 - Accounts Receivable

Note 7 - Accounts Receivable	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Accounts Receivable [Member]
Notes to Financial Statements
Accounts and Nontrade Receivable [Text Block]	Note 7. At March 31, 2024 December 31, 2023 March 31, 2024 December 31, 2023 (Unaudited) (Audited) Gross accounts receivable – trade $ 13,202 $ 9,195 Less: allowance for doubtful accounts (274 ) (272 ) Accounts receivable – trade, net $ 12,928 $ 8,923 The Company increased the allowance for credit losses in the amount of approximately $2,000 and $0 for the three March 31, 2024 2023 Accounts receivable – trade, net for the Company as of January 1, 2023 March 31, 2023	Note 8. At December 31, 2023 2022 Year Ended December 31, 2023 2022 Gross accounts receivable – trade $ 9,195 $ 384 Less: allowance for doubtful accounts (272 ) — Accounts receivable – trade, net $ 8,923 $ 384 Bad debt expense was approximately $47,000 and $0 for the twelve December 31, 2023 2022 The increase in accounts receivable was attributable to the consolidation of Progressive Care at July 1, 2023.

Note 8 - Inventory

Note 8 - Inventory	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Inventory Disclosure [Text Block]	Note 8. At March 31, 2024 December 31, 2023 March 31, 2024 December 31, 2023 (Unaudited) (Audited) Finished goods $ 5,670 $ 5,195 Less reserve for obsolete inventory (60 ) (60 ) Total $ 5,610 $ 5,135	Note 10. At December 31, 2023 2022 December 31, 2023 December 31, 2022 Finished goods $ 5,195 $ 1,287 Less reserve for obsolete inventory (60 ) — Total $ 5,135 $ 1,287 The increase in inventory was attributable to the consolidation of Progressive Care as of July 1, 2023.

Note 9 - VAT Receivable

Note 9 - VAT Receivable	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
VAT Accounts Receivable [Text Block]	Note 9. On January 1, 2021, March 31, 2024 December 31, 2023	Note 11. On January 1, 2021, December 31, 2023 2022 $433,000

Note 10 - Prepaid Expenses

Note 10 - Prepaid Expenses	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Prepaid Expenses [Text Block]	Note 10. Prepaid expenses current and long term amounted to approximately $404,000 and $61,000, respectively at March 31, 2024 December 31, 2023	Note 12. Prepaid expenses current and long term amounted to approximately $640,000 and $61,000, respectively at December 31, 2023 $46,000 $49,000 December 31, 2022 The increase in prepaid expenses was attributable to the consolidation of Progressive Care as of July 1, 2023.

Note 11 - Property and Equipmen

Note 11 - Property and Equipment, Net	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 11. Property and equipment, net consisted of the following (in thousands): March 31, 2024 December 31, 2023 (Unaudited) (Audited) Building $ 2,116 $ 2,116 Vehicles 585 595 Office furniture and fixtures 543 527 Land 184 184 Leasehold improvements 167 124 Computer equipment 117 117 Rental equipment 63 60 Appliques 2,160 2,160 Website development 611 587 Construction in progress — 22 Property and equipment gross 6,546 6,492 Less: accumulated depreciation (2,700 ) (2,503 ) Property and equipment, net $ 3,846 $ 3,989 Depreciation expense was approximately $203,000 and $155,000 for the three March 31, 2024 2023	Note 13. Property and equipment consisted of the following (in thousands): December 31, 2023 December 31, 2022 Building $ 2,116 $ — Vehicles 595 — Office furniture and fixtures 527 128 Land 184 — Leasehold improvements 124 48 Computer equipment 117 72 Rental equipment 60 38 Appliques 2,160 2,160 Website development 587 665 Construction in progress 22 — Property and equipment gross 6,492 3,111 Less: accumulated depreciation (2,503 ) (1,865 ) Property and equipment, net $ 3,989 $ 1,246 Depreciation expense was approximately $758,000 and $465,000 for the twelve December 31, 2023 2022 The increase in property and equipment was attributable to the consolidation of Progressive Care as of July 1, 2023.

Note 12 - Intangible Assets, Ne

Note 12 - Intangible Assets, Net	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	Note 12. Intangible assets, net consisted of the following (in thousands): March 31, 2024 (Unaudited) Gross amount Accumulated amortization Net Amount Pharmacy records $ 8,130 $ (1,219 ) $ 6,911 Trade names 4,700 (353 ) 4,347 Developed technology 2,880 (432 ) 2,448 Customer Contracts 250 (231 ) 19 Total intangible assets $ 15,960 $ (2,235 ) $ 13,725 December 31, 2023 (Audited) Gross amount Accumulated amortization Net Amount Pharmacy records $ 8,130 $ (807 ) $ 7,323 Trade names 4,700 (224 ) 4,476 Developed technology 2,880 (281 ) 2,599 Customer Contracts 250 (225 ) 25 Total intangible assets $ 15,960 $ (1,537 ) $ 14,423 Amortization of customer contracts is included in depreciation and amortization in the accompanying Condensed Consolidated Statements of Comprehensive Income (Loss). For the three March 31, 2024 2023 Year Amount 2024 (remaining nine months) $ 2,023 2025 2,672 2026 2,672 2027 2,672 2028 1,571 Thereafter 2,115 Total $ 13,725	Note 14. Goodwill The following table reflects changes in the carrying amount of goodwill during the periods presented by reportable segments (in thousands): e-Commerce Operations Healthcare Operations Total Balances as of December 31, 2021 Goodwill $ — $ — $ — Accumulated impairment losses — — — Goodwill, net as of December 31, 2021 — — — Changes in Goodwill during the year ended December 31, 2022: Goodwill acquired — — — Impairment losses — — — Balances as of December 31, 2022 Goodwill — — — Accumulated impairment losses — — — Goodwill, net as of December 31, 2022 — — — Changes in Goodwill during the year ended December 31, 2023: Goodwill acquired — 14,626 14,626 Impairment losses — (13,895 ) (13,895 ) Balances as of December 31, 2023 Goodwill — 14,626 14,626 Accumulated impairment losses — (13,895 ) (13,895 ) Goodwill, net as of December 31, 2023 $ — $ 731 $ 731 1. Increase related to book tax difference of intangible assets arising from the business combination without transfer of consideration. The initial recognition of goodwill resulting from the acquisition of Progressive Care on July 1, 2023. December 31, 2023. The Company performed an annual impairment test as of December 31, 2023, 3. 11% 13.5%. As a result of the 2023 95% December 31, 2023. December 31, 2023. Intangible Assets Intangible assets, net consisted of the following (in thousands): December 31, 2023 Gross amount Accumulated amortization Net Amount Pharmacy records $ 8,130 $ (807 ) $ 7,323 Trade names 4,700 (224 ) 4,476 Developed technology 2,880 (281 ) 2,599 Customer Contracts 250 (225 ) 25 Total intangible assets $ 15,960 $ (1,537 ) $ 14,423 December 31, 2022 Gross amount Accumulated amortization Net Amount Pharmacy records $ — $ — $ — Trade names — — — Developed technology — — — Customer Contracts 250 (200 ) 50 Total intangible assets $ 250 $ (200 ) $ 50 Amortization of pharmacy records, trade names, developed technology, and customer contracts is included in depreciation and amortization in the accompanying Consolidated Statements of Comprehensive Income Loss. For the twelve December 31, 2023 2022 2024 $ 2,721 2025 2,672 2026 2,672 2027 2,672 2028 1,571 Thereafter 2,115 Total $ 14,423

Note 13 - Accounts Payable and

Note 13 - Accounts Payable and Accrued Expenses	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 13. Accounts payable and accrued expenses consisted of the following (in thousands): March 31, 2024 December 31, 2023 (Unaudited) (Audited) Accounts payable $ 13,978 $ 12,142 Accrued wages and payroll liabilities 378 200 Accrued PBM fees 366 571 Customer deposits payable 54 76 Accrued other liabilities 117 187 Total $ 14,893 $ 13,176	Note 16. Accounts payable and accrued expenses consisted of the following (in thousands): December 31, 2023 December 31, 2022 Accounts payable $ 12,142 $ 1,200 Accrued wages and payroll liabilities 200 23 Accrued PBM fees 571 — Customer deposits payable 76 86 Accrued legal fees — 85 Pre-merger accrued other liabilities — 88 Accrued other liabilities 187 41 Total $ 13,176 $ 1,523 The increase in accounts payable and accrued expenses was attributable to the consolidation of Progressive Care at July 1, 2023.

Note 14 - Notes Payable

Note 14 - Notes Payable	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 14. Notes payable consisted of the following (in thousands): March 31, 2024 December 31, 2023 (Unaudited) (Audited) A. Mortgage note payable - commercial bank - collateralized $ 1,118 $ 1,140 B. Note payable - uncollateralized 25 25 C. Notes payable - collateralized 229 255 Insurance premiums financing 26 103 Subtotal 1,398 1,523 Less: current portion of notes payable (233 ) (312 ) Long-term portion of notes payable $ 1,165 $ 1,211 (A) Mortgage Note Payable – collateralized In 2018, 400 December 14, 2028 January 2019, not December 14, 2028. (B) Note Payable – Uncollateralized As of March 31, 2024 (C) Notes Payable – Collateralized On July 16, 2020 ( £250,000, July 16, 2021, Base Rate July 16, 2020), July 15, 2026, first £4,166.67 13 July 16, 2020. 5 In April 2021, September 2021, March 31, 2024 December 31, 2023 In July 2022, January 2023. March 31, 2024 December 31, 2023 In September 2022, October 2022. March 31, 2024 December 31, 2023 Principal outstanding as of March 31, 2024 Year Amount 2024 (remaining nine months) $ 187 2025 215 2026 119 2027 124 2028 753 Thereafter — Total $ 1,398	Note 17. Notes payable consisted of the following (in thousands): December 31, 2023 December 31, 2022 A. Mortgage note payable - commercial bank - collateralized $ 1,140 $ — B. Note payable - uncollateralized 25 — C. Notes payable - collateralized 255 216 Insurance premiums financing 103 — Subtotal 1,523 216 Less: current portion of notes payable (312 ) (60 ) Long-term portion of notes payable $ 1,211 $ 156 (A) Mortgage Note Payable – collateralized In 2018, 400 December 14, 2028 January 2019, not December 14, 2028. (B) Note Payable – Uncollateralized As of December 31, 2023 (C) Notes Payable – Collateralized On July 16, 2020 ( £250,000, July 16, 2021, July 16, 2020), July 15, 2026, first £4,166.67 13 July 16, 2020. 5 December 31, 2023 In April 2021, September 2021, December 31, 2023 In July 2022, January 2023. December 31, 2023 In September 2022, October 2022. December 31, 2023 Principal outstanding as of December 31, 2023 Year Amount 2024 $ 312 2025 215 2026 119 2027 124 2028 753 Thereafter — Total $ 1,523

Note 15 - Equity

Note 15 - Equity	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Equity [Text Block]	Note 15. Equity Preferred Stock We have authorized 3,333,333 shares of $0.0001 par value of preferred stock. No preferred stock was outstanding for any year presented. As of March 31, 2024 Common Stock We have authorized 50,000,000 shares of $0.0001 par value common stock. As of March 31, 2024 Listing on the Nasdaq Capital Market Our common stock and warrants have been trading on the Nasdaq Capital Market under the symbols “NXPL” and “NXPLW,” respectively, since January 21, 2022. January 21, 2022, April 2023 On April 5, 2023, April 4, 2023. April 11, 2023, 4 2 506 not not may not For the three March 31, 2024 2023 three March 31, 2024 2023	Note 18. Preferred Stock We have authorized 3,333,333 shares of $0.0001 par value of preferred stock. No preferred stock was outstanding for any year presented. Common Stock We have authorized 50,000,000 shares of $0.0001 par value common stock. As of December 31, 2023 2022 Capital Structure On May 28, 2021, 1 No 1 5 Listing on the Nasdaq Capital Market Our common stock and warrants have been trading on the Nasdaq Capital Market under the symbols “NXPL” and “NXPLW,” respectively, since January 21, 2022. January 21, 2022, April 2023 On April 5, 2023, April 4, 2023. April 11, 2023, 4 2 506 not not may not December 2022 December ) On December 9, 2022, three The offering closed on December 14, 2022, On December 9, 2022, three six January 2022 January ) On January 2, 2022, The Company received gross proceeds from the sale of the common stock of $7,225,038. Legal and registration fees amounted to $220,000, resulting in net proceeds of approximately $7.0 million. Prior to the private placement close, proceeds of approximately $1.4 million, were received and recorded as a stock subscription payable, for the year ended December 31, 2022

Note 16 - Related Party Transac

Note 16 - Related Party Transactions	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 16. On July 12, 2022, September 22, 2022, no December 31, 2022. April 2023, Progressive Care Inc September 2, 2022, November 11, 2022, September 2, 2022, March 6, 2019, 1 December 30, 2022. On February 1, 2023, May 2023 three March 31, 2023 three March 31, 2024 July 1, 2023. On May 5, 2023, one one On May 9, 2023, one On July 1, 2023, Also, on July 1, 2023, Next Borough Capital Fund, LP. July 7, 2023, July 7, 2024, March 31, 2024 December 31, 2023	Note 25. As of December 31, 2023 December 31, 2023 December 31, 2022 The Company uses an American Express account for Orbital Satcom Corp and an American Express account for GTC, both in the name of David Phipps who personally guarantees the balance owed. For the year ended December 31, 2023 2022 two On July 12, 2022, September 22, 2022, no December 31, 2022. April 2023, January January January 5, 2022. Investor Position held at NextPlat Shares of Common Stock Purchased Aggregate Purchase Price Charles M. Fernandez Executive Chairman and Chief Executive Officer 679,013 $ 2,200,002 David Phipps Director and President of Orbsat. Chief Executive Officer of Global Operations 46,297 $ 150,002 Douglas Ellenoff Vice Chairman and Chief Business Development Strategist 46,297 $ 150,002 Shares are deemed to be indirectly beneficially owned through Sabrina Allan, Mr. Ellenoff’s wife. Mr. Ellenoff has the power to vote and dispose of the shares. Louis Cusimano Director 15,433 $ 50,003 Paul R. Thomson Senior Vice President – Mergers, Acquisitions and Special Projects 15,433 $ 50,003 On January 20, 2022, January Progressive Care Inc September 2, 2022, November 11, 2022, September 2, 2022, March 6, 2019, 1 December 30, 2022. On February 1, 2023, May 2023 twelve December 31, 2023 six December 31, 2023 July 1, 2023. On May 5, 2023, one one On May 9, 2023, one On July 1, 2023, Also, on July 1, 2023, Next Borough Capital Fund, LP. July 7, 2023, July 7, 2024, December 31, 2023 December December 14, 2022, three Investor Position held at NextPlat Shares of Common Stock Purchased Warrants to purchase Common Stock Aggregate Purchase Price eAperion Partners LLC, principal Charles M. Fernandez Executive Chairman and Chief Executive Officer 1,085,714 1,085,714 $ 1,900,000 David Phipps Director and President of NextPlat. Chief Executive Officer of Global Operations 28,500 28,500 $ 49,875 RLB Market Investments LLC, principal, Rodney Barreto Director 1,085,714 1,085,714 $ 1,900,000

Note 17 - Commitments and Conti

Note 17 - Commitments and Contingencies	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 17. Litigation On June 22, 2021, not June 2, 2021 not not June 21, 2022. not No. 1:21 22436 On July 5, 2022, June 22, 2021, A jury trial is set to occur during the trial court's two August 21, 2024. From time to time, the Company may not no	Note 24. Litigation On June 22, 2021, not June 2, 2021 not not June 21, 2022. not No. 1:21 22436 On July 5, 2022, June 22, 2021, A jury trial is set to occur during the trial court's two August 21, 2024. From time to time, the Company may not no

Note 18 - Leases

Note 18 - Leases	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	Note 18. The Company has entered into a number of lease arrangements under which the Company is the lessee. These leases are classified as operating leases. In addition, the Company has elected the short-term lease practical expedient in ASC Topic 842 one Finance Lease Agreements In May 2018, March 2025 Operating Lease Agreements Right of use ("ROU") assets for operating leases are periodically reduced by impairment losses. We use the long-lived assets impairment guidance in ASC Subtopic 360 10, March 31, 2024 December 31, 2023 We monitor for events or changes in circumstances that require a reassessment of one On December 2, 2021, June 13, 2022, August 31, 2027. not For our facilities in Poole, England, we rent office and warehouse space of approximately 2,660 square feet for £30,000 October 6, 2022, October 31, 2023 twelve Progressive Care entered into a lease agreement for its Orlando pharmacy in August 2020. February 2026. February 2021, Progressive Care leases its North Miami Beach pharmacy location under an operating lease agreement with a lease commencement date in September 2021. August 2026. Progressive Care also leases its Palm Beach County pharmacy locations under operating lease agreements expiring in February 2025.	Note 22. The Company has entered into a number of lease arrangements under which the Company is the lessee. These leases are classified as operating leases. In addition, the Company has elected the short-term lease practical expedient in ASC Topic 842 one Finance Lease Agreements In May 2018, March 2025 In December 2020, November 2023. Operating Lease Agreements On December 2, 2021, June 13, 2022, August 31, 2027. not For our facilities in Poole, England, we rent office and warehouse space of approximately 2,660 square feet for £30,000 October 6, 2022, October 31, 2023 twelve Progressive Care entered into a lease agreement for its Orlando pharmacy in August 2020. February 2026. February 2021, Progressive Care leases its North Miami Beach pharmacy location under an operating lease agreement with a lease commencement date in September 2021. August 2026. Progressive Care also leases its Palm Beach County pharmacy locations under operating lease agreements expiring in February 2024. During June 2023 twenty-five 25 300 June 7, 2023, June 6, 2026. Variable expenses generally represent the Company’s share of the landlord’s operating expenses. Right of use assets for operating leases are periodically reduced by impairment losses. We use the long-lived assets impairment guidance in ASC Subtopic 360 10, December 31, 2023 2022 not We monitor for events or changes in circumstances that require a reassessment of one We recognized lease costs associated with all leases as follows (in thousands): For the Year Ended December 31, 2023 2022 Operating lease cost: Fixed rent expense $ 427 $ 101 Variable rent expense 111 — Finance lease cost: Amortization of right-of-use assets 15 — Interest expense 1 — Total Lease Costs $ 554 $ 101 Supplemental cash flow information related to leases was as follows (in thousand): For the Year Ended December 31, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 464 $ 101 Financing cash flows from finance leases 15 — Total cash paid for lease liabilities $ 479 $ 101 Supplemental balance sheet information related to leases was as follows (in thousands): December 31, 2023 December 31, 2022 Operating leases: Operating lease right-of-use assets, net $ 1,566 $ 855 Operating lease liabilities: Current portion 532 209 Long-term portion 929 650 $ 1,461 $ 859 Weighted average remaining lease term (years) 2.96 5.50 Weighted average discount rate 4.65 % 3.75 % Finance leases: Finance lease right-of-use assets, net 22 $ — Finance lease liabilities: Current portion 18 — Long-term portion 5 — $ 23 $ — Weighted average remaining lease term (years) 1.25 — Weighted average discount rate 6.00 % — Future minimum lease payments are as follows (in thousands): Years Ending December 31, Finance Lease Operating Lease Total Future Lease Commitments 2024 $ 19 $ 582 $ 601 2025 5 580 585 2026 — 262 262 2027 — 121 121 Total lease payments to be paid 24 1,545 1,569 Less: future interest expense (1 ) (84 ) (85 ) Lease liabilities 23 1,461 1,484 Less: current maturities (18 ) (532 ) (550 ) Long-term portion of lease liabilities $ 5 $ 929 $ 934

Note 19 - Reportable Segments

Note 19 - Reportable Segments	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 19. The Company has two 19 340B 340B The Company evaluates the performance of each of the segments based on profit or loss after general and administrative expenses. While the Company believes there are synergies between the two For the Three Months Ended March 31, 2024 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ — $ 11,324 $ — $ 11,324 e-Commerce revenue 2,865 — — 2,865 Pharmacy 340B contract revenue — 3,304 — 3,304 Revenues, net $ 2,865 $ 14,628 $ — $ 17,493 Expenses: Cost of revenue 2,060 10,623 — 12,683 Selling, general and administrative 1,166 899 (60 ) 2,005 Salaries, wages and payroll taxes 508 2,116 — 2,624 Impairment loss — 132 — 132 Professional fees 507 478 — 985 Depreciation and amortization 130 776 — 906 4,371 15,024 (60 ) 19,335 Loss before other (income) expense (1,506 ) (396 ) 60 (1,842 ) Other (expense) income (203 ) (25 ) (60 ) (168 ) Loss before income taxes (1,303 ) (371 ) — (1,674 ) Income taxes (27 ) — — (27 ) Net loss $ (1,330 ) $ (371 ) $ — $ (1,701 ) For the Three Months Ended March 31, 2023 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ — $ — $ — $ — e-Commerce revenue 2,876 — — 2,876 Pharmacy 340B contract revenue — — — — Revenues, net $ 2,876 $ — $ — $ 2,876 Expenses: Cost of revenue 2,255 — — 2,255 Selling, general and administrative 788 — — 788 Salaries, wages and payroll taxes 588 — — 588 Professional fees 321 — — 321 Depreciation and amortization 162 — — 162 4,114 — — 4,114 Loss before other (income) expense (1,238 ) — — (1,238 ) Other (expense) income (83 ) — — (83 ) Loss before income taxes (1,155 ) — — (1,155 ) Income taxes — — — — Loss before equity method investment (1,155 ) — — (1,155 ) Equity in net loss of affiliate (32 ) — — (32 ) Net loss $ (1,187 ) $ — $ — $ (1,187 ) e-Commerce Operations Healthcare Operations Eliminations Total Total assets as of March 31, 2024 $ 40,342 $ 41,398 $ (16,679 ) $ 65,061 Total assets as of December 31, 2023 $ 40,764 $ 40,384 $ (16,679 ) $ 64,469	Note 23. Reportable Segments The Company has two 19 340B 340B The Company evaluates the performance of each of the segments based on profit or loss after general and administrative expenses. While the Company believes there are synergies between the two The following tables present a summary of the reportable segments (in thousands): For the Twelve Months Ended December 31, 2023 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ — $ 21,412 $ — $ 21,412 e-Commerce revenue 10,977 — — 10,977 Pharmacy 340B contract revenue — 5,367 — 5,367 Revenues, net $ 10,977 $ 26,779 $ — $ 37,756 Expenses: Cost of revenue 8,122 18,323 — 26,445 Selling, general and administrative 6,633 3,277 — 9,910 Salaries, wages and payroll taxes 2,670 3,973 — 6,643 Goodwill impairment — 13,895 — 13,895 Professional fees 1,595 506 (120 ) 1,981 Depreciation and amortization 647 1,463 — 2,110 Total expenses 19,667 41,437 (120 ) 60,984 Loss before other (income) expense $ (8,690 ) $ (14,658 ) $ 120 $ (23,228 ) For the Twelve Months Ended December 31, 2022 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ — $ — $ — $ — e-Commerce revenue 11,710 — — 11,710 Pharmacy 340B contract revenue — — — — Revenues, net $ 11,710 $ — $ — $ 11,710 Expenses: Cost of revenue 9,221 — — 9,221 Selling, general and administrative 5,085 — — 5,085 Salaries, wages and payroll taxes 2,565 — — 2,565 Professional fees 1,552 — — 1,552 Depreciation and amortization 490 — — 490 Total expenses 18,913 — — 18,913 Loss before other (income) expense $ (7,203 ) $ — $ — $ (7,203 ) e-Commerce Operations Healthcare Operations Eliminations Total Total assets as of December 31, 2023 $ 40,764 $ 40,384 $ (16,679 ) $ 64,469 Total assets as of December 31, 2022 $ 28,644 $ — $ — $ 28,644 Capital expenditures for the year ended December 31, 2023

Note 20 - Concentrations

Note 20 - Concentrations	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	Note 20. e-Commerce operations concentrations: Customers: Sales to customers through Amazon accounted for 39.9% and 57.2% of the Company’s revenues during the three March 31, 2024 2023 No 10% Suppliers: The following table sets forth information as to each supplier that accounted for 10% three March 31, 2024 2023 For the Three Months Ended March 31, 2024 For the Three Months Ended March 31, 2023 Globalstar Europe $ 213 10.2 % $ — — % Garmin $ 301 14.3 % $ 594 20.9 % Iridium Satellite $ 270 27.2 % $ — — % Geographic The following table sets forth revenue as to each geographic location, for the (in thousands, unaudited): For the Three Months Ended March 31, 2024 For the Three Months Ended March 31, 2023 Europe $ 1,430 49.9 % $ 2,063 71.7 % North America 523 18.3 % 586 20.4 % South America 23 0.8 % 9 0.3 % Asia and Pacific 413 14.4 % 159 5.5 % Africa 476 16.6 % 59 2.1 % $ 2,865 100 % $ 2,876 100 % Healthcare operations concentrations: Suppliers: Progressive Care had significant concentrations with one vendor. The purchases from this significant vendor were 98% of total vendor purchases for the three March 31, 2024 Customers: Progressive Care s trade receivables are primarily from prescription medications billed to various insurance providers. Ultimately, the insured is responsible for payment should the insurance company not Progressive Care derives a significant portion of sales from prescription drug sales reimbursed through prescription drug plans administered by pharmacy benefit managers (“PBM”) companies. Prescription reimbursements from our three Three Months Ended March 31, 2024 A 33 % B 21 % C 16 %	Note 26. e-Commerce operations concentrations: Customers: Amazon accounted for 51.6% and 54.3% of the Company’s revenues during the years ended December 31, 2023 2022 No 10% Suppliers: The following table sets forth information as to each supplier that accounted for 10% December 31, 2023 2022 December 31, 2023 December 31, 2022 Garmin $ 1,921 22.4 % $ 1,821 20.9 % Globalstar Europe $ 958 11.2 % $ 635 7.3 % Network Innovations $ 935 10.7 % $ 980 11.2 % Iridium Satellite $ 913 10.9 % $ — — % Satcom Global $ 761 8.9 % $ 744 8.5 % Geographic The following table sets forth revenue as to each geographic location, for the years ended December 31, 2023 2022 Year Ended Year Ended December 31, 2023 December 31, 2022 Europe $ 6,687 60.9 % $ 8,617 73.7 % North America 2,575 23.4 % 2,152 18.3 % South America 62 0.6 % 45 0.4 % Asia and Pacific 1,510 13.8 % 760 6.5 % Africa 143 1.3 % 136 1.1 % $ 10,977 100.0 % $ 11,710 100.0 % Healthcare operations concentrations: Suppliers: Progressive Care had significant concentrations with one vendor. The purchases from this significant vendor were approximately 99.0% of total vendor purchases for the six December 31, 2023 Customers: Progressive Care s trade receivables are primarily from prescription medications billed to various insurance providers. Ultimately, the insured is responsible for payment should the insurance company not Progressive Care generated reimbursements from three six December 31, 2023 2023 A 31 % B 29 % C 14 %

Note 21 - Subsequent Events

Note 21 - Subsequent Events	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Subsequent Events [Text Block]	Note 21. Acquisition of Outfitter Satellite On March 25, 2024, fitter Satellite, Inc. (“Outfitter”) in an all-cash transaction for an aggregate purchase price of $760,000.00, subject to certain adjustments (the “Aggregate Consideration”). The closing of the transaction occurred on April 1, 2024 At the closing, $660,000.00 of the Aggregate Consideration was paid to Mr. McKinley with the remaining $100,000.00 to be paid upon delivery of Outfitter’s audited financial statements for the 2022 2023 Outfitter provides consumers, commercial and government customers, with advanced satellite-based connectivity solutions from leading brands, including Iridium, Inmarsat and Globalstar. RXMD Merger On April 12, 2024, Merger Agreement Merger Sub Merger On April 9, 2024, Company Lock-Up Agreements Parent Lock-Up Agreements Hybrid Lock-Up Agreements Lock-Up Agreements no	Note 27. On March 25, 2024, April 1, 2024.

Note 1 - Organization and Nat_2

Note 1 - Organization and Nature of Operations.	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Nature of Operations [Text Block]	1. The term “Company” refers to NextPlat Corp and its wholly, majority owned and controlled subsidiaries, except where the context requires otherwise or where otherwise indicated. NextPlat Corp: NextPlat Corp, a Nevada corporation (the “Company”, “NextPlat”, “we”), formerly Orbsat Corp was incorporated in 1997. two 25 third Web3 Our wholly-owned subsidiary, Global Telesat Communications Limited (“GTC”), was formed under the laws of England and Wales in 2008. February 19, 2015, Our wholly-owned subsidiary, Orbital Satcom Corp. (“Orbital Satcom”), a Nevada corporation, was formed on November 14, 2014. On June 22, 2022, not Progressive Care Inc.: Progressive Care Inc. (“Progressive Care”) was incorporated under the laws of the state of Delaware on October 31, 2006. Progressive, through its wholly-owned subsidiaries, Pharmco, LLC (“Pharmco 901” 1002, 1002” 1103 1204 1103” 1204” Pharmco 901 November 29, 2005 901 October 21, 2010. 901 not Pharmco 1103 1103 June 1, 2019. Pharmco 1002 1002 July 1, 2018. ClearMetrX was formed on June 10, 2020 third 340B RXMD Therapeutics was formed on October 1, 2019. no Florida Sunshine Brands, LLC: Florida Sunshine Brands, LLC (“Florida Sunshine”) is a Florida limited liability company and incorporated December 6, 2023.	Note 1. Nature of Operations. The term “Company” refers to NextPlat Corp and its wholly, majority owned and controlled subsidiaries, except where the context requires otherwise or where otherwise indicated. NextPlat Corp: NextPlat Corp, a Nevada corporation (the “Company”, “NextPlat”, “we”), formerly Orbsat Corp was incorporated in 1997. two 25 third Our wholly-owned subsidiary, Global Telesat Communications Limited (“GTC”), was formed under the laws of England and Wales in 2008. February 19, 2015, Our wholly-owned subsidiary, Orbital Satcom Corp. (“Orbital Satcom”), a Nevada corporation, was formed on November 14, 2014. On June 22, 2022, not Progressive Care Inc.: Progressive Care Inc. (“Progressive Care”) was incorporated under the laws of the state of Delaware on October 31, 2006. Progressive, through its wholly-owned subsidiaries, Pharmco, LLC (“Pharmco 901” 1002, 1002” 1103 1204 1103” 1204” Pharmco 901 November 29, 2005 901 October 21, 2010. 901 not Pharmco 1103 1103 June 1, 2019. Pharmco 1002 1002 July 1, 2018. ClearMetrX was formed on June 10, 2020 third 340B RXMD Therapeutics was formed on October 1, 2019. no

Note 2 - Basis of Presentatio_2

Note 2 - Basis of Presentation and Principles of Consolidation	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	Note 2. The accompanying Condensed Consolidated Financial Statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”), consistent in all material respects with those applied in the 2023 10 not 2023 10 not Business acquisition of Progressive Care, Inc. On July 1, 2023, July 1, 2023, The exercise of the stock options, along with the entry into the voting agreement, resulted in a change in control of Progressive Care under the voting interest model in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 805, Business Combination, July 1, 2023. The accompanying Unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany transactions and balances have been eliminated in consolidation. Use of Estimates In preparing the Consolidated Financial Statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the statements of financial condition, and revenues and expenses for the years then ended. Actual results may not	Note 2. These consolidated financial statements have been prepared by management in accordance with general accepted accounting principles in the United States of America (“U.S. GAAP”) and this basis assumes that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Business acquisition of Progressive Care, Inc. On July 1, 2023, July 1, 2023, The exercise of the stock options, along with the entry into the voting agreement, resulted in a change in control of Progressive Care under the voting interest model in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 805, Business Combination, July 1, 2023. The accompanying Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany transactions and balances have been eliminated in consolidation. Use of Estimates In preparing the Consolidated Financial Statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the statements of financial condition, and revenues and expenses for the years then ended. Actual results may not Reclassification Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no

Note 3 - Summary of Significa_2

Note 3 - Summary of Significant Accounting Policies	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 3. The significant accounting policies of the Company were described in Note 1 10 December 31, 2023 no three March 31, 2024. Cash The Company places its cash with high credit quality financial institutions. The Company’s account at these institutions are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. All cash amounts in excess of $250,000, approximately $1.0 million, are unsecured. The Company has a deposit placement agreement for Insured Cash Sweep Service (“ICS”). This service is a secure, and convenient way to access FDIC protection on large deposits, earn a return, and enjoy flexibility. The Company believes that the ICS agreement will mitigate its credit risk as it relates to uninsured FDIC amounts in excess of $250,000. Foreign Currency Translation The Company’s reporting currency is U.S. Dollars. The accounts of one The relevant translation rates are as follows: for the three March 31, 2024 three March 31, 2023 December 31, 2023 Unearned Revenue Contract liabilities are shown separately in the condensed consolidated balance sheets as current liabilities. At March 31, 2024 December 31, 2023 Direct and Indirect Remuneration ( “ DIR ” ) Progressive Care reports DIR fees as a reduction of revenue on the accompanying Consolidated Statements of Operations. DIR fees are fees charged by PBMs to pharmacies for network participation as well as periodic reimbursement reconciliations. The Company accrues an estimate of PBM fees, including DIR fees, which are assessed or expected to be assessed by payers at some point after adjudication of a claim, as a reduction of prescription revenue at the time revenue is recognized. Changes in the estimate of such fees are recorded as an adjustment to revenue when the change becomes known. Through December 31, 2023, not two two three January – April 20xx July – August 20xx December 31, 2023, not second 2024. may January 1, 2024, Recent Accounting Pronouncements Accounting Pronouncements Issued but not In November 2023, 2023 07, 280 2023 07” 2023 07 December 15, 2023, December 15, 2024, Q1 2025, December 31, 2024. not In December 2023, 2023 09, 740 2023 09” 2023 09 December 15, 2024, January 1, 2025. not Other accounting standards that have been issued or proposed by FASB that do not not Subsequent Events The Company has evaluated subsequent events through May 15, 2024, 21	Note 3. The significant accounting policies of the Company are described below the fiscal year ended December 31, 2023. July 1, 2023 December 31, 2023. Discontinued Operations The Company’s former operations were developing and manufacturing products and services, which reduce fuel costs, save power and energy and protect the environment. The products and services were made available for sale into markets in the public and private sectors. In December 2009, The remaining liabilities for discontinued operations are presented in the consolidated balance sheets under the caption “Liabilities from discontinued operation” and relates to the discontinued operations of developing and manufacturing of energy saving and fuel-efficient products and services. The carrying amounts of the major classes of these liabilities as of December 31, 2023 2022 December 31, 2023 December 31, 2022 Assets of discontinued operations $ — $ — Liabilities Accounts payables and accrued expenses $ — $ (112 ) Liabilities from discontinued operations $ — $ (112 ) Liquidity January 2022 On December 31, 2021, “December “December January 2, 2022, December December 31, 2021. December December 31, 2021. The closing of the December January 5, 2022. December December 2022 On December 9, 2022, three On December 9, 2022, three six The offering closed on December 14, 2022, April 2023 On April 5, 2023, April 4, 2023. April 11, 2023, 4 2 506 As of the date of this report, the Company’s existing cash resources and existing borrowing availability are sufficient to support planned operations for the next 12 one Cash and Cash Equivalents The Company places its cash with high credit quality financial institutions. The Company’s account at this institution is insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. All cash amounts in excess of $250,000, approximately $3.1 million, are unsecured. In April 2023, $250,000. Accounts Receivable and Allowance for Doubtful Accounts The Company has a policy of reserving for questionable accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may may Progressive Care trade accounts receivable are stated at the invoiced amount. Trade accounts receivable primarily include amounts from third no Inventories Inventories are valued at the lower of cost or net realizable value, using the first first not Prepaid Expenses Prepaid expenses current and long term amounted to approximately $640,000 and $61,000, respectively for the year ended December 31, 2023 December 31, 2022 Investments The Company applies the equity method of accounting to investments when it has significant influence, but not 15 The Company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not December 31, 2023 not Foreign Currency Translation The Company’s reporting currency is U.S. Dollars. The accounts of one The relevant translation rates are as follows: for the year ended December 31, 2023 December 31, 2022 Revenue Recognition and Unearned Revenue In accordance with ASU No. 2016 12, Revenue from Contracts with Customers (Topic 606 1 606 10 25 7; 2 3 4 5 6 606 not December 15, 2017, no one e-Commerce Operations: The Company recognizes revenue from satellite services when earned, as services are rendered or delivered to customers. Equipment sales revenue is recognized when the equipment is delivered to and accepted by the customer. Only equipment sales are subject to warranty. Historically, the Company has not The Company’s customers generally purchase a combination of our products and services as part of a multiple element arrangement. The Company’s assessment of which revenue recognition guidance is appropriate to account for each element in an arrangement can involve significant judgment. This assessment has a significant impact on the amount and timing of revenue recognition. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, five five 606, Contract liabilities are shown separately in the consolidated balance sheets as current liabilities. At December 31, 2023 December 31, 2022 Healthcare Operations: The Company provides prescription pharmaceuticals, COVID- 19 340B 340B 340B 340B The Company recognizes product sales from prescriptions dispensed to patients (customers) at the time the drugs are physically delivered to a customer or when a customer picks up their prescription, which is the point in time when control transfers to the customer. 340B 340B third 340B 340B not not The Company accrues an estimate of PBM fees, including direct and indirect remuneration (“DIR”) fees, which are assessed or expected to be assessed by payers at some point after adjudication of a claim, as a reduction of prescription revenue at the time revenue is recognized. Changes in the estimate of such fees are recorded as an adjustment to revenue when the change becomes known. DIR fees are fees charged by PBMs to pharmacies for network participation as well as periodic reimbursement reconciliations. For some PBMs, DIR fees are charged at the time of the settlement of a pharmacy claim. Other PBMs do not two two three January – April 2023 July – August 2023). not may Billings for most prescription orders are with third The Company recognizes revenue from TPA services as it satisfies the performance obligations under the TPA contract with a 340B one may not For each TPA contract, the Company recognizes revenue by measuring the progress toward complete satisfaction of each performance obligation. The Company uses various observable output methods in measuring progress toward satisfaction of each performance obligation, most notably gross billings under each contract. ASC 606 may The Company recognizes COVID- 19 Cost of Product Sales and Services Cost of sales consists primarily of materials, airtime and overhead costs incurred internally and amounts incurred to contract manufacturers to produce our products, airtime and other implementation costs incurred to install our products and train customer personnel, and customer service and third Shipping and handling costs are included as a component of costs of product sales in the Company’s consolidated statements of operations because the Company includes in revenue the related costs that the Company bills its customers. Advertising Costs incurred for producing and communicating advertising for the Company are charged to operations as incurred. Advertising expense was approximately $188,000 and $93,000 for the years ended December 31, 2023 2022 Intangible Assets Acquired intangible assets with finite lives other than goodwill are amortized over their useful lives. For intangible assets acquired in a business combination, the estimated fair values of the assets received are used to establish their recorded values. Acquired intangible assets other than goodwill are amortized over their useful lives unless the lives are determined to be indefinite. Valuation techniques consistent with the market approach, income approach, and/or cost approach are used to measure fair value. Intangible assets subject to amortization represent the fair value of pharmacy records, tradenames and customer contracts acquired, and capitalized software development costs. In valuing these assets, the Company makes assumptions regarding useful lives and projected growth rates, and significant judgment is required. The Company periodically reviews its identifiable intangible assets for impairment as events or changes in circumstances indicate that the carrying amount of such assets may not Pharmacy records and developed software are amortized over 5 years. Tradenames and customer contracts are amortized over 10 years. Useful lives of intangible assets are periodically evaluated for reasonableness and the assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may no Business acquisitions The Company records business acquisitions using the acquisition method of accounting. All of the assets acquired, liabilities assumed, and contractual contingencies are recognized at their fair value on the acquisition date. The application of the acquisition method of accounting for business combinations requires management to make significant estimates and assumptions in the determination of the fair value of assets acquired and liabilities assumed in order to properly allocate purchase price consideration between assets that are depreciated and amortized and goodwill. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Acquisition-related expenses and restructuring costs are recognized separately from the business combination and are expensed as incurred. The Company uses a measurement period following the acquisition date to gather information that existed as of the acquisition date that is needed to determine the fair value of the assets acquired, liabilities assumed and equity interests. The measurement period ends once all information is obtained, but no one Goodwill Goodwill represents the excess of the purchase price over the value assigned to net tangible and identifiable intangible assets. Progressive Care, which is our Healthcare Operations, is considered to be the reporting unit for goodwill. Valuation techniques consistent with the market approach, income approach, and/or cost approach are used to measure fair value. Goodwill and other indefinite-lived intangible assets are assessed annually for impairment in the fourth may Property and Equipment Property and equipment are carried at historical cost less accumulated depreciation. Depreciation is based on the estimated service lives of the depreciable assets and is calculated using the straight-line method. Expenditures that increase the value or productive capacity of assets are capitalized. Fully depreciated assets are retained in the property and equipment, and accumulated depreciation accounts until they are removed from service. When property and equipment are retired, sold or otherwise disposed of, the asset’s carrying amount and related accumulated depreciation are removed from the accounts and any gain or loss is included in operations. Repairs and maintenance are expensed as incurred. The estimated useful lives of property and equipment are generally as follows: Years Building 40 Building improvements Remaining life of the building Leasehold improvements Lessor of the estimated useful life or life of the lease Office furniture and fixtures 4-5 Computer equipment 3-4 Rental equipment 4 Vehicles 3-5 Appliques 10 Website development 2 Depreciation expense for the years ended December 31, 2023 2022 Impairment of Long-lived Assets The Company reviews its long-lived assets, comprised of property and equipment, right-of-use assets, and intangible assets, whenever events or changes in circumstances indicate that the carrying amount of an asset may not 360 10, Accounting for the Impairment or Disposal of Long-Lived Assets the assets to the fair value based on estimated discounted future cash flows. If required, an impairment loss is recorded for that portion of the asset’s carrying value in excess of fair value. As of December 31, 2023, no not December 31, 2023 and December 31, 2022 , respectively. Fair Value of Financial Instruments Derivatives are required to be recorded on the balance sheet at fair value. These derivatives, including embedded derivatives in the Company’s structured borrowings, are separately valued and accounted for on the Company’s balance sheet. Fair values for exchange traded securities and derivatives are based on quoted market prices. Where market prices are not The Company did not Stock-based Compensation Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 The Company estimated the fair value of stock options granted using the Black-Scholes option-pricing formula. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The Company’s determination of the fair value using the option-pricing model is affected by the stock price as well as assumptions regarding the number of highly subjective variables. In June 2018, 2018 07, 718 718, December 15, 2018. January 1, 2019. Income Taxes The Company accounts for income taxes pursuant to the provision of ASC 740 10, 740 10” not not The Company follows the provision of ASC 740 10 may 740 10, not not Tax positions that meet the more likely than not 50 The Company believes its tax positions are all more likely than not not The Company has adopted ASC 740 10 25, not not three Leases Effective January 1, 2019, 842, Leases not In calculating the right of use asset and lease liability, the Company has elected to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 Research and Development The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730 10, 730 10” 730 10, December 31, 2023 2022 no Accumulated Other Comprehensive Income (Loss) Comprehensive income (loss) is comprised of net income (loss) and all changes to the statements of stockholders’ equity. For the Company, comprehensive income (loss) for the years ended December 31, 2023 2022 Earnings per Common Share Net income (loss) per common share is calculated in accordance with ASC Topic 260: 260” not Related Party Transactions A party is considered to be related to the Company if the party directly or indirectly or through one may one one one one 25 Recent Accounting Pronouncements Accounting Pronouncements Recently Adopted In August 2023, 2023 04, 405 No. 121”, No. 121. In July 2023, 2023 03, 205 220 480 505 718 No. 120, no In June 2016, 2016 13, 326 2016 13” November 2018, 2018 19, 326, not April 2019, 2019 04, 326, 815, 825, 2016 13. March 2020, 2020 03, 842 326. 2016 13 December 15, 2022, Any new accounting standards, not not not Accounting Pronouncements Issued but not In December 2023, 2023 09, 740 2023 09” 2023 09 December 15, 2024, January 1, 2025. not In November 2023, 2023 07, 280 2023 07” 2023 07 December 15, 2023, December 15, 2024, January 1, 2024. not Management has evaluated other recently issued accounting pronouncements and does not

Note 4 - Acquisition

Note 4 - Acquisition	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Business Combination Disclosure [Text Block]	Note 4. On July 1, 2023, Also, on July 1, 2023, As a result of the RXMD Warrant exercises and the entry into the voting agreement, the Company concluded that there was a change in control in Progressive Care. As of July 1, 2023, 50% July 1, 2023, July 1, 2023 805. July 1, 2023. Progressive Care contributed revenues of approximately $26.8 million and a net loss of approximately $14.7 million to the Company for the period from July 1, 2023 December 31, 2023. January 1, 2023 ( For the Year Ended December 31, 2023 For the Year Ended December 31, 2022 (Unaudited) (Unaudited) Revenue $ 60,704 $ 52,312 Earnings $ (15,854 ) $ (13,867 ) The Company did not The following table summarizes the consideration transferred to acquire a controlling interest in Progressive Care and the amounts of identified assets acquired and liabilities assumed at the acquisition date, as well as the fair value of the noncontrolling interest in Progressive Care at the acquisition date (in thousands): Purchase Price Allocation Total purchase consideration $ 16,679 Fair value of non-controlling interest 23,180 Total consideration $ 39,859 Identifiable net assets acquired: Cash $ 7,352 Accounts receivable, net 6,478 Accounts receivable, other 506 Inventory 1,631 Prepaid expenses 220 Property and equipment, net 2,883 Right of use assets, net 405 Intangible assets, net: Trade name 4,700 Development technology 2,880 Pharmacy records 8,130 Deposits 39 Accounts payable and accrued expenses (8,231 ) Notes payable and accrued interest - current portion (149 ) Lease liabilities - current portion (208 ) Notes payable - long term (1,173 ) Lease liabilities - long term (230 ) Deferred tax liability (1) — Net assets acquired $ 25,233 Goodwill $ 14,626 ( 1 no not not July 1, 2023, December 31, 2023 805 740 45 2, The total consideration is based on the fair value of the Company’s common stock outstanding at July 1, 2023, July 1, 2023 July 1, 2023 July 1, 2023. As a result of NextPlat obtaining control over Progressive Care, NextPlat’s previously held equity interest in Progressive Care was remeasured to fair value, resulting in a gain of approximately $11.4 million , which has been recognized in the line item “Gain on remeasurement of fair value of equity interest in affiliate prior to acquisition” on the condensed consolidated statements of comprehensive income (loss). The fair value of the noncontrolling interest of approximately $23.2 million and the fair value of the previously held equity interest of approximately $16.7 million in Progressive Care were estimated by applying a market approach and an income approach, respectively. These fair value measurements of the noncontrolling interest and the previously held equity interest are based on significant inputs not 3 1 2 3 4 The goodwill is attributable to the workforce of the acquired business and the significant synergies expected to arise after NextPlat’s acquisition of a controlling interest in Progressive Care. The goodwill is not The initial recognition of the Progressive Care's identifiable intangible assets, resulting from the acquisition on July 1, 2023 3

Note 5 - Fair Value

Note 5 - Fair Value	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 4. Accounting standards define fair value as the price that would be received from selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards establish a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value and also establishes the following three may Level 1: Level 2: 1 not Level 3: no The following methods and assumptions were used by the Company in estimating fair value disclosures for financial instruments: ● Cash, accounts receivable, and accounts payable and accrued liabilities: ● Notes payable and lease liabilities: 2 Identifiable Intangible Assets The initial recognition of the Progressive Care's identifiable intangible assets, resulting from the acquisition on July 1, 2023 3	Note 5. Accounting standards define fair value as the price that would be received from selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards establish a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value and also establishes the following three may Level 1: Level 2: 1 not Level 3: no The following methods and assumptions were used by the Company in estimating fair value disclosures for financial instruments: ● Cash, accounts receivable, and accounts payable and accrued liabilities: ● Notes payable and lease liabilities: 2

Note 6 - Revenue

Note 6 - Revenue	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	Note 5. e-Commerce r The Company recognizes revenue from satellite services when earned, as services are rendered or delivered to customers. Equipment sales revenue is recognized when the equipment is delivered to and accepted by the customer. Only equipment sales are subject to warranty. Historically, the Company has not Healthcare revenue: The Company recognizes pharmacy revenue and 340B third The Company accrues an estimate of pharmacy benefit manager (“PBM”) fees, including direct and indirect remuneration (“DIR”) fees, which are assessed or expected to be assessed by payers at some point after adjudication of a claim, as a reduction of revenue at the time revenue is recognized. Changes in the estimate of such fees are recorded as an adjustment to revenue when the change becomes known. The Company recognizes COVID- 19 The following table disaggregates net revenues by categories (in thousands): Three Months Ended March 31, 2024 2023 Sales of products, net: Pharmacy prescription and other revenue, net of PBM fees $ 11,324 $ — e-Commerce revenue 2,865 2,876 Sub total 14,189 2,876 Revenues from services: Pharmacy 340B contract revenue 3,304 — Revenues, net $ 17,493 $ 2,876	Note 6. e-Commerce revenue: The Company recognizes revenue from satellite services when earned, as services are rendered or delivered to customers. Equipment sales revenue is recognized when the equipment is delivered to and accepted by the customer. Only equipment sales are subject to warranty. Historically, the Company has not Healthcare revenue: The Company recognizes pharmacy revenue and 340B third The Company accrues an estimate of pharmacy benefit manager (“PBM”) fees, including direct and indirect remuneration (“DIR”) fees, which are assessed or expected to be assessed by payers at some point after adjudication of a claim, as a reduction of revenue at the time revenue is recognized. Changes in the estimate of such fees are recorded as an adjustment to revenue when the change becomes known. The Company recognizes COVID- 19 The following table disaggregates net revenues by categories (in thousands): For the Twelve Months Ended December 31, 2023 e-Commerce Operations Healthcare Operations Total Sales of products, net Prescription revenue, net of PBM fees $ — $ 21,412 $ 21,412 e-Commerce revenue 10,977 — 10,977 Subtotal 10,977 21,412 32,389 Revenues from services: Pharmacy 340B contract revenue — 5,367 5,367 Revenues, net $ 10,977 $ 26,779 $ 37,756 For the Twelve Months Ended December 31, 2022 e-Commerce Operations Healthcare Operations Total Sales of products, net Prescription revenue, net of PBM fees $ — $ — $ — e-Commerce revenue 11,710 — 11,710 Subtotal 11,710 — 11,710 Revenues from services: Pharmacy 340B contract revenue — — — Revenues, net $ 11,710 $ — $ 11,710

Note 7 - Earnings (Loss) Per Sh

Note 7 - Earnings (Loss) Per Share	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 6. Net income (loss) per common share is calculated in accordance with Accounting Standards Codification (“ASC”) Topic 260: 260” not The components of basic and diluted EPS were as follows (in thousands, except per share data). Three Months Ended March 31, 2024 2023 Net loss attributable to NextPlat Corp common shareholders $ (1,481 ) $ (1,187 ) Basic weighted average common shares outstanding 18,725 14,415 Potentially dilutive common shares — — Diluted weighted average common shares outstanding 18,725 14,415 Weighted average loss per common share - basic and diluted $ (0.08 ) $ (0.08 ) Potentially dilutive common shares excluded from the calculation of diluted weighted average loss per common share: Stock options 105 100 105 100	Note 7. Net income (loss) per common share is calculated in accordance with Accounting Standards Codification (“ASC”) Topic 260: 260” not Year Ended December 31, 2023 2022 Net loss attributable to NextPlat Corp common shareholders $ (3,778 ) $ (9,161 ) Basic weighted average common shares outstanding 17,494 9,592 Potentially dilutive common shares — — Diluted weighted average common shares outstanding 17,494 9,592 Basic weighted average earnings (loss) per common share $ (0.22 ) $ (0.96 ) Diluted weighted average earnings (loss) per common share $ (0.22 ) $ (0.96 ) Potentially dilutive common shares excluded from the calculation of diluted weighted average loss per common share: Stock options 136 265 Common stock purchase warrants 675 1,403 811 1,668

Note 8 - Accounts Receivable

Note 8 - Accounts Receivable	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Accounts Receivable [Member]
Notes to Financial Statements
Accounts and Nontrade Receivable [Text Block]	Note 7. At March 31, 2024 December 31, 2023 March 31, 2024 December 31, 2023 (Unaudited) (Audited) Gross accounts receivable – trade $ 13,202 $ 9,195 Less: allowance for doubtful accounts (274 ) (272 ) Accounts receivable – trade, net $ 12,928 $ 8,923 The Company increased the allowance for credit losses in the amount of approximately $2,000 and $0 for the three March 31, 2024 2023 Accounts receivable – trade, net for the Company as of January 1, 2023 March 31, 2023	Note 8. At December 31, 2023 2022 Year Ended December 31, 2023 2022 Gross accounts receivable – trade $ 9,195 $ 384 Less: allowance for doubtful accounts (272 ) — Accounts receivable – trade, net $ 8,923 $ 384 Bad debt expense was approximately $47,000 and $0 for the twelve December 31, 2023 2022 The increase in accounts receivable was attributable to the consolidation of Progressive Care at July 1, 2023.

Note 9 - Accounts Receivable -

Note 9 - Accounts Receivable - Other, net	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Accounts Receivable, Other, Net [Text Block]	Note 9. At December 31, 2023 2022 Year Ended December 31, 2023 2022 Performance bonuses $ 1,602 $ — Customers 192 — Other 52 — $ 1,846 $ — Performance bonuses, paid annually by PBMs, are estimated based on historical pharmacy performance and prior payments received. Other receivables are loans to employees. The increase in accounts receivable - other was attributable to the consolidation of Progressive Care at July 1, 2023.

Note 10 - Inventory

Note 10 - Inventory	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Inventory Disclosure [Text Block]	Note 8. At March 31, 2024 December 31, 2023 March 31, 2024 December 31, 2023 (Unaudited) (Audited) Finished goods $ 5,670 $ 5,195 Less reserve for obsolete inventory (60 ) (60 ) Total $ 5,610 $ 5,135	Note 10. At December 31, 2023 2022 December 31, 2023 December 31, 2022 Finished goods $ 5,195 $ 1,287 Less reserve for obsolete inventory (60 ) — Total $ 5,135 $ 1,287 The increase in inventory was attributable to the consolidation of Progressive Care as of July 1, 2023.

Note 11 - VAT Receivable

Note 11 - VAT Receivable	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
VAT Accounts Receivable [Text Block]	Note 9. On January 1, 2021, March 31, 2024 December 31, 2023	Note 11. On January 1, 2021, December 31, 2023 2022 $433,000

Note 12 - Prepaid Expenses

Note 12 - Prepaid Expenses	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Prepaid Expenses [Text Block]	Note 10. Prepaid expenses current and long term amounted to approximately $404,000 and $61,000, respectively at March 31, 2024 December 31, 2023	Note 12. Prepaid expenses current and long term amounted to approximately $640,000 and $61,000, respectively at December 31, 2023 $46,000 $49,000 December 31, 2022 The increase in prepaid expenses was attributable to the consolidation of Progressive Care as of July 1, 2023.

Note 13 - Property and Equipmen

Note 13 - Property and Equipment, Net	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 11. Property and equipment, net consisted of the following (in thousands): March 31, 2024 December 31, 2023 (Unaudited) (Audited) Building $ 2,116 $ 2,116 Vehicles 585 595 Office furniture and fixtures 543 527 Land 184 184 Leasehold improvements 167 124 Computer equipment 117 117 Rental equipment 63 60 Appliques 2,160 2,160 Website development 611 587 Construction in progress — 22 Property and equipment gross 6,546 6,492 Less: accumulated depreciation (2,700 ) (2,503 ) Property and equipment, net $ 3,846 $ 3,989 Depreciation expense was approximately $203,000 and $155,000 for the three March 31, 2024 2023	Note 13. Property and equipment consisted of the following (in thousands): December 31, 2023 December 31, 2022 Building $ 2,116 $ — Vehicles 595 — Office furniture and fixtures 527 128 Land 184 — Leasehold improvements 124 48 Computer equipment 117 72 Rental equipment 60 38 Appliques 2,160 2,160 Website development 587 665 Construction in progress 22 — Property and equipment gross 6,492 3,111 Less: accumulated depreciation (2,503 ) (1,865 ) Property and equipment, net $ 3,989 $ 1,246 Depreciation expense was approximately $758,000 and $465,000 for the twelve December 31, 2023 2022 The increase in property and equipment was attributable to the consolidation of Progressive Care as of July 1, 2023.

Note 14 - Goodwill and Intangib

Note 14 - Goodwill and Intangible Assets, Net	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	Note 12. Intangible assets, net consisted of the following (in thousands): March 31, 2024 (Unaudited) Gross amount Accumulated amortization Net Amount Pharmacy records $ 8,130 $ (1,219 ) $ 6,911 Trade names 4,700 (353 ) 4,347 Developed technology 2,880 (432 ) 2,448 Customer Contracts 250 (231 ) 19 Total intangible assets $ 15,960 $ (2,235 ) $ 13,725 December 31, 2023 (Audited) Gross amount Accumulated amortization Net Amount Pharmacy records $ 8,130 $ (807 ) $ 7,323 Trade names 4,700 (224 ) 4,476 Developed technology 2,880 (281 ) 2,599 Customer Contracts 250 (225 ) 25 Total intangible assets $ 15,960 $ (1,537 ) $ 14,423 Amortization of customer contracts is included in depreciation and amortization in the accompanying Condensed Consolidated Statements of Comprehensive Income (Loss). For the three March 31, 2024 2023 Year Amount 2024 (remaining nine months) $ 2,023 2025 2,672 2026 2,672 2027 2,672 2028 1,571 Thereafter 2,115 Total $ 13,725	Note 14. Goodwill The following table reflects changes in the carrying amount of goodwill during the periods presented by reportable segments (in thousands): e-Commerce Operations Healthcare Operations Total Balances as of December 31, 2021 Goodwill $ — $ — $ — Accumulated impairment losses — — — Goodwill, net as of December 31, 2021 — — — Changes in Goodwill during the year ended December 31, 2022: Goodwill acquired — — — Impairment losses — — — Balances as of December 31, 2022 Goodwill — — — Accumulated impairment losses — — — Goodwill, net as of December 31, 2022 — — — Changes in Goodwill during the year ended December 31, 2023: Goodwill acquired — 14,626 14,626 Impairment losses — (13,895 ) (13,895 ) Balances as of December 31, 2023 Goodwill — 14,626 14,626 Accumulated impairment losses — (13,895 ) (13,895 ) Goodwill, net as of December 31, 2023 $ — $ 731 $ 731 1. Increase related to book tax difference of intangible assets arising from the business combination without transfer of consideration. The initial recognition of goodwill resulting from the acquisition of Progressive Care on July 1, 2023. December 31, 2023. The Company performed an annual impairment test as of December 31, 2023, 3. 11% 13.5%. As a result of the 2023 95% December 31, 2023. December 31, 2023. Intangible Assets Intangible assets, net consisted of the following (in thousands): December 31, 2023 Gross amount Accumulated amortization Net Amount Pharmacy records $ 8,130 $ (807 ) $ 7,323 Trade names 4,700 (224 ) 4,476 Developed technology 2,880 (281 ) 2,599 Customer Contracts 250 (225 ) 25 Total intangible assets $ 15,960 $ (1,537 ) $ 14,423 December 31, 2022 Gross amount Accumulated amortization Net Amount Pharmacy records $ — $ — $ — Trade names — — — Developed technology — — — Customer Contracts 250 (200 ) 50 Total intangible assets $ 250 $ (200 ) $ 50 Amortization of pharmacy records, trade names, developed technology, and customer contracts is included in depreciation and amortization in the accompanying Consolidated Statements of Comprehensive Income Loss. For the twelve December 31, 2023 2022 2024 $ 2,721 2025 2,672 2026 2,672 2027 2,672 2028 1,571 Thereafter 2,115 Total $ 14,423

Note 15 - Equity Method Investm

Note 15 - Equity Method Investment	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Equity Method Investments and Joint Ventures Disclosure [Text Block]	Note 15. On August 30, 2022, one one may In addition, on August 30, 2022, third On September 13, 2022, September 12, 2022, two October 7, 2022, On November 11, 2022, On December 29, 2022, one On May 5, 2023, one one three May 9, 2023, Simultaneous with the closing of the Unit Purchase on May 9, 2023, September 2, 2022, one three At the same time, Progressive Care and NextPlat entered into a First Amendment (the “Amendment”) to that certain Securities Purchase Agreement dated November 16, 2022 ( three As a result of the common stock purchase warrant exercises and the entry into the voting agreement as described in Note 4, July 1, 2023, 50% July 1, 2023, July 1, 2023 805. July 1, 2023. The following summarizes the Company’s consolidated balance sheet description equity method investment as follows as of December 31, 2023 Carrying Amount December 31, 2022, beginning balance $ 5,261 Investment in Progressive Care Inc. and Subsidiaries 1,506 Gain on equity method investment 11,352 Portion of loss from Progressive Care, Inc. and Subsidiaries (1,604 ) Depreciation expense due to cost basis difference (1) (49 ) Interest earned from convertible note receivable 21 Interest earned from amortization of premium on convertible note receivable 199 Elimination of intercompany interest earned (7 ) Change in accounting method as of July 1, 2023 (16,679 ) December 31, 2023, carrying amount $ — The following summarizes the Company’s consolidated statements of operations and comprehensive loss description equity in net loss of affiliate for the year ended December 31, 2023 For the Year Ended December 31, 2023 Portion of loss from Progressive Care, Inc. and Subsidiaries $ (1,604 ) Depreciation expense due to cost basis difference (1) (49 ) Interest earned from convertible note receivable 21 Interest earned from amortization of premium on convertible note receivable 199 Elimination of intercompany interest earned (7 ) Equity in net loss of affiliate $ (1,440 ) ( 1 NextPlat records depreciation expense on its estimated cost basis difference which is subject to change

Note 16 - Accounts Payable and

Note 16 - Accounts Payable and Accrued Expenses	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 13. Accounts payable and accrued expenses consisted of the following (in thousands): March 31, 2024 December 31, 2023 (Unaudited) (Audited) Accounts payable $ 13,978 $ 12,142 Accrued wages and payroll liabilities 378 200 Accrued PBM fees 366 571 Customer deposits payable 54 76 Accrued other liabilities 117 187 Total $ 14,893 $ 13,176	Note 16. Accounts payable and accrued expenses consisted of the following (in thousands): December 31, 2023 December 31, 2022 Accounts payable $ 12,142 $ 1,200 Accrued wages and payroll liabilities 200 23 Accrued PBM fees 571 — Customer deposits payable 76 86 Accrued legal fees — 85 Pre-merger accrued other liabilities — 88 Accrued other liabilities 187 41 Total $ 13,176 $ 1,523 The increase in accounts payable and accrued expenses was attributable to the consolidation of Progressive Care at July 1, 2023.

Note 17 - Notes Payable

Note 17 - Notes Payable	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 14. Notes payable consisted of the following (in thousands): March 31, 2024 December 31, 2023 (Unaudited) (Audited) A. Mortgage note payable - commercial bank - collateralized $ 1,118 $ 1,140 B. Note payable - uncollateralized 25 25 C. Notes payable - collateralized 229 255 Insurance premiums financing 26 103 Subtotal 1,398 1,523 Less: current portion of notes payable (233 ) (312 ) Long-term portion of notes payable $ 1,165 $ 1,211 (A) Mortgage Note Payable – collateralized In 2018, 400 December 14, 2028 January 2019, not December 14, 2028. (B) Note Payable – Uncollateralized As of March 31, 2024 (C) Notes Payable – Collateralized On July 16, 2020 ( £250,000, July 16, 2021, Base Rate July 16, 2020), July 15, 2026, first £4,166.67 13 July 16, 2020. 5 In April 2021, September 2021, March 31, 2024 December 31, 2023 In July 2022, January 2023. March 31, 2024 December 31, 2023 In September 2022, October 2022. March 31, 2024 December 31, 2023 Principal outstanding as of March 31, 2024 Year Amount 2024 (remaining nine months) $ 187 2025 215 2026 119 2027 124 2028 753 Thereafter — Total $ 1,398	Note 17. Notes payable consisted of the following (in thousands): December 31, 2023 December 31, 2022 A. Mortgage note payable - commercial bank - collateralized $ 1,140 $ — B. Note payable - uncollateralized 25 — C. Notes payable - collateralized 255 216 Insurance premiums financing 103 — Subtotal 1,523 216 Less: current portion of notes payable (312 ) (60 ) Long-term portion of notes payable $ 1,211 $ 156 (A) Mortgage Note Payable – collateralized In 2018, 400 December 14, 2028 January 2019, not December 14, 2028. (B) Note Payable – Uncollateralized As of December 31, 2023 (C) Notes Payable – Collateralized On July 16, 2020 ( £250,000, July 16, 2021, July 16, 2020), July 15, 2026, first £4,166.67 13 July 16, 2020. 5 December 31, 2023 In April 2021, September 2021, December 31, 2023 In July 2022, January 2023. December 31, 2023 In September 2022, October 2022. December 31, 2023 Principal outstanding as of December 31, 2023 Year Amount 2024 $ 312 2025 215 2026 119 2027 124 2028 753 Thereafter — Total $ 1,523

Note 18 - Equity

Note 18 - Equity	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Equity [Text Block]	Note 15. Equity Preferred Stock We have authorized 3,333,333 shares of $0.0001 par value of preferred stock. No preferred stock was outstanding for any year presented. As of March 31, 2024 Common Stock We have authorized 50,000,000 shares of $0.0001 par value common stock. As of March 31, 2024 Listing on the Nasdaq Capital Market Our common stock and warrants have been trading on the Nasdaq Capital Market under the symbols “NXPL” and “NXPLW,” respectively, since January 21, 2022. January 21, 2022, April 2023 On April 5, 2023, April 4, 2023. April 11, 2023, 4 2 506 not not may not For the three March 31, 2024 2023 three March 31, 2024 2023	Note 18. Preferred Stock We have authorized 3,333,333 shares of $0.0001 par value of preferred stock. No preferred stock was outstanding for any year presented. Common Stock We have authorized 50,000,000 shares of $0.0001 par value common stock. As of December 31, 2023 2022 Capital Structure On May 28, 2021, 1 No 1 5 Listing on the Nasdaq Capital Market Our common stock and warrants have been trading on the Nasdaq Capital Market under the symbols “NXPL” and “NXPLW,” respectively, since January 21, 2022. January 21, 2022, April 2023 On April 5, 2023, April 4, 2023. April 11, 2023, 4 2 506 not not may not December 2022 December ) On December 9, 2022, three The offering closed on December 14, 2022, On December 9, 2022, three six January 2022 January ) On January 2, 2022, The Company received gross proceeds from the sale of the common stock of $7,225,038. Legal and registration fees amounted to $220,000, resulting in net proceeds of approximately $7.0 million. Prior to the private placement close, proceeds of approximately $1.4 million, were received and recorded as a stock subscription payable, for the year ended December 31, 2022

Note 19 - Warrants

Note 19 - Warrants	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Warrants Disclosure [Text Block]	Note 19. Underwriter Warrants In addition to, but separate from, the registered warrants included in the units sold in the June June five June June As of December 31, 2023 2022 Placement Agent Warrants On December 9, 2022, December In addition to, but separate from, the unregistered warrants included in the units sold in the December three six As of December 31, 2023 2022 Stock Based Compensation Warrants For the year ended December 31, 2023 December 31, 2023 2022 A summary of the status of the Company’s total outstanding warrants and changes during the year ended December 31, 2023 Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Balance at January 1, 2022 2,530,092 $ 5.00 4.42 Granted 5,124,480 $ 1.75 3.05 Exercised — $ — — Forfeited — $ — — Cancelled — $ — — Balance outstanding and exercisable at December 31, 2022 7,654,572 $ 2.83 3.15 Balance at January 1, 2023 7,654,572 $ 2.83 3.15 Granted 20,000 $ 1.65 3.00 Exercised (105,000 ) $ 1.75 — Forfeited — $ — — Cancelled — $ — — Balance outstanding and exercisable at December 31, 2023 7,569,572 $ 2.85 2.15 As of December 31, 2023 December 31, 2022 As of December 31, 2022 As of December 31, 2023 The Company determined that the warrants do not 480

Note 20 - Stock-based Compensat

Note 20 - Stock-based Compensation	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	Note 20. For the years ended December 31, 2023 2022 Stock Award Plans The Company maintains stock incentive plans to attract, motivate and retain management, key employees, directors, and consultants. These plans provide for discretionary awards of, among others, stock options, stock awards, stock unit awards, and stock appreciation rights to participants (collectively, share-based awards). Restricted Stock Awards The following table summarizes our restricted stock awards activity: Number of Units Weighted Average Grant Date Fair Value Outstanding as of December 31, 2021 867,500 $ 4.20 Granted 136,000 $ 2.72 Vested (543,500 ) $ 3.78 Forfeited — $ — Outstanding as of December 31, 2022 460,000 $ 4.32 Granted 559,000 $ 1.65 Vested (794,000 ) $ 2.42 Forfeited — $ — Outstanding as of December 31, 2023 225,000 $ 4.33 As of December 31, 2022 As of December 31, 2023 Stock Options Stock options outstanding at December 31, 2023 2022 A summary of the status of the Company’s outstanding stock options and changes during the years ended December 31, 2023 2022 Number of Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Life (Years) Balance at January 1, 2022 2,179,892 $ 4.54 $ 2.44 5.93 Granted 190,000 $ 1.92 $ 1.43 6.85 Exercised — $ — $ — — Cancelled (250,000 ) $ 5.35 $ — — Expired (191 ) $ — $ — — Balance outstanding at December 31, 2022 2,119,701 $ 4.16 $ 2.25 5.23 Options exercisable at December 31, 2022 1,259,701 $ 3.51 $ 1.68 6.25 Balance at January 1, 2023 2,119,701 $ 4.16 $ 2.25 5.23 Granted 395,000 $ 2.37 $ 2.37 4.06 Exercised — $ — $ — — Cancelled (266,284 ) $ 5.88 $ — — Expired (3,084 ) $ — $ — — Balance outstanding at December 31, 2023 2,245,333 $ 3.63 $ 2.88 4.26 Options exercisable at December 31, 2023 1,771,997 $ 3.31 $ 2.86 4.63 For the year ended December 31, 2022 For the year ended December 31, 2023 As of December 31, 2022 As of December 31, 2023

Note 21 - Income Taxes

Note 21 - Income Taxes	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 21. The Company accounts for income taxes under ASC Topic 740: 740 The tax reform bill that Congress voted to approve December 20, 2017, $10.0 35%, 21%. not For U.S. purposes, the Company has not 382, not may not 382 may not 382 The components of earnings before income taxes for the years ended December 31, 2023 2022 Year Ended December 31, 2023 2022 Net loss after loss in equity method investment and before income taxes: Domestic $ (12,672 ) $ (9,436 ) Foreign 293 362 $ (12,379 ) $ (9,074 ) Income tax provision (benefit) consists of the following for the years ended December 31, 2023 2022 Year Ended December 31, 2023 2022 Income tax (benefit) provision: Current Federal $ (11 ) $ — State — — Foreign 39 87 Total current 28 87 Deferred: Federal — — State — — Foreign — — Total deferred — — Total income tax (benefit) provision $ 28 $ 87 The Company’s wholly owned subsidiary, GTC, is a United Kingdom (“UK”) Limited Company and files tax returns in the UK. Its estimated tax liability for December 31, 2023 2022 Progressive Care's estimated tax liability for December 31, 2023 A reconciliation of the income tax provision (benefit) by applying the statutory United States federal income tax rate to income (loss) before income taxes is as follows (in thousands): Year Ended December 31, 2023 2022 Federal income tax (benefit) provision at statutory rate $ (2,655 ) $ (1,984 ) State tax expense net of federal tax benefit — (411 ) State tax expense federal impact — 45 Provision true-up adjustments (488 ) — State rate change adjustment — (214 ) Foreign taxes at rate different than US Taxes 60 87 Net operating loss deduction (310 ) — Permanent differences (22 ) — Other true-ups 99 106 Change in valuation allowance 3,344 2,458 Income tax (benefit) provision $ 28 $ 87 Deferred tax assets and liabilities are provided for significant income and expense items recognized in different years for tax and financial reporting purposes. Temporary differences, which give rise to a net deferred tax asset is as follows (in thousands): December 31, 2023 December 31, 2022 Deferred tax assets: Net operating loss carryforward $ 8,016 $ 3,658 Property plant and equipment and intangibles asset 327 130 Equity method investment loss 806 441 Other tax carry-overs 613 — Reserves and allowances 85 — Stock-based compensation 3,861 1,949 Total deferred tax assets $ 13,708 $ 6,178 Deferred tax liabilities: Book basis of intangible assets in excess of tax basis $ 3,650 $ — Total deferred tax liabilities $ 3,650 $ — Net deferred tax asset before valuation allowance $ 10,058 $ 6,178 Less: valuation allowance (10,058 ) (6,178 ) Net deferred tax asset $ — $ — Nextplat Corp's net operating loss carryforward increased from approximately $14.8 million at December 31, 2022 December 31, 2023 December 31, 2023 2022 2023 $17.8 2036 Progressive Care's December 31, 2022 December 31, 2023. December 31, 2023 2022, 2023 $13.8 2032 The Internal Revenue Code includes a provision, referred to as Global Intangible Low-Taxed Income (“GILTI”), which provides for a 10.5% The Company is subject to taxation in the U.S. and various states and foreign jurisdictions. U.S. federal income tax returns for 2020 2019 No December 31, 2023 2022 not December 31, 2023 2022 no

Note 22 - Leases

Note 22 - Leases	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	Note 18. The Company has entered into a number of lease arrangements under which the Company is the lessee. These leases are classified as operating leases. In addition, the Company has elected the short-term lease practical expedient in ASC Topic 842 one Finance Lease Agreements In May 2018, March 2025 Operating Lease Agreements Right of use ("ROU") assets for operating leases are periodically reduced by impairment losses. We use the long-lived assets impairment guidance in ASC Subtopic 360 10, March 31, 2024 December 31, 2023 We monitor for events or changes in circumstances that require a reassessment of one On December 2, 2021, June 13, 2022, August 31, 2027. not For our facilities in Poole, England, we rent office and warehouse space of approximately 2,660 square feet for £30,000 October 6, 2022, October 31, 2023 twelve Progressive Care entered into a lease agreement for its Orlando pharmacy in August 2020. February 2026. February 2021, Progressive Care leases its North Miami Beach pharmacy location under an operating lease agreement with a lease commencement date in September 2021. August 2026. Progressive Care also leases its Palm Beach County pharmacy locations under operating lease agreements expiring in February 2025.	Note 22. The Company has entered into a number of lease arrangements under which the Company is the lessee. These leases are classified as operating leases. In addition, the Company has elected the short-term lease practical expedient in ASC Topic 842 one Finance Lease Agreements In May 2018, March 2025 In December 2020, November 2023. Operating Lease Agreements On December 2, 2021, June 13, 2022, August 31, 2027. not For our facilities in Poole, England, we rent office and warehouse space of approximately 2,660 square feet for £30,000 October 6, 2022, October 31, 2023 twelve Progressive Care entered into a lease agreement for its Orlando pharmacy in August 2020. February 2026. February 2021, Progressive Care leases its North Miami Beach pharmacy location under an operating lease agreement with a lease commencement date in September 2021. August 2026. Progressive Care also leases its Palm Beach County pharmacy locations under operating lease agreements expiring in February 2024. During June 2023 twenty-five 25 300 June 7, 2023, June 6, 2026. Variable expenses generally represent the Company’s share of the landlord’s operating expenses. Right of use assets for operating leases are periodically reduced by impairment losses. We use the long-lived assets impairment guidance in ASC Subtopic 360 10, December 31, 2023 2022 not We monitor for events or changes in circumstances that require a reassessment of one We recognized lease costs associated with all leases as follows (in thousands): For the Year Ended December 31, 2023 2022 Operating lease cost: Fixed rent expense $ 427 $ 101 Variable rent expense 111 — Finance lease cost: Amortization of right-of-use assets 15 — Interest expense 1 — Total Lease Costs $ 554 $ 101 Supplemental cash flow information related to leases was as follows (in thousand): For the Year Ended December 31, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 464 $ 101 Financing cash flows from finance leases 15 — Total cash paid for lease liabilities $ 479 $ 101 Supplemental balance sheet information related to leases was as follows (in thousands): December 31, 2023 December 31, 2022 Operating leases: Operating lease right-of-use assets, net $ 1,566 $ 855 Operating lease liabilities: Current portion 532 209 Long-term portion 929 650 $ 1,461 $ 859 Weighted average remaining lease term (years) 2.96 5.50 Weighted average discount rate 4.65 % 3.75 % Finance leases: Finance lease right-of-use assets, net 22 $ — Finance lease liabilities: Current portion 18 — Long-term portion 5 — $ 23 $ — Weighted average remaining lease term (years) 1.25 — Weighted average discount rate 6.00 % — Future minimum lease payments are as follows (in thousands): Years Ending December 31, Finance Lease Operating Lease Total Future Lease Commitments 2024 $ 19 $ 582 $ 601 2025 5 580 585 2026 — 262 262 2027 — 121 121 Total lease payments to be paid 24 1,545 1,569 Less: future interest expense (1 ) (84 ) (85 ) Lease liabilities 23 1,461 1,484 Less: current maturities (18 ) (532 ) (550 ) Long-term portion of lease liabilities $ 5 $ 929 $ 934

Note 23 - Reportable Segments

Note 23 - Reportable Segments	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 19. The Company has two 19 340B 340B The Company evaluates the performance of each of the segments based on profit or loss after general and administrative expenses. While the Company believes there are synergies between the two For the Three Months Ended March 31, 2024 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ — $ 11,324 $ — $ 11,324 e-Commerce revenue 2,865 — — 2,865 Pharmacy 340B contract revenue — 3,304 — 3,304 Revenues, net $ 2,865 $ 14,628 $ — $ 17,493 Expenses: Cost of revenue 2,060 10,623 — 12,683 Selling, general and administrative 1,166 899 (60 ) 2,005 Salaries, wages and payroll taxes 508 2,116 — 2,624 Impairment loss — 132 — 132 Professional fees 507 478 — 985 Depreciation and amortization 130 776 — 906 4,371 15,024 (60 ) 19,335 Loss before other (income) expense (1,506 ) (396 ) 60 (1,842 ) Other (expense) income (203 ) (25 ) (60 ) (168 ) Loss before income taxes (1,303 ) (371 ) — (1,674 ) Income taxes (27 ) — — (27 ) Net loss $ (1,330 ) $ (371 ) $ — $ (1,701 ) For the Three Months Ended March 31, 2023 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ — $ — $ — $ — e-Commerce revenue 2,876 — — 2,876 Pharmacy 340B contract revenue — — — — Revenues, net $ 2,876 $ — $ — $ 2,876 Expenses: Cost of revenue 2,255 — — 2,255 Selling, general and administrative 788 — — 788 Salaries, wages and payroll taxes 588 — — 588 Professional fees 321 — — 321 Depreciation and amortization 162 — — 162 4,114 — — 4,114 Loss before other (income) expense (1,238 ) — — (1,238 ) Other (expense) income (83 ) — — (83 ) Loss before income taxes (1,155 ) — — (1,155 ) Income taxes — — — — Loss before equity method investment (1,155 ) — — (1,155 ) Equity in net loss of affiliate (32 ) — — (32 ) Net loss $ (1,187 ) $ — $ — $ (1,187 ) e-Commerce Operations Healthcare Operations Eliminations Total Total assets as of March 31, 2024 $ 40,342 $ 41,398 $ (16,679 ) $ 65,061 Total assets as of December 31, 2023 $ 40,764 $ 40,384 $ (16,679 ) $ 64,469	Note 23. Reportable Segments The Company has two 19 340B 340B The Company evaluates the performance of each of the segments based on profit or loss after general and administrative expenses. While the Company believes there are synergies between the two The following tables present a summary of the reportable segments (in thousands): For the Twelve Months Ended December 31, 2023 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ — $ 21,412 $ — $ 21,412 e-Commerce revenue 10,977 — — 10,977 Pharmacy 340B contract revenue — 5,367 — 5,367 Revenues, net $ 10,977 $ 26,779 $ — $ 37,756 Expenses: Cost of revenue 8,122 18,323 — 26,445 Selling, general and administrative 6,633 3,277 — 9,910 Salaries, wages and payroll taxes 2,670 3,973 — 6,643 Goodwill impairment — 13,895 — 13,895 Professional fees 1,595 506 (120 ) 1,981 Depreciation and amortization 647 1,463 — 2,110 Total expenses 19,667 41,437 (120 ) 60,984 Loss before other (income) expense $ (8,690 ) $ (14,658 ) $ 120 $ (23,228 ) For the Twelve Months Ended December 31, 2022 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ — $ — $ — $ — e-Commerce revenue 11,710 — — 11,710 Pharmacy 340B contract revenue — — — — Revenues, net $ 11,710 $ — $ — $ 11,710 Expenses: Cost of revenue 9,221 — — 9,221 Selling, general and administrative 5,085 — — 5,085 Salaries, wages and payroll taxes 2,565 — — 2,565 Professional fees 1,552 — — 1,552 Depreciation and amortization 490 — — 490 Total expenses 18,913 — — 18,913 Loss before other (income) expense $ (7,203 ) $ — $ — $ (7,203 ) e-Commerce Operations Healthcare Operations Eliminations Total Total assets as of December 31, 2023 $ 40,764 $ 40,384 $ (16,679 ) $ 64,469 Total assets as of December 31, 2022 $ 28,644 $ — $ — $ 28,644 Capital expenditures for the year ended December 31, 2023

Note 24 - Commitments and Conti

Note 24 - Commitments and Contingencies	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 17. Litigation On June 22, 2021, not June 2, 2021 not not June 21, 2022. not No. 1:21 22436 On July 5, 2022, June 22, 2021, A jury trial is set to occur during the trial court's two August 21, 2024. From time to time, the Company may not no	Note 24. Litigation On June 22, 2021, not June 2, 2021 not not June 21, 2022. not No. 1:21 22436 On July 5, 2022, June 22, 2021, A jury trial is set to occur during the trial court's two August 21, 2024. From time to time, the Company may not no

Note 25 - Related Party Transac

Note 25 - Related Party Transactions	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 16. On July 12, 2022, September 22, 2022, no December 31, 2022. April 2023, Progressive Care Inc September 2, 2022, November 11, 2022, September 2, 2022, March 6, 2019, 1 December 30, 2022. On February 1, 2023, May 2023 three March 31, 2023 three March 31, 2024 July 1, 2023. On May 5, 2023, one one On May 9, 2023, one On July 1, 2023, Also, on July 1, 2023, Next Borough Capital Fund, LP. July 7, 2023, July 7, 2024, March 31, 2024 December 31, 2023	Note 25. As of December 31, 2023 December 31, 2023 December 31, 2022 The Company uses an American Express account for Orbital Satcom Corp and an American Express account for GTC, both in the name of David Phipps who personally guarantees the balance owed. For the year ended December 31, 2023 2022 two On July 12, 2022, September 22, 2022, no December 31, 2022. April 2023, January January January 5, 2022. Investor Position held at NextPlat Shares of Common Stock Purchased Aggregate Purchase Price Charles M. Fernandez Executive Chairman and Chief Executive Officer 679,013 $ 2,200,002 David Phipps Director and President of Orbsat. Chief Executive Officer of Global Operations 46,297 $ 150,002 Douglas Ellenoff Vice Chairman and Chief Business Development Strategist 46,297 $ 150,002 Shares are deemed to be indirectly beneficially owned through Sabrina Allan, Mr. Ellenoff’s wife. Mr. Ellenoff has the power to vote and dispose of the shares. Louis Cusimano Director 15,433 $ 50,003 Paul R. Thomson Senior Vice President – Mergers, Acquisitions and Special Projects 15,433 $ 50,003 On January 20, 2022, January Progressive Care Inc September 2, 2022, November 11, 2022, September 2, 2022, March 6, 2019, 1 December 30, 2022. On February 1, 2023, May 2023 twelve December 31, 2023 six December 31, 2023 July 1, 2023. On May 5, 2023, one one On May 9, 2023, one On July 1, 2023, Also, on July 1, 2023, Next Borough Capital Fund, LP. July 7, 2023, July 7, 2024, December 31, 2023 December December 14, 2022, three Investor Position held at NextPlat Shares of Common Stock Purchased Warrants to purchase Common Stock Aggregate Purchase Price eAperion Partners LLC, principal Charles M. Fernandez Executive Chairman and Chief Executive Officer 1,085,714 1,085,714 $ 1,900,000 David Phipps Director and President of NextPlat. Chief Executive Officer of Global Operations 28,500 28,500 $ 49,875 RLB Market Investments LLC, principal, Rodney Barreto Director 1,085,714 1,085,714 $ 1,900,000

Note 26 - Concentrations

Note 26 - Concentrations	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	Note 20. e-Commerce operations concentrations: Customers: Sales to customers through Amazon accounted for 39.9% and 57.2% of the Company’s revenues during the three March 31, 2024 2023 No 10% Suppliers: The following table sets forth information as to each supplier that accounted for 10% three March 31, 2024 2023 For the Three Months Ended March 31, 2024 For the Three Months Ended March 31, 2023 Globalstar Europe $ 213 10.2 % $ — — % Garmin $ 301 14.3 % $ 594 20.9 % Iridium Satellite $ 270 27.2 % $ — — % Geographic The following table sets forth revenue as to each geographic location, for the (in thousands, unaudited): For the Three Months Ended March 31, 2024 For the Three Months Ended March 31, 2023 Europe $ 1,430 49.9 % $ 2,063 71.7 % North America 523 18.3 % 586 20.4 % South America 23 0.8 % 9 0.3 % Asia and Pacific 413 14.4 % 159 5.5 % Africa 476 16.6 % 59 2.1 % $ 2,865 100 % $ 2,876 100 % Healthcare operations concentrations: Suppliers: Progressive Care had significant concentrations with one vendor. The purchases from this significant vendor were 98% of total vendor purchases for the three March 31, 2024 Customers: Progressive Care s trade receivables are primarily from prescription medications billed to various insurance providers. Ultimately, the insured is responsible for payment should the insurance company not Progressive Care derives a significant portion of sales from prescription drug sales reimbursed through prescription drug plans administered by pharmacy benefit managers (“PBM”) companies. Prescription reimbursements from our three Three Months Ended March 31, 2024 A 33 % B 21 % C 16 %	Note 26. e-Commerce operations concentrations: Customers: Amazon accounted for 51.6% and 54.3% of the Company’s revenues during the years ended December 31, 2023 2022 No 10% Suppliers: The following table sets forth information as to each supplier that accounted for 10% December 31, 2023 2022 December 31, 2023 December 31, 2022 Garmin $ 1,921 22.4 % $ 1,821 20.9 % Globalstar Europe $ 958 11.2 % $ 635 7.3 % Network Innovations $ 935 10.7 % $ 980 11.2 % Iridium Satellite $ 913 10.9 % $ — — % Satcom Global $ 761 8.9 % $ 744 8.5 % Geographic The following table sets forth revenue as to each geographic location, for the years ended December 31, 2023 2022 Year Ended Year Ended December 31, 2023 December 31, 2022 Europe $ 6,687 60.9 % $ 8,617 73.7 % North America 2,575 23.4 % 2,152 18.3 % South America 62 0.6 % 45 0.4 % Asia and Pacific 1,510 13.8 % 760 6.5 % Africa 143 1.3 % 136 1.1 % $ 10,977 100.0 % $ 11,710 100.0 % Healthcare operations concentrations: Suppliers: Progressive Care had significant concentrations with one vendor. The purchases from this significant vendor were approximately 99.0% of total vendor purchases for the six December 31, 2023 Customers: Progressive Care s trade receivables are primarily from prescription medications billed to various insurance providers. Ultimately, the insured is responsible for payment should the insurance company not Progressive Care generated reimbursements from three six December 31, 2023 2023 A 31 % B 29 % C 14 %

Note 27 - Subsequent Events

Note 27 - Subsequent Events	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes to Financial Statements
Subsequent Events [Text Block]	Note 21. Acquisition of Outfitter Satellite On March 25, 2024, fitter Satellite, Inc. (“Outfitter”) in an all-cash transaction for an aggregate purchase price of $760,000.00, subject to certain adjustments (the “Aggregate Consideration”). The closing of the transaction occurred on April 1, 2024 At the closing, $660,000.00 of the Aggregate Consideration was paid to Mr. McKinley with the remaining $100,000.00 to be paid upon delivery of Outfitter’s audited financial statements for the 2022 2023 Outfitter provides consumers, commercial and government customers, with advanced satellite-based connectivity solutions from leading brands, including Iridium, Inmarsat and Globalstar. RXMD Merger On April 12, 2024, Merger Agreement Merger Sub Merger On April 9, 2024, Company Lock-Up Agreements Parent Lock-Up Agreements Hybrid Lock-Up Agreements Lock-Up Agreements no	Note 27. On March 25, 2024, April 1, 2024.

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash The Company places its cash with high credit quality financial institutions. The Company’s account at these institutions are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. All cash amounts in excess of $250,000, approximately $1.0 million, are unsecured. The Company has a deposit placement agreement for Insured Cash Sweep Service (“ICS”). This service is a secure, and convenient way to access FDIC protection on large deposits, earn a return, and enjoy flexibility. The Company believes that the ICS agreement will mitigate its credit risk as it relates to uninsured FDIC amounts in excess of $250,000.	Cash and Cash Equivalents The Company places its cash with high credit quality financial institutions. The Company’s account at this institution is insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. All cash amounts in excess of $250,000, approximately $3.1 million, are unsecured. In April 2023, $250,000.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation The Company’s reporting currency is U.S. Dollars. The accounts of one The relevant translation rates are as follows: for the three March 31, 2024 three March 31, 2023 December 31, 2023	Foreign Currency Translation The Company’s reporting currency is U.S. Dollars. The accounts of one The relevant translation rates are as follows: for the year ended December 31, 2023 December 31, 2022
Revenue from Contract with Customer [Policy Text Block]	Unearned Revenue Contract liabilities are shown separately in the condensed consolidated balance sheets as current liabilities. At March 31, 2024 December 31, 2023 Direct and Indirect Remuneration ( “ DIR ” ) Progressive Care reports DIR fees as a reduction of revenue on the accompanying Consolidated Statements of Operations. DIR fees are fees charged by PBMs to pharmacies for network participation as well as periodic reimbursement reconciliations. The Company accrues an estimate of PBM fees, including DIR fees, which are assessed or expected to be assessed by payers at some point after adjudication of a claim, as a reduction of prescription revenue at the time revenue is recognized. Changes in the estimate of such fees are recorded as an adjustment to revenue when the change becomes known. Through December 31, 2023, not two two three January – April 20xx July – August 20xx December 31, 2023, not second 2024. may January 1, 2024,	Revenue Recognition and Unearned Revenue In accordance with ASU No. 2016 12, Revenue from Contracts with Customers (Topic 606 1 606 10 25 7; 2 3 4 5 6 606 not December 15, 2017, no one e-Commerce Operations: The Company recognizes revenue from satellite services when earned, as services are rendered or delivered to customers. Equipment sales revenue is recognized when the equipment is delivered to and accepted by the customer. Only equipment sales are subject to warranty. Historically, the Company has not The Company’s customers generally purchase a combination of our products and services as part of a multiple element arrangement. The Company’s assessment of which revenue recognition guidance is appropriate to account for each element in an arrangement can involve significant judgment. This assessment has a significant impact on the amount and timing of revenue recognition. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, five five 606, Contract liabilities are shown separately in the consolidated balance sheets as current liabilities. At December 31, 2023 December 31, 2022 Healthcare Operations: The Company provides prescription pharmaceuticals, COVID- 19 340B 340B 340B 340B The Company recognizes product sales from prescriptions dispensed to patients (customers) at the time the drugs are physically delivered to a customer or when a customer picks up their prescription, which is the point in time when control transfers to the customer. 340B 340B third 340B 340B not not The Company accrues an estimate of PBM fees, including direct and indirect remuneration (“DIR”) fees, which are assessed or expected to be assessed by payers at some point after adjudication of a claim, as a reduction of prescription revenue at the time revenue is recognized. Changes in the estimate of such fees are recorded as an adjustment to revenue when the change becomes known. DIR fees are fees charged by PBMs to pharmacies for network participation as well as periodic reimbursement reconciliations. For some PBMs, DIR fees are charged at the time of the settlement of a pharmacy claim. Other PBMs do not two two three January – April 2023 July – August 2023). not may Billings for most prescription orders are with third The Company recognizes revenue from TPA services as it satisfies the performance obligations under the TPA contract with a 340B one may not For each TPA contract, the Company recognizes revenue by measuring the progress toward complete satisfaction of each performance obligation. The Company uses various observable output methods in measuring progress toward satisfaction of each performance obligation, most notably gross billings under each contract. ASC 606 may The Company recognizes COVID- 19
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Accounting Pronouncements Issued but not In November 2023, 2023 07, 280 2023 07” 2023 07 December 15, 2023, December 15, 2024, Q1 2025, December 31, 2024. not In December 2023, 2023 09, 740 2023 09” 2023 09 December 15, 2024, January 1, 2025. not Other accounting standards that have been issued or proposed by FASB that do not not	Recent Accounting Pronouncements Accounting Pronouncements Recently Adopted In August 2023, 2023 04, 405 No. 121”, No. 121. In July 2023, 2023 03, 205 220 480 505 718 No. 120, no In June 2016, 2016 13, 326 2016 13” November 2018, 2018 19, 326, not April 2019, 2019 04, 326, 815, 825, 2016 13. March 2020, 2020 03, 842 326. 2016 13 December 15, 2022, Any new accounting standards, not not not Accounting Pronouncements Issued but not In December 2023, 2023 09, 740 2023 09” 2023 09 December 15, 2024, January 1, 2025. not In November 2023, 2023 07, 280 2023 07” 2023 07 December 15, 2023, December 15, 2024, January 1, 2024. not Management has evaluated other recently issued accounting pronouncements and does not
Subsequent Events, Policy [Policy Text Block]	Subsequent Events The Company has evaluated subsequent events through May 15, 2024, 21
Discontinued Operations, Policy [Policy Text Block]		Discontinued Operations The Company’s former operations were developing and manufacturing products and services, which reduce fuel costs, save power and energy and protect the environment. The products and services were made available for sale into markets in the public and private sectors. In December 2009, The remaining liabilities for discontinued operations are presented in the consolidated balance sheets under the caption “Liabilities from discontinued operation” and relates to the discontinued operations of developing and manufacturing of energy saving and fuel-efficient products and services. The carrying amounts of the major classes of these liabilities as of December 31, 2023 2022 December 31, 2023 December 31, 2022 Assets of discontinued operations $ — $ — Liabilities Accounts payables and accrued expenses $ — $ (112 ) Liabilities from discontinued operations $ — $ (112 )
Liquidity [Policy Text Block]		Liquidity January 2022 On December 31, 2021, “December “December January 2, 2022, December December 31, 2021. December December 31, 2021. The closing of the December January 5, 2022. December December 2022 On December 9, 2022, three On December 9, 2022, three six The offering closed on December 14, 2022, April 2023 On April 5, 2023, April 4, 2023. April 11, 2023, 4 2 506 As of the date of this report, the Company’s existing cash resources and existing borrowing availability are sufficient to support planned operations for the next 12 one
Receivable [Policy Text Block]		Accounts Receivable and Allowance for Doubtful Accounts The Company has a policy of reserving for questionable accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may may Progressive Care trade accounts receivable are stated at the invoiced amount. Trade accounts receivable primarily include amounts from third no
Inventory, Policy [Policy Text Block]		Inventories Inventories are valued at the lower of cost or net realizable value, using the first first not
Prepaid Expenses [Policy Text Block]		Prepaid Expenses Prepaid expenses current and long term amounted to approximately $640,000 and $61,000, respectively for the year ended December 31, 2023 December 31, 2022
Equity Method Investments [Policy Text Block]		Investments The Company applies the equity method of accounting to investments when it has significant influence, but not 15 The Company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not December 31, 2023 not
Cost of Goods and Service [Policy Text Block]		Cost of Product Sales and Services Cost of sales consists primarily of materials, airtime and overhead costs incurred internally and amounts incurred to contract manufacturers to produce our products, airtime and other implementation costs incurred to install our products and train customer personnel, and customer service and third Shipping and handling costs are included as a component of costs of product sales in the Company’s consolidated statements of operations because the Company includes in revenue the related costs that the Company bills its customers.
Advertising Cost [Policy Text Block]		Advertising Costs incurred for producing and communicating advertising for the Company are charged to operations as incurred. Advertising expense was approximately $188,000 and $93,000 for the years ended December 31, 2023 2022
Intangible Assets, Finite-Lived, Policy [Policy Text Block]		Intangible Assets Acquired intangible assets with finite lives other than goodwill are amortized over their useful lives. For intangible assets acquired in a business combination, the estimated fair values of the assets received are used to establish their recorded values. Acquired intangible assets other than goodwill are amortized over their useful lives unless the lives are determined to be indefinite. Valuation techniques consistent with the market approach, income approach, and/or cost approach are used to measure fair value. Intangible assets subject to amortization represent the fair value of pharmacy records, tradenames and customer contracts acquired, and capitalized software development costs. In valuing these assets, the Company makes assumptions regarding useful lives and projected growth rates, and significant judgment is required. The Company periodically reviews its identifiable intangible assets for impairment as events or changes in circumstances indicate that the carrying amount of such assets may not Pharmacy records and developed software are amortized over 5 years. Tradenames and customer contracts are amortized over 10 years. Useful lives of intangible assets are periodically evaluated for reasonableness and the assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may no
Business Combinations Policy [Policy Text Block]		Business acquisitions The Company records business acquisitions using the acquisition method of accounting. All of the assets acquired, liabilities assumed, and contractual contingencies are recognized at their fair value on the acquisition date. The application of the acquisition method of accounting for business combinations requires management to make significant estimates and assumptions in the determination of the fair value of assets acquired and liabilities assumed in order to properly allocate purchase price consideration between assets that are depreciated and amortized and goodwill. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Acquisition-related expenses and restructuring costs are recognized separately from the business combination and are expensed as incurred. The Company uses a measurement period following the acquisition date to gather information that existed as of the acquisition date that is needed to determine the fair value of the assets acquired, liabilities assumed and equity interests. The measurement period ends once all information is obtained, but no one
Goodwill and Intangible Assets, Policy [Policy Text Block]		Goodwill Goodwill represents the excess of the purchase price over the value assigned to net tangible and identifiable intangible assets. Progressive Care, which is our Healthcare Operations, is considered to be the reporting unit for goodwill. Valuation techniques consistent with the market approach, income approach, and/or cost approach are used to measure fair value. Goodwill and other indefinite-lived intangible assets are assessed annually for impairment in the fourth may
Property, Plant and Equipment, Policy [Policy Text Block]		Property and Equipment Property and equipment are carried at historical cost less accumulated depreciation. Depreciation is based on the estimated service lives of the depreciable assets and is calculated using the straight-line method. Expenditures that increase the value or productive capacity of assets are capitalized. Fully depreciated assets are retained in the property and equipment, and accumulated depreciation accounts until they are removed from service. When property and equipment are retired, sold or otherwise disposed of, the asset’s carrying amount and related accumulated depreciation are removed from the accounts and any gain or loss is included in operations. Repairs and maintenance are expensed as incurred. The estimated useful lives of property and equipment are generally as follows: Years Building 40 Building improvements Remaining life of the building Leasehold improvements Lessor of the estimated useful life or life of the lease Office furniture and fixtures 4-5 Computer equipment 3-4 Rental equipment 4 Vehicles 3-5 Appliques 10 Website development 2 Depreciation expense for the years ended December 31, 2023 2022
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]		Impairment of Long-lived Assets The Company reviews its long-lived assets, comprised of property and equipment, right-of-use assets, and intangible assets, whenever events or changes in circumstances indicate that the carrying amount of an asset may not 360 10, Accounting for the Impairment or Disposal of Long-Lived Assets the assets to the fair value based on estimated discounted future cash flows. If required, an impairment loss is recorded for that portion of the asset’s carrying value in excess of fair value. As of December 31, 2023, no not December 31, 2023 and December 31, 2022 , respectively.
Fair Value of Financial Instruments, Policy [Policy Text Block]		Fair Value of Financial Instruments Derivatives are required to be recorded on the balance sheet at fair value. These derivatives, including embedded derivatives in the Company’s structured borrowings, are separately valued and accounted for on the Company’s balance sheet. Fair values for exchange traded securities and derivatives are based on quoted market prices. Where market prices are not The Company did not
Share-Based Payment Arrangement [Policy Text Block]		Stock-based Compensation Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 The Company estimated the fair value of stock options granted using the Black-Scholes option-pricing formula. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The Company’s determination of the fair value using the option-pricing model is affected by the stock price as well as assumptions regarding the number of highly subjective variables. In June 2018, 2018 07, 718 718, December 15, 2018. January 1, 2019.
Income Tax, Policy [Policy Text Block]		Income Taxes The Company accounts for income taxes pursuant to the provision of ASC 740 10, 740 10” not not The Company follows the provision of ASC 740 10 may 740 10, not not Tax positions that meet the more likely than not 50 The Company believes its tax positions are all more likely than not not The Company has adopted ASC 740 10 25, not not three
Lessee, Leases [Policy Text Block]		Leases Effective January 1, 2019, 842, Leases not In calculating the right of use asset and lease liability, the Company has elected to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12
Research and Development Expense, Policy [Policy Text Block]		Research and Development The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730 10, 730 10” 730 10, December 31, 2023 2022 no
Comprehensive Income, Policy [Policy Text Block]		Accumulated Other Comprehensive Income (Loss) Comprehensive income (loss) is comprised of net income (loss) and all changes to the statements of stockholders’ equity. For the Company, comprehensive income (loss) for the years ended December 31, 2023 2022
Earnings Per Share, Policy [Policy Text Block]		Earnings per Common Share Net income (loss) per common share is calculated in accordance with ASC Topic 260: 260” not
Related Party Transactions [Policy Text Block]		Related Party Transactions A party is considered to be related to the Company if the party directly or indirectly or through one may one one one one 25

Note 5 - Revenue (Tables)

Note 5 - Revenue (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended March 31, 2024 2023 Sales of products, net: Pharmacy prescription and other revenue, net of PBM fees $ 11,324 $ — e-Commerce revenue 2,865 2,876 Sub total 14,189 2,876 Revenues from services: Pharmacy 340B contract revenue 3,304 — Revenues, net $ 17,493 $ 2,876	For the Twelve Months Ended December 31, 2023 e-Commerce Operations Healthcare Operations Total Sales of products, net Prescription revenue, net of PBM fees $ — $ 21,412 $ 21,412 e-Commerce revenue 10,977 — 10,977 Subtotal 10,977 21,412 32,389 Revenues from services: Pharmacy 340B contract revenue — 5,367 5,367 Revenues, net $ 10,977 $ 26,779 $ 37,756 For the Twelve Months Ended December 31, 2022 e-Commerce Operations Healthcare Operations Total Sales of products, net Prescription revenue, net of PBM fees $ — $ — $ — e-Commerce revenue 11,710 — 11,710 Subtotal 11,710 — 11,710 Revenues from services: Pharmacy 340B contract revenue — — — Revenues, net $ 11,710 $ — $ 11,710

Note 6 - Loss Per Share (Tables

Note 6 - Loss Per Share (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended March 31, 2024 2023 Net loss attributable to NextPlat Corp common shareholders $ (1,481 ) $ (1,187 ) Basic weighted average common shares outstanding 18,725 14,415 Potentially dilutive common shares — — Diluted weighted average common shares outstanding 18,725 14,415 Weighted average loss per common share - basic and diluted $ (0.08 ) $ (0.08 ) Potentially dilutive common shares excluded from the calculation of diluted weighted average loss per common share: Stock options 105 100 105 100	Year Ended December 31, 2023 2022 Net loss attributable to NextPlat Corp common shareholders $ (3,778 ) $ (9,161 ) Basic weighted average common shares outstanding 17,494 9,592 Potentially dilutive common shares — — Diluted weighted average common shares outstanding 17,494 9,592 Basic weighted average earnings (loss) per common share $ (0.22 ) $ (0.96 ) Diluted weighted average earnings (loss) per common share $ (0.22 ) $ (0.96 ) Potentially dilutive common shares excluded from the calculation of diluted weighted average loss per common share: Stock options 136 265 Common stock purchase warrants 675 1,403 811 1,668

Note 7 - Accounts Receivable (T

Note 7 - Accounts Receivable (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	March 31, 2024 December 31, 2023 (Unaudited) (Audited) Gross accounts receivable – trade $ 13,202 $ 9,195 Less: allowance for doubtful accounts (274 ) (272 ) Accounts receivable – trade, net $ 12,928 $ 8,923	Year Ended December 31, 2023 2022 Gross accounts receivable – trade $ 9,195 $ 384 Less: allowance for doubtful accounts (272 ) — Accounts receivable – trade, net $ 8,923 $ 384

Note 8 - Inventory (Tables)

Note 8 - Inventory (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, 2024 December 31, 2023 (Unaudited) (Audited) Finished goods $ 5,670 $ 5,195 Less reserve for obsolete inventory (60 ) (60 ) Total $ 5,610 $ 5,135	December 31, 2023 December 31, 2022 Finished goods $ 5,195 $ 1,287 Less reserve for obsolete inventory (60 ) — Total $ 5,135 $ 1,287

Note 11 - Property and Equipm_2

Note 11 - Property and Equipment, Net (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes Tables
Property, Plant and Equipment [Table Text Block]	March 31, 2024 December 31, 2023 (Unaudited) (Audited) Building $ 2,116 $ 2,116 Vehicles 585 595 Office furniture and fixtures 543 527 Land 184 184 Leasehold improvements 167 124 Computer equipment 117 117 Rental equipment 63 60 Appliques 2,160 2,160 Website development 611 587 Construction in progress — 22 Property and equipment gross 6,546 6,492 Less: accumulated depreciation (2,700 ) (2,503 ) Property and equipment, net $ 3,846 $ 3,989	December 31, 2023 December 31, 2022 Building $ 2,116 $ — Vehicles 595 — Office furniture and fixtures 527 128 Land 184 — Leasehold improvements 124 48 Computer equipment 117 72 Rental equipment 60 38 Appliques 2,160 2,160 Website development 587 665 Construction in progress 22 — Property and equipment gross 6,492 3,111 Less: accumulated depreciation (2,503 ) (1,865 ) Property and equipment, net $ 3,989 $ 1,246

Note 12 - Intangible Assets, _2

Note 12 - Intangible Assets, Net (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	March 31, 2024 (Unaudited) Gross amount Accumulated amortization Net Amount Pharmacy records $ 8,130 $ (1,219 ) $ 6,911 Trade names 4,700 (353 ) 4,347 Developed technology 2,880 (432 ) 2,448 Customer Contracts 250 (231 ) 19 Total intangible assets $ 15,960 $ (2,235 ) $ 13,725 December 31, 2023 (Audited) Gross amount Accumulated amortization Net Amount Pharmacy records $ 8,130 $ (807 ) $ 7,323 Trade names 4,700 (224 ) 4,476 Developed technology 2,880 (281 ) 2,599 Customer Contracts 250 (225 ) 25 Total intangible assets $ 15,960 $ (1,537 ) $ 14,423	December 31, 2023 Gross amount Accumulated amortization Net Amount Pharmacy records $ 8,130 $ (807 ) $ 7,323 Trade names 4,700 (224 ) 4,476 Developed technology 2,880 (281 ) 2,599 Customer Contracts 250 (225 ) 25 Total intangible assets $ 15,960 $ (1,537 ) $ 14,423 December 31, 2022 Gross amount Accumulated amortization Net Amount Pharmacy records $ — $ — $ — Trade names — — — Developed technology — — — Customer Contracts 250 (200 ) 50 Total intangible assets $ 250 $ (200 ) $ 50
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year Amount 2024 (remaining nine months) $ 2,023 2025 2,672 2026 2,672 2027 2,672 2028 1,571 Thereafter 2,115 Total $ 13,725	2024 $ 2,721 2025 2,672 2026 2,672 2027 2,672 2028 1,571 Thereafter 2,115 Total $ 14,423

Note 13 - Accounts Payable an_2

Note 13 - Accounts Payable and Accrued Expenses (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	March 31, 2024 December 31, 2023 (Unaudited) (Audited) Accounts payable $ 13,978 $ 12,142 Accrued wages and payroll liabilities 378 200 Accrued PBM fees 366 571 Customer deposits payable 54 76 Accrued other liabilities 117 187 Total $ 14,893 $ 13,176	December 31, 2023 December 31, 2022 Accounts payable $ 12,142 $ 1,200 Accrued wages and payroll liabilities 200 23 Accrued PBM fees 571 — Customer deposits payable 76 86 Accrued legal fees — 85 Pre-merger accrued other liabilities — 88 Accrued other liabilities 187 41 Total $ 13,176 $ 1,523

Note 14 - Notes Payable (Tables

Note 14 - Notes Payable (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes Tables
Schedule of Debt [Table Text Block]	March 31, 2024 December 31, 2023 (Unaudited) (Audited) A. Mortgage note payable - commercial bank - collateralized $ 1,118 $ 1,140 B. Note payable - uncollateralized 25 25 C. Notes payable - collateralized 229 255 Insurance premiums financing 26 103 Subtotal 1,398 1,523 Less: current portion of notes payable (233 ) (312 ) Long-term portion of notes payable $ 1,165 $ 1,211	December 31, 2023 December 31, 2022 A. Mortgage note payable - commercial bank - collateralized $ 1,140 $ — B. Note payable - uncollateralized 25 — C. Notes payable - collateralized 255 216 Insurance premiums financing 103 — Subtotal 1,523 216 Less: current portion of notes payable (312 ) (60 ) Long-term portion of notes payable $ 1,211 $ 156
Schedule of Maturities of Long-Term Debt [Table Text Block]	Year Amount 2024 (remaining nine months) $ 187 2025 215 2026 119 2027 124 2028 753 Thereafter — Total $ 1,398	Year Amount 2024 $ 312 2025 215 2026 119 2027 124 2028 753 Thereafter — Total $ 1,523

Note 19 - Reportable Segments (

Note 19 - Reportable Segments (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes Tables
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	For the Three Months Ended March 31, 2024 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ — $ 11,324 $ — $ 11,324 e-Commerce revenue 2,865 — — 2,865 Pharmacy 340B contract revenue — 3,304 — 3,304 Revenues, net $ 2,865 $ 14,628 $ — $ 17,493 Expenses: Cost of revenue 2,060 10,623 — 12,683 Selling, general and administrative 1,166 899 (60 ) 2,005 Salaries, wages and payroll taxes 508 2,116 — 2,624 Impairment loss — 132 — 132 Professional fees 507 478 — 985 Depreciation and amortization 130 776 — 906 4,371 15,024 (60 ) 19,335 Loss before other (income) expense (1,506 ) (396 ) 60 (1,842 ) Other (expense) income (203 ) (25 ) (60 ) (168 ) Loss before income taxes (1,303 ) (371 ) — (1,674 ) Income taxes (27 ) — — (27 ) Net loss $ (1,330 ) $ (371 ) $ — $ (1,701 ) For the Three Months Ended March 31, 2023 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ — $ — $ — $ — e-Commerce revenue 2,876 — — 2,876 Pharmacy 340B contract revenue — — — — Revenues, net $ 2,876 $ — $ — $ 2,876 Expenses: Cost of revenue 2,255 — — 2,255 Selling, general and administrative 788 — — 788 Salaries, wages and payroll taxes 588 — — 588 Professional fees 321 — — 321 Depreciation and amortization 162 — — 162 4,114 — — 4,114 Loss before other (income) expense (1,238 ) — — (1,238 ) Other (expense) income (83 ) — — (83 ) Loss before income taxes (1,155 ) — — (1,155 ) Income taxes — — — — Loss before equity method investment (1,155 ) — — (1,155 ) Equity in net loss of affiliate (32 ) — — (32 ) Net loss $ (1,187 ) $ — $ — $ (1,187 )	For the Twelve Months Ended December 31, 2023 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ — $ 21,412 $ — $ 21,412 e-Commerce revenue 10,977 — — 10,977 Pharmacy 340B contract revenue — 5,367 — 5,367 Revenues, net $ 10,977 $ 26,779 $ — $ 37,756 Expenses: Cost of revenue 8,122 18,323 — 26,445 Selling, general and administrative 6,633 3,277 — 9,910 Salaries, wages and payroll taxes 2,670 3,973 — 6,643 Goodwill impairment — 13,895 — 13,895 Professional fees 1,595 506 (120 ) 1,981 Depreciation and amortization 647 1,463 — 2,110 Total expenses 19,667 41,437 (120 ) 60,984 Loss before other (income) expense $ (8,690 ) $ (14,658 ) $ 120 $ (23,228 ) For the Twelve Months Ended December 31, 2022 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ — $ — $ — $ — e-Commerce revenue 11,710 — — 11,710 Pharmacy 340B contract revenue — — — — Revenues, net $ 11,710 $ — $ — $ 11,710 Expenses: Cost of revenue 9,221 — — 9,221 Selling, general and administrative 5,085 — — 5,085 Salaries, wages and payroll taxes 2,565 — — 2,565 Professional fees 1,552 — — 1,552 Depreciation and amortization 490 — — 490 Total expenses 18,913 — — 18,913 Loss before other (income) expense $ (7,203 ) $ — $ — $ (7,203 )
Reconciliation of Assets from Segment to Consolidated [Table Text Block]	e-Commerce Operations Healthcare Operations Eliminations Total Total assets as of March 31, 2024 $ 40,342 $ 41,398 $ (16,679 ) $ 65,061 Total assets as of December 31, 2023 $ 40,764 $ 40,384 $ (16,679 ) $ 64,469	e-Commerce Operations Healthcare Operations Eliminations Total Total assets as of December 31, 2023 $ 40,764 $ 40,384 $ (16,679 ) $ 64,469 Total assets as of December 31, 2022 $ 28,644 $ — $ — $ 28,644

Note 20 - Concentrations (Table

Note 20 - Concentrations (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	For the Three Months Ended March 31, 2024 For the Three Months Ended March 31, 2023 Globalstar Europe $ 213 10.2 % $ — — % Garmin $ 301 14.3 % $ 594 20.9 % Iridium Satellite $ 270 27.2 % $ — — % For the Three Months Ended March 31, 2024 For the Three Months Ended March 31, 2023 Europe $ 1,430 49.9 % $ 2,063 71.7 % North America 523 18.3 % 586 20.4 % South America 23 0.8 % 9 0.3 % Asia and Pacific 413 14.4 % 159 5.5 % Africa 476 16.6 % 59 2.1 % $ 2,865 100 % $ 2,876 100 % Three Months Ended March 31, 2024 A 33 % B 21 % C 16 %	December 31, 2023 December 31, 2022 Garmin $ 1,921 22.4 % $ 1,821 20.9 % Globalstar Europe $ 958 11.2 % $ 635 7.3 % Network Innovations $ 935 10.7 % $ 980 11.2 % Iridium Satellite $ 913 10.9 % $ — — % Satcom Global $ 761 8.9 % $ 744 8.5 % Year Ended Year Ended December 31, 2023 December 31, 2022 Europe $ 6,687 60.9 % $ 8,617 73.7 % North America 2,575 23.4 % 2,152 18.3 % South America 62 0.6 % 45 0.4 % Asia and Pacific 1,510 13.8 % 760 6.5 % Africa 143 1.3 % 136 1.1 % $ 10,977 100.0 % $ 11,710 100.0 % 2023 A 31 % B 29 % C 14 %

Note 3 - Summary of Significa_3

Note 3 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Disposal Groups, Including Discontinued Operations [Table Text Block]	December 31, 2023 December 31, 2022 Assets of discontinued operations $ — $ — Liabilities Accounts payables and accrued expenses $ — $ (112 ) Liabilities from discontinued operations $ — $ (112 )
Schedule of Estimated Useful Life of Property and Equipment [Table Text Block]	Years Building 40 Building improvements Remaining life of the building Leasehold improvements Lessor of the estimated useful life or life of the lease Office furniture and fixtures 4-5 Computer equipment 3-4 Rental equipment 4 Vehicles 3-5 Appliques 10 Website development 2

Note 4 - Acquisition (Tables)

Note 4 - Acquisition (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Business Acquisition, Pro Forma Information [Table Text Block]	For the Year Ended December 31, 2023 For the Year Ended December 31, 2022 (Unaudited) (Unaudited) Revenue $ 60,704 $ 52,312 Earnings $ (15,854 ) $ (13,867 )
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	Purchase Price Allocation Total purchase consideration $ 16,679 Fair value of non-controlling interest 23,180 Total consideration $ 39,859 Identifiable net assets acquired: Cash $ 7,352 Accounts receivable, net 6,478 Accounts receivable, other 506 Inventory 1,631 Prepaid expenses 220 Property and equipment, net 2,883 Right of use assets, net 405 Intangible assets, net: Trade name 4,700 Development technology 2,880 Pharmacy records 8,130 Deposits 39 Accounts payable and accrued expenses (8,231 ) Notes payable and accrued interest - current portion (149 ) Lease liabilities - current portion (208 ) Notes payable - long term (1,173 ) Lease liabilities - long term (230 ) Deferred tax liability (1) — Net assets acquired $ 25,233 Goodwill $ 14,626

Note 6 - Revenue (Tables)

Note 6 - Revenue (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended March 31, 2024 2023 Sales of products, net: Pharmacy prescription and other revenue, net of PBM fees $ 11,324 $ — e-Commerce revenue 2,865 2,876 Sub total 14,189 2,876 Revenues from services: Pharmacy 340B contract revenue 3,304 — Revenues, net $ 17,493 $ 2,876	For the Twelve Months Ended December 31, 2023 e-Commerce Operations Healthcare Operations Total Sales of products, net Prescription revenue, net of PBM fees $ — $ 21,412 $ 21,412 e-Commerce revenue 10,977 — 10,977 Subtotal 10,977 21,412 32,389 Revenues from services: Pharmacy 340B contract revenue — 5,367 5,367 Revenues, net $ 10,977 $ 26,779 $ 37,756 For the Twelve Months Ended December 31, 2022 e-Commerce Operations Healthcare Operations Total Sales of products, net Prescription revenue, net of PBM fees $ — $ — $ — e-Commerce revenue 11,710 — 11,710 Subtotal 11,710 — 11,710 Revenues from services: Pharmacy 340B contract revenue — — — Revenues, net $ 11,710 $ — $ 11,710

Note 7 - Earnings (Loss) Per _2

Note 7 - Earnings (Loss) Per Share (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended March 31, 2024 2023 Net loss attributable to NextPlat Corp common shareholders $ (1,481 ) $ (1,187 ) Basic weighted average common shares outstanding 18,725 14,415 Potentially dilutive common shares — — Diluted weighted average common shares outstanding 18,725 14,415 Weighted average loss per common share - basic and diluted $ (0.08 ) $ (0.08 ) Potentially dilutive common shares excluded from the calculation of diluted weighted average loss per common share: Stock options 105 100 105 100	Year Ended December 31, 2023 2022 Net loss attributable to NextPlat Corp common shareholders $ (3,778 ) $ (9,161 ) Basic weighted average common shares outstanding 17,494 9,592 Potentially dilutive common shares — — Diluted weighted average common shares outstanding 17,494 9,592 Basic weighted average earnings (loss) per common share $ (0.22 ) $ (0.96 ) Diluted weighted average earnings (loss) per common share $ (0.22 ) $ (0.96 ) Potentially dilutive common shares excluded from the calculation of diluted weighted average loss per common share: Stock options 136 265 Common stock purchase warrants 675 1,403 811 1,668

Note 8 - Accounts Receivable (T

Note 8 - Accounts Receivable (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	March 31, 2024 December 31, 2023 (Unaudited) (Audited) Gross accounts receivable – trade $ 13,202 $ 9,195 Less: allowance for doubtful accounts (274 ) (272 ) Accounts receivable – trade, net $ 12,928 $ 8,923	Year Ended December 31, 2023 2022 Gross accounts receivable – trade $ 9,195 $ 384 Less: allowance for doubtful accounts (272 ) — Accounts receivable – trade, net $ 8,923 $ 384

Note 9 - Accounts Receivable _2

Note 9 - Accounts Receivable - Other, net (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Other Accounts Receivable [Table Text Block]	Year Ended December 31, 2023 2022 Performance bonuses $ 1,602 $ — Customers 192 — Other 52 — $ 1,846 $ —

Note 10 - Inventory (Tables)

Note 10 - Inventory (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, 2024 December 31, 2023 (Unaudited) (Audited) Finished goods $ 5,670 $ 5,195 Less reserve for obsolete inventory (60 ) (60 ) Total $ 5,610 $ 5,135	December 31, 2023 December 31, 2022 Finished goods $ 5,195 $ 1,287 Less reserve for obsolete inventory (60 ) — Total $ 5,135 $ 1,287

Note 13 - Property and Equipm_2

Note 13 - Property and Equipment, Net (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes Tables
Property, Plant and Equipment [Table Text Block]	March 31, 2024 December 31, 2023 (Unaudited) (Audited) Building $ 2,116 $ 2,116 Vehicles 585 595 Office furniture and fixtures 543 527 Land 184 184 Leasehold improvements 167 124 Computer equipment 117 117 Rental equipment 63 60 Appliques 2,160 2,160 Website development 611 587 Construction in progress — 22 Property and equipment gross 6,546 6,492 Less: accumulated depreciation (2,700 ) (2,503 ) Property and equipment, net $ 3,846 $ 3,989	December 31, 2023 December 31, 2022 Building $ 2,116 $ — Vehicles 595 — Office furniture and fixtures 527 128 Land 184 — Leasehold improvements 124 48 Computer equipment 117 72 Rental equipment 60 38 Appliques 2,160 2,160 Website development 587 665 Construction in progress 22 — Property and equipment gross 6,492 3,111 Less: accumulated depreciation (2,503 ) (1,865 ) Property and equipment, net $ 3,989 $ 1,246

Note 14 - Goodwill and Intang_2

Note 14 - Goodwill and Intangible Assets, Net (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes Tables
Schedule of Goodwill Reportable Segments [Table Text Block]		e-Commerce Operations Healthcare Operations Total Balances as of December 31, 2021 Goodwill $ — $ — $ — Accumulated impairment losses — — — Goodwill, net as of December 31, 2021 — — — Changes in Goodwill during the year ended December 31, 2022: Goodwill acquired — — — Impairment losses — — — Balances as of December 31, 2022 Goodwill — — — Accumulated impairment losses — — — Goodwill, net as of December 31, 2022 — — — Changes in Goodwill during the year ended December 31, 2023: Goodwill acquired — 14,626 14,626 Impairment losses — (13,895 ) (13,895 ) Balances as of December 31, 2023 Goodwill — 14,626 14,626 Accumulated impairment losses — (13,895 ) (13,895 ) Goodwill, net as of December 31, 2023 $ — $ 731 $ 731
Schedule of Finite-Lived Intangible Assets [Table Text Block]	March 31, 2024 (Unaudited) Gross amount Accumulated amortization Net Amount Pharmacy records $ 8,130 $ (1,219 ) $ 6,911 Trade names 4,700 (353 ) 4,347 Developed technology 2,880 (432 ) 2,448 Customer Contracts 250 (231 ) 19 Total intangible assets $ 15,960 $ (2,235 ) $ 13,725 December 31, 2023 (Audited) Gross amount Accumulated amortization Net Amount Pharmacy records $ 8,130 $ (807 ) $ 7,323 Trade names 4,700 (224 ) 4,476 Developed technology 2,880 (281 ) 2,599 Customer Contracts 250 (225 ) 25 Total intangible assets $ 15,960 $ (1,537 ) $ 14,423	December 31, 2023 Gross amount Accumulated amortization Net Amount Pharmacy records $ 8,130 $ (807 ) $ 7,323 Trade names 4,700 (224 ) 4,476 Developed technology 2,880 (281 ) 2,599 Customer Contracts 250 (225 ) 25 Total intangible assets $ 15,960 $ (1,537 ) $ 14,423 December 31, 2022 Gross amount Accumulated amortization Net Amount Pharmacy records $ — $ — $ — Trade names — — — Developed technology — — — Customer Contracts 250 (200 ) 50 Total intangible assets $ 250 $ (200 ) $ 50
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year Amount 2024 (remaining nine months) $ 2,023 2025 2,672 2026 2,672 2027 2,672 2028 1,571 Thereafter 2,115 Total $ 13,725	2024 $ 2,721 2025 2,672 2026 2,672 2027 2,672 2028 1,571 Thereafter 2,115 Total $ 14,423

Note 15 - Equity Method Inves_2

Note 15 - Equity Method Investment (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Equity Method Investments [Table Text Block]	Carrying Amount December 31, 2022, beginning balance $ 5,261 Investment in Progressive Care Inc. and Subsidiaries 1,506 Gain on equity method investment 11,352 Portion of loss from Progressive Care, Inc. and Subsidiaries (1,604 ) Depreciation expense due to cost basis difference (1) (49 ) Interest earned from convertible note receivable 21 Interest earned from amortization of premium on convertible note receivable 199 Elimination of intercompany interest earned (7 ) Change in accounting method as of July 1, 2023 (16,679 ) December 31, 2023, carrying amount $ — For the Year Ended December 31, 2023 Portion of loss from Progressive Care, Inc. and Subsidiaries $ (1,604 ) Depreciation expense due to cost basis difference (1) (49 ) Interest earned from convertible note receivable 21 Interest earned from amortization of premium on convertible note receivable 199 Elimination of intercompany interest earned (7 ) Equity in net loss of affiliate $ (1,440 )

Note 16 - Accounts Payable an_2

Note 16 - Accounts Payable and Accrued Expenses (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	March 31, 2024 December 31, 2023 (Unaudited) (Audited) Accounts payable $ 13,978 $ 12,142 Accrued wages and payroll liabilities 378 200 Accrued PBM fees 366 571 Customer deposits payable 54 76 Accrued other liabilities 117 187 Total $ 14,893 $ 13,176	December 31, 2023 December 31, 2022 Accounts payable $ 12,142 $ 1,200 Accrued wages and payroll liabilities 200 23 Accrued PBM fees 571 — Customer deposits payable 76 86 Accrued legal fees — 85 Pre-merger accrued other liabilities — 88 Accrued other liabilities 187 41 Total $ 13,176 $ 1,523

Note 17 - Notes Payable (Tables

Note 17 - Notes Payable (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes Tables
Schedule of Debt [Table Text Block]	March 31, 2024 December 31, 2023 (Unaudited) (Audited) A. Mortgage note payable - commercial bank - collateralized $ 1,118 $ 1,140 B. Note payable - uncollateralized 25 25 C. Notes payable - collateralized 229 255 Insurance premiums financing 26 103 Subtotal 1,398 1,523 Less: current portion of notes payable (233 ) (312 ) Long-term portion of notes payable $ 1,165 $ 1,211	December 31, 2023 December 31, 2022 A. Mortgage note payable - commercial bank - collateralized $ 1,140 $ — B. Note payable - uncollateralized 25 — C. Notes payable - collateralized 255 216 Insurance premiums financing 103 — Subtotal 1,523 216 Less: current portion of notes payable (312 ) (60 ) Long-term portion of notes payable $ 1,211 $ 156
Schedule of Maturities of Long-Term Debt [Table Text Block]	Year Amount 2024 (remaining nine months) $ 187 2025 215 2026 119 2027 124 2028 753 Thereafter — Total $ 1,398	Year Amount 2024 $ 312 2025 215 2026 119 2027 124 2028 753 Thereafter — Total $ 1,523

Note 19 - Warrants (Tables)

Note 19 - Warrants (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Balance at January 1, 2022 2,530,092 $ 5.00 4.42 Granted 5,124,480 $ 1.75 3.05 Exercised — $ — — Forfeited — $ — — Cancelled — $ — — Balance outstanding and exercisable at December 31, 2022 7,654,572 $ 2.83 3.15 Balance at January 1, 2023 7,654,572 $ 2.83 3.15 Granted 20,000 $ 1.65 3.00 Exercised (105,000 ) $ 1.75 — Forfeited — $ — — Cancelled — $ — — Balance outstanding and exercisable at December 31, 2023 7,569,572 $ 2.85 2.15

Note 20 - Stock-based Compens_2

Note 20 - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]	Number of Units Weighted Average Grant Date Fair Value Outstanding as of December 31, 2021 867,500 $ 4.20 Granted 136,000 $ 2.72 Vested (543,500 ) $ 3.78 Forfeited — $ — Outstanding as of December 31, 2022 460,000 $ 4.32 Granted 559,000 $ 1.65 Vested (794,000 ) $ 2.42 Forfeited — $ — Outstanding as of December 31, 2023 225,000 $ 4.33
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Number of Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Life (Years) Balance at January 1, 2022 2,179,892 $ 4.54 $ 2.44 5.93 Granted 190,000 $ 1.92 $ 1.43 6.85 Exercised — $ — $ — — Cancelled (250,000 ) $ 5.35 $ — — Expired (191 ) $ — $ — — Balance outstanding at December 31, 2022 2,119,701 $ 4.16 $ 2.25 5.23 Options exercisable at December 31, 2022 1,259,701 $ 3.51 $ 1.68 6.25 Balance at January 1, 2023 2,119,701 $ 4.16 $ 2.25 5.23 Granted 395,000 $ 2.37 $ 2.37 4.06 Exercised — $ — $ — — Cancelled (266,284 ) $ 5.88 $ — — Expired (3,084 ) $ — $ — — Balance outstanding at December 31, 2023 2,245,333 $ 3.63 $ 2.88 4.26 Options exercisable at December 31, 2023 1,771,997 $ 3.31 $ 2.86 4.63

Note 21 - Income Taxes (Tables)

Note 21 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	Year Ended December 31, 2023 2022 Net loss after loss in equity method investment and before income taxes: Domestic $ (12,672 ) $ (9,436 ) Foreign 293 362 $ (12,379 ) $ (9,074 )
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Year Ended December 31, 2023 2022 Income tax (benefit) provision: Current Federal $ (11 ) $ — State — — Foreign 39 87 Total current 28 87 Deferred: Federal — — State — — Foreign — — Total deferred — — Total income tax (benefit) provision $ 28 $ 87
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, 2023 2022 Federal income tax (benefit) provision at statutory rate $ (2,655 ) $ (1,984 ) State tax expense net of federal tax benefit — (411 ) State tax expense federal impact — 45 Provision true-up adjustments (488 ) — State rate change adjustment — (214 ) Foreign taxes at rate different than US Taxes 60 87 Net operating loss deduction (310 ) — Permanent differences (22 ) — Other true-ups 99 106 Change in valuation allowance 3,344 2,458 Income tax (benefit) provision $ 28 $ 87
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2023 December 31, 2022 Deferred tax assets: Net operating loss carryforward $ 8,016 $ 3,658 Property plant and equipment and intangibles asset 327 130 Equity method investment loss 806 441 Other tax carry-overs 613 — Reserves and allowances 85 — Stock-based compensation 3,861 1,949 Total deferred tax assets $ 13,708 $ 6,178 Deferred tax liabilities: Book basis of intangible assets in excess of tax basis $ 3,650 $ — Total deferred tax liabilities $ 3,650 $ — Net deferred tax asset before valuation allowance $ 10,058 $ 6,178 Less: valuation allowance (10,058 ) (6,178 ) Net deferred tax asset $ — $ —

Note 22 - Leases (Tables)

Note 22 - Leases (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Lease, Cost [Table Text Block]	For the Year Ended December 31, 2023 2022 Operating lease cost: Fixed rent expense $ 427 $ 101 Variable rent expense 111 — Finance lease cost: Amortization of right-of-use assets 15 — Interest expense 1 — Total Lease Costs $ 554 $ 101
Schedule of Supplemental Cash Flow Information Related to Leases [Table Text Block]	For the Year Ended December 31, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 464 $ 101 Financing cash flows from finance leases 15 — Total cash paid for lease liabilities $ 479 $ 101
Schedule of Supplemental Balance Sheet Information Related to Leases [Table Text Block]	December 31, 2023 December 31, 2022 Operating leases: Operating lease right-of-use assets, net $ 1,566 $ 855 Operating lease liabilities: Current portion 532 209 Long-term portion 929 650 $ 1,461 $ 859 Weighted average remaining lease term (years) 2.96 5.50 Weighted average discount rate 4.65 % 3.75 % Finance leases: Finance lease right-of-use assets, net 22 $ — Finance lease liabilities: Current portion 18 — Long-term portion 5 — $ 23 $ — Weighted average remaining lease term (years) 1.25 — Weighted average discount rate 6.00 % —
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	Years Ending December 31, Finance Lease Operating Lease Total Future Lease Commitments 2024 $ 19 $ 582 $ 601 2025 5 580 585 2026 — 262 262 2027 — 121 121 Total lease payments to be paid 24 1,545 1,569 Less: future interest expense (1 ) (84 ) (85 ) Lease liabilities 23 1,461 1,484 Less: current maturities (18 ) (532 ) (550 ) Long-term portion of lease liabilities $ 5 $ 929 $ 934

Note 23 - Reportable Segments (

Note 23 - Reportable Segments (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes Tables
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	For the Three Months Ended March 31, 2024 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ — $ 11,324 $ — $ 11,324 e-Commerce revenue 2,865 — — 2,865 Pharmacy 340B contract revenue — 3,304 — 3,304 Revenues, net $ 2,865 $ 14,628 $ — $ 17,493 Expenses: Cost of revenue 2,060 10,623 — 12,683 Selling, general and administrative 1,166 899 (60 ) 2,005 Salaries, wages and payroll taxes 508 2,116 — 2,624 Impairment loss — 132 — 132 Professional fees 507 478 — 985 Depreciation and amortization 130 776 — 906 4,371 15,024 (60 ) 19,335 Loss before other (income) expense (1,506 ) (396 ) 60 (1,842 ) Other (expense) income (203 ) (25 ) (60 ) (168 ) Loss before income taxes (1,303 ) (371 ) — (1,674 ) Income taxes (27 ) — — (27 ) Net loss $ (1,330 ) $ (371 ) $ — $ (1,701 ) For the Three Months Ended March 31, 2023 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ — $ — $ — $ — e-Commerce revenue 2,876 — — 2,876 Pharmacy 340B contract revenue — — — — Revenues, net $ 2,876 $ — $ — $ 2,876 Expenses: Cost of revenue 2,255 — — 2,255 Selling, general and administrative 788 — — 788 Salaries, wages and payroll taxes 588 — — 588 Professional fees 321 — — 321 Depreciation and amortization 162 — — 162 4,114 — — 4,114 Loss before other (income) expense (1,238 ) — — (1,238 ) Other (expense) income (83 ) — — (83 ) Loss before income taxes (1,155 ) — — (1,155 ) Income taxes — — — — Loss before equity method investment (1,155 ) — — (1,155 ) Equity in net loss of affiliate (32 ) — — (32 ) Net loss $ (1,187 ) $ — $ — $ (1,187 )	For the Twelve Months Ended December 31, 2023 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ — $ 21,412 $ — $ 21,412 e-Commerce revenue 10,977 — — 10,977 Pharmacy 340B contract revenue — 5,367 — 5,367 Revenues, net $ 10,977 $ 26,779 $ — $ 37,756 Expenses: Cost of revenue 8,122 18,323 — 26,445 Selling, general and administrative 6,633 3,277 — 9,910 Salaries, wages and payroll taxes 2,670 3,973 — 6,643 Goodwill impairment — 13,895 — 13,895 Professional fees 1,595 506 (120 ) 1,981 Depreciation and amortization 647 1,463 — 2,110 Total expenses 19,667 41,437 (120 ) 60,984 Loss before other (income) expense $ (8,690 ) $ (14,658 ) $ 120 $ (23,228 ) For the Twelve Months Ended December 31, 2022 e-Commerce Operations Healthcare Operations Eliminations Total Pharmacy prescription and other revenue, net of PBM fees $ — $ — $ — $ — e-Commerce revenue 11,710 — — 11,710 Pharmacy 340B contract revenue — — — — Revenues, net $ 11,710 $ — $ — $ 11,710 Expenses: Cost of revenue 9,221 — — 9,221 Selling, general and administrative 5,085 — — 5,085 Salaries, wages and payroll taxes 2,565 — — 2,565 Professional fees 1,552 — — 1,552 Depreciation and amortization 490 — — 490 Total expenses 18,913 — — 18,913 Loss before other (income) expense $ (7,203 ) $ — $ — $ (7,203 )
Reconciliation of Assets from Segment to Consolidated [Table Text Block]	e-Commerce Operations Healthcare Operations Eliminations Total Total assets as of March 31, 2024 $ 40,342 $ 41,398 $ (16,679 ) $ 65,061 Total assets as of December 31, 2023 $ 40,764 $ 40,384 $ (16,679 ) $ 64,469	e-Commerce Operations Healthcare Operations Eliminations Total Total assets as of December 31, 2023 $ 40,764 $ 40,384 $ (16,679 ) $ 64,469 Total assets as of December 31, 2022 $ 28,644 $ — $ — $ 28,644

Note 25 - Related Party Trans_2

Note 25 - Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Related Party Transactions [Table Text Block]	Investor Position held at NextPlat Shares of Common Stock Purchased Aggregate Purchase Price Charles M. Fernandez Executive Chairman and Chief Executive Officer 679,013 $ 2,200,002 David Phipps Director and President of Orbsat. Chief Executive Officer of Global Operations 46,297 $ 150,002 Douglas Ellenoff Vice Chairman and Chief Business Development Strategist 46,297 $ 150,002 Shares are deemed to be indirectly beneficially owned through Sabrina Allan, Mr. Ellenoff’s wife. Mr. Ellenoff has the power to vote and dispose of the shares. Louis Cusimano Director 15,433 $ 50,003 Paul R. Thomson Senior Vice President – Mergers, Acquisitions and Special Projects 15,433 $ 50,003 Investor Position held at NextPlat Shares of Common Stock Purchased Warrants to purchase Common Stock Aggregate Purchase Price eAperion Partners LLC, principal Charles M. Fernandez Executive Chairman and Chief Executive Officer 1,085,714 1,085,714 $ 1,900,000 David Phipps Director and President of NextPlat. Chief Executive Officer of Global Operations 28,500 28,500 $ 49,875 RLB Market Investments LLC, principal, Rodney Barreto Director 1,085,714 1,085,714 $ 1,900,000

Note 26 - Concentrations (Table

Note 26 - Concentrations (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	For the Three Months Ended March 31, 2024 For the Three Months Ended March 31, 2023 Globalstar Europe $ 213 10.2 % $ — — % Garmin $ 301 14.3 % $ 594 20.9 % Iridium Satellite $ 270 27.2 % $ — — % For the Three Months Ended March 31, 2024 For the Three Months Ended March 31, 2023 Europe $ 1,430 49.9 % $ 2,063 71.7 % North America 523 18.3 % 586 20.4 % South America 23 0.8 % 9 0.3 % Asia and Pacific 413 14.4 % 159 5.5 % Africa 476 16.6 % 59 2.1 % $ 2,865 100 % $ 2,876 100 % Three Months Ended March 31, 2024 A 33 % B 21 % C 16 %	December 31, 2023 December 31, 2022 Garmin $ 1,921 22.4 % $ 1,821 20.9 % Globalstar Europe $ 958 11.2 % $ 635 7.3 % Network Innovations $ 935 10.7 % $ 980 11.2 % Iridium Satellite $ 913 10.9 % $ — — % Satcom Global $ 761 8.9 % $ 744 8.5 % Year Ended Year Ended December 31, 2023 December 31, 2022 Europe $ 6,687 60.9 % $ 8,617 73.7 % North America 2,575 23.4 % 2,152 18.3 % South America 62 0.6 % 45 0.4 % Asia and Pacific 1,510 13.8 % 760 6.5 % Africa 143 1.3 % 136 1.1 % $ 10,977 100.0 % $ 11,710 100.0 % 2023 A 31 % B 29 % C 14 %

Note 1 - Organization and Nat_3

Note 1 - Organization and Nature of Operations. (Details Textual)	Mar. 31, 2024	Dec. 31, 2023	Dec. 06, 2023
Florida Sunshine Brands, LLC [Member]
Subsidiary, Ownership Percentage, Parent			51%
Florida Sunshine Brands, LLC [Member] | Outer Brands FS, LLC [Member]
Subsidiary, Ownership Percentage, Noncontrolling Owner			49%
Progressive Care [Member] | Pharmco 901 [Member]
Subsidiary, Ownership Percentage, Parent	100%	100%

Note 2 - Basis of Presentatio_3

Note 2 - Basis of Presentation and Principles of Consolidation (Details Textual)	Jul. 01, 2023
Progressive Care [Member]
Business Acquisition, Percentage of Voting Interests Acquired	53%

Note 3 - Summary of Significa_4

Note 3 - Summary of Significant Accounting Policies (Details Textual)	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Mar. 31, 2023	Dec. 31, 2022 USD ($)
Cash, FDIC Insured Amount	$ 250,000	$ 250,000
Cash, Uninsured Amount	1,000,000	3,100,000
Contract with Customer, Liability	$ 140,000	$ 42,000		$ 36,000
Closing Rate [Member]
Foreign Currency Exchange Rate, Translation	1.28	1.27	1.23	1.21
Yearly Average Rate [Member]
Foreign Currency Exchange Rate, Translation	1.27	1.24	1.22	1.24
Maximum [Member]
Cash, FDIC Insured Amount	$ 250,000	$ 250,000

Note 4 - Fair Value (Details Te

Note 4 - Fair Value (Details Textual) $ in Millions	Jul. 01, 2023 USD ($)
Progressive Care [Member] | Fair Value, Inputs, Level 3 [Member]
Finite-Lived Intangible Assets, Fair Value Disclosure	$ 14.7

Note 5 - Revenue - Disaggregati

Note 5 - Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Revenue	$ 17,493	$ 2,876	$ 37,756	$ 11,710
Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue	11,324	0	21,412	0
E-Commerce [Member]
Revenue			10,977	11,710
Pharmacy Prescription, Other Revenue and E-Commerce [Member]
Revenue			32,389	11,710
Pharmacy 340B Contract [Member]
Revenue	3,304	0	5,367	0
E-Commerce Revenue [Member]
Revenue	17,493		10,977	11,710
E-Commerce Revenue [Member] | Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue	11,324		0	0
E-Commerce Revenue [Member] | E-Commerce [Member]
Revenue	2,865		10,977	11,710
E-Commerce Revenue [Member] | Pharmacy Prescription, Other Revenue and E-Commerce [Member]
Revenue	14,189		10,977	11,710
E-Commerce Revenue [Member] | Pharmacy 340B Contract [Member]
Revenue	$ 3,304		0	0
Healthcare Operations [Member]
Revenue		2,876	26,779	0
Healthcare Operations [Member] | Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue		0	21,412	0
Healthcare Operations [Member] | E-Commerce [Member]
Revenue		2,876	0	0
Healthcare Operations [Member] | Pharmacy Prescription, Other Revenue and E-Commerce [Member]
Revenue		2,876	21,412	0
Healthcare Operations [Member] | Pharmacy 340B Contract [Member]
Revenue		$ 0	$ 5,367	$ 0

Note 6 - Loss Per Share - Earni

Note 6 - Loss Per Share - Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Net loss attributable to NextPlat Corp common shareholders	$ (1,481)	$ (1,187)	$ (3,778)	$ (9,161)
Basic weighted average common shares outstanding (in shares)	18,725	14,415	17,494	9,592
Potentially dilutive common shares (in shares)	0	0	0	0
Diluted weighted average common shares outstanding (in shares)	18,725	14,415	17,494	9,592
Weighted average loss per common share - basic and diluted (in dollars per share)	$ (0.08)	$ (0.08)	$ (0.22)	$ (0.96)
Antidilutive securities (in shares)	105	100	811	1,668
Share-Based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	105	100	136	265

Note 7 - Accounts Receivable (D

Note 7 - Accounts Receivable (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Jan. 01, 2023
Accounts Receivable, Credit Loss Expense (Reversal)	$ 2,000	$ 0	$ 47,000	$ 0
Accounts Receivable, after Allowance for Credit Loss	$ 12,928,000	$ 1,000,000	$ 8,923,000	$ 384,000	$ 400,000

Note 7 - Accounts Receivable -

Note 7 - Accounts Receivable - Summary of Accounts Receivable (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Jan. 01, 2023	Dec. 31, 2022
Gross accounts receivable – trade	$ 13,202	$ 9,195			$ 384
Less: allowance for doubtful accounts	(274)	(272)			0
Accounts receivable – trade, net	$ 12,928	$ 8,923	$ 1,000	$ 400	$ 384

Note 8 - Inventory - Summary of

Note 8 - Inventory - Summary of Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Finished goods	$ 5,670	$ 5,195	$ 1,287
Less reserve for obsolete inventory	(60)	(60)	0
Total	$ 5,610	$ 5,135	$ 1,287

Note 9 - VAT Receivable (Detail

Note 9 - VAT Receivable (Details Textual) - USD ($)	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Value Added Tax Receivable, Current	$ 357,000	$ 342,000	$ 433,000

Note 10 - Prepaid Expenses (Det

Note 10 - Prepaid Expenses (Details Textual) - USD ($)	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Prepaid Expense, Current	$ 404,000	$ 640,000	$ 46,000
Prepaid Expense, Noncurrent	$ 61,000	$ 61,000	$ 49,000

Note 11 - Property and Equipm_3

Note 11 - Property and Equipment, Net (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Depreciation	$ 203,000	$ 155,000	$ 758,000	$ 465,000

Note 11 - Property and Equipm_4

Note 11 - Property and Equipment, Net - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Property and equipment gross	$ 6,546	$ 6,492	$ 3,111
Less: accumulated depreciation	(2,700)	(2,503)	(1,865)
Property and equipment, net	3,846	3,989	1,246
Building [Member]
Property and equipment gross	2,116	2,116	0
Vehicles [Member]
Property and equipment gross	585	595	0
Furniture and Fixtures [Member]
Property and equipment gross	543	527	128
Land [Member]
Property and equipment gross	184	184	0
Leasehold Improvements [Member]
Property and equipment gross	167	124	48
Computer Equipment [Member]
Property and equipment gross	117	117	72
Rental Equipment [Member]
Property and equipment gross	63	60	38
Appliques [Member]
Property and equipment gross	2,160	2,160	2,160
Website Development [Member]
Property and equipment gross	611	587	665
Construction in Progress [Member]
Property and equipment gross	$ 0	$ 22	$ 0

Note 12 - Intangible Assets, _3

Note 12 - Intangible Assets, Net (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Amortization of Intangible Assets	$ 698,000	$ 6,000	$ 1,337,000	$ 25,000

Note 12 - Goodwill and Intangib

Note 12 - Goodwill and Intangible Assets, Net - Summary of Finite-lived Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets, Gross	$ 15,960	$ 15,960	$ 250
Finite Lived Intangible Assets, Accumulated Amortization	(2,235)	(1,537)	(200)
Finite Lived Intangible Assets, Net	13,725	14,423	50
Pharmacy Records [Member]
Finite-Lived Intangible Assets, Gross	8,130	8,130	0
Finite Lived Intangible Assets, Accumulated Amortization	(1,219)	(807)	0
Finite Lived Intangible Assets, Net	6,911	7,323	0
Trade Names [Member]
Finite-Lived Intangible Assets, Gross	4,700	4,700	0
Finite Lived Intangible Assets, Accumulated Amortization	(353)	(224)	0
Finite Lived Intangible Assets, Net	4,347	4,476	0
Computer Software, Intangible Asset [Member]
Finite-Lived Intangible Assets, Gross	2,880	2,880	0
Finite Lived Intangible Assets, Accumulated Amortization	(432)	(281)	0
Finite Lived Intangible Assets, Net	2,448	2,599	0
Customer Contracts [Member]
Finite-Lived Intangible Assets, Gross	250	250	250
Finite Lived Intangible Assets, Accumulated Amortization	(231)	(225)	(200)
Finite Lived Intangible Assets, Net	$ 19	$ 25	$ 50

Note 12 - Goodwill and Intang_2

Note 12 - Goodwill and Intangible Assets, Net - Future Amortization of Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
2024 (remaining nine months)	$ 2,023
2024	2,672	$ 2,721
2025	2,672	2,672
2026	2,672	2,672
2027	1,571	2,672
Thereafter	2,115
Total	$ 13,725	$ 14,423	$ 50

Note 13 - Accounts Payable an_3

Note 13 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expense (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Accounts payable	$ 13,978	$ 12,142	$ 1,200
Accrued wages and payroll liabilities	378	200	23
Accrued PBM fees	366	571	0
Customer deposits payable	54	76	86
Accrued other liabilities	117	187	41
Total	$ 14,893	$ 13,176	$ 1,523

Note 14 - Notes Payable (Detail

Note 14 - Notes Payable (Details Textual)		1 Months Ended			12 Months Ended
	Jul. 16, 2020 GBP (£)	Sep. 30, 2022 USD ($)	Jul. 31, 2022 USD ($)	Apr. 30, 2021 USD ($)	Dec. 31, 2018 USD ($)	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Jul. 16, 2020 USD ($)	Jul. 16, 2020 GBP (£)
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]	Base Rate [Member]
Long-Term Debt						$ 1,398,000	$ 1,523,000
Collateralized Promissory Note [Member] | Progressive Care [Member]
Debt Instrument, Face Amount					$ 1,530,000
Debt Instrument, Interest Rate, Stated Percentage					4.75%
Debt Instrument, Number of Payments					119
Debt Instrument, Periodic Payment					$ 11,901
Coronavirus Loans [Member] | HSBC UK Bank PLC [Member]
Debt Instrument, Face Amount								$ 338,343	£ 250,000
Foreign Currency Exchange Rate, Translation								1.353372	1.353372
Debt Instrument, Basis Spread on Variable Rate	4%
Debt Instrument, Interest Rate, Effective Percentage								0.10%	0.10%
Debt Instrument, Term (Year)	6 years
Debt Instrument, Periodic Payment, Principal | £	£ 4,166.67
Debt Instrument, Prepayment Limit, Percentage of Balance of Debenture								10%	10%
Long-Term Debt							165,000
Note Obligation for Pharmacy Equipment [Member] | Progressive Care [Member]
Debt Instrument, Face Amount				$ 30,000
Debt Instrument, Interest Rate, Stated Percentage				6.90%
Debt Instrument, Number of Payments				46
Debt Instrument, Periodic Payment				$ 331
Long-Term Debt						5,000	6,500
Note Obligation to Purchase Pharmacy Equipment [Member] | Progressive Care [Member]
Debt Instrument, Face Amount			$ 90,000
Debt Instrument, Interest Rate, Stated Percentage			8.78%
Debt Instrument, Number of Payments			60
Debt Instrument, Periodic Payment			$ 1,859
Long-Term Debt						70,000	74,000
Note Obligation for Vehicles [Member] | Progressive Care [Member]
Debt Instrument, Face Amount		$ 25,000
Debt Instrument, Interest Rate, Stated Percentage		8.29%
Debt Instrument, Number of Payments		24
Debt Instrument, Periodic Payment		$ 1,143
Long-Term Debt						$ 7,000	$ 10,000

Note 14 - Notes Payable - Sched

Note 14 - Notes Payable - Schedule of Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Note payable	$ 1,398	$ 1,523	$ 216
Less: current portion of notes payable	(233)	(312)	(60)
Long-term portion of notes payable	1,165	1,211	156
Mortgage Note Payable Commercial Bank Collateralized [Member]
Note payable	1,118	1,140	0
Note Payable Uncollateralized [Member]
Note payable	25	25	0
Note Payable Collateralized [Member]
Note payable	229	255	216
Insurance Premium Financing [Member]
Note payable	$ 26	$ 103	$ 0

Note 14 - Notes Payable - Sch_2

Note 14 - Notes Payable - Schedule of Future Maturities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
2024 (remaining nine months)	$ 187
2025	215	$ 312
2026	119	215
2027	124	119
2028	753	124
Thereafter	0
Total	$ 1,398	$ 1,523

Note 15 - Equity (Details Textu

Note 15 - Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended		12 Months Ended
	Apr. 11, 2023	Apr. 05, 2023	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 14, 2022	Dec. 09, 2022
Preferred Stock, Shares Authorized (in shares)			3,333,333		3,333,333	3,333,333
Preferred Stock, Par or Stated Value Per Share (in dollars per share)			$ 0.0001		$ 0.0001	$ 0.0001
Preferred Stock, Shares Outstanding (in shares)			0		0
Common Stock, Shares Authorized (in shares)			50,000,000		50,000,000	50,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)			$ 0.0001		$ 0.0001	$ 0.0001
Common Stock, Shares, Issued (in shares)			18,724,596		18,724,596	14,402,025
Share-Based Payment Arrangement, Expense			$ 600	$ 200	$ 5,400	$ 3,000
Share-Based Payment Arrangement, Expense, Tax Benefit			$ 0	$ 0
December 2022 Private Placement [Member]
Warrants and Rights Outstanding, Term (Year)							3 years	3 years
December 2022 Private Placement [Member] | Dawson James [Member]
Warrants and Rights Outstanding, Term (Year)								3 years
April 2023 Private Placement [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001	$ 0.0001
Stock Issued During Period, Shares, New Issues (in shares)	3,428,571	3,428,571
Shares Issued, Price Per Share (in dollars per share)	$ 1.75	$ 1.75
Proceeds from Issuance of Private Placement	$ 6,000

Note 16 - Related Party Trans_2

Note 16 - Related Party Transactions (Details Textual)

1 Months Ended

3 Months Ended

12 Months Ended

Jul. 07, 2023 USD ($)

Jul. 01, 2023 USD ($) shares

May 09, 2023 shares

May 05, 2023 USD ($) $ / shares shares

May 01, 2023 USD ($)

Feb. 01, 2023 USD ($)

Dec. 30, 2022

Sep. 02, 2022 USD ($)

Jul. 12, 2022 USD ($)

Apr. 30, 2023 USD ($)

Mar. 31, 2024 USD ($) $ / shares

Mar. 31, 2023 USD ($)

Dec. 31, 2023 USD ($) $ / shares

Dec. 31, 2022 USD ($) $ / shares

Aug. 30, 2022 USD ($) shares

Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares

$ 0.0001

$ 0.0001

$ 0.0001

Proceeds from Warrant Exercises | $

$ 184,000

$ 0

Reverse Stock Split [Member]

Stockholders' Equity Note, Stock Split, Conversion Ratio

200

Predecessor Company [Member]

Investment Owned, Balance, Shares (in shares) | shares

105,000

Progressive Care [Member]

Investment Owned, Balance, Shares (in shares) | shares

402,269

455,000

3,000

Investment Owned, Price Per Share (in dollars per share) | $ / shares

$ 2.2

Investment Owned, Cost | $

$ 1,000,000

$ 8,300,000

Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares

$ 0.0001

Proceeds from Warrant Exercises | $

$ 506,000

Investment Owned, Balance, Shares From Warrants Exercised (in shares) | shares

230,000

Iliad [Member] | Secured Convertible Promissory Note [Member]

Payments to Acquire Notes Receivable | $

$ 1,000,000

Debt Conversion Agreement [Member] | Predecessor Company [Member]

Long-Term Debt, Gross | $

$ 2,800,000

Lauren Sturges Fernandez [Member]

Annual Salary | $

$ 95,000

$ 125,000

Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold | $

$ 10,995

$ 10,995

CEO and Board Member [Member] | Iliad [Member] | Secured Convertible Promissory Note [Member]

Payments to Acquire Notes Receivable, Including Contributions by Related Parties | $

2,300,000

Chief Operating Officer [Member] | Iliad [Member] | Secured Convertible Promissory Note [Member]

Payments to Acquire Notes Receivable | $

$ 400,000

NextPlat Corp [Member] | Progressive Care [Member] | Debt Converted to Common Stock [Member]

Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares

570,599

570,599

NextPlat Corp [Member] | Predecessor Company [Member]

Investment Owned, Balance, Shares (in shares) | shares

45,653

Chief Executive Officer [Member] | Progressive Care [Member] | Inducement Warrant [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares

190,000

Chief Executive Officer [Member] | Progressive Care [Member] | Debt Converted to Common Stock [Member]

Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares

228,240

Chief Executive Officer [Member] | Predecessor Company [Member]

Investment Owned, Balance, Shares (in shares) | shares

18,261

Chief Executive Officer [Member] | Progressive Care [Member]

Investment Owned, Balance, Shares From Warrants Exercised (in shares) | shares

211,470

Board Member [Member] | Progressive Care [Member] | Inducement Warrant [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares

30,000

Board Member [Member] | Progressive Care [Member] | Debt Converted to Common Stock [Member]

Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares

228,240

Board Member [Member] | Predecessor Company [Member]

Investment Owned, Balance, Shares (in shares) | shares

18,261

Board Member [Member] | Progressive Care [Member]

Investment Owned, Balance, Shares From Warrants Exercised (in shares) | shares

130,571

Progressive Care [Member]

Management and Administrative Service Revenue, Per Month | $

$ 20,000

$ 25,000

Proceeds From Management and Administrative Service | $

$ 60,000

$ 50,000

235,000

Fernandez And Barreto [Member] | Progressive Care [Member]

Related Party, Ownership Percentage

53%

Related Party [Member]

Notes Receivable, Principal | $

$ 250,000

Notes Receivable, Interest Rate

7%

Financing Receivable, before Allowance for Credit Loss | $

$ 260,000

$ 256,000

Note 18 - Leases (Details Textu

Note 18 - Leases (Details Textual)			1 Months Ended			3 Months Ended			12 Months Ended
	Dec. 02, 2021 USD ($) ft²	May 31, 2018 USD ($)	Sep. 30, 2021 USD ($)	Aug. 31, 2020 USD ($)	May 31, 2018 USD ($)	Mar. 31, 2024 USD ($) ft²	Mar. 31, 2024 GBP (£) ft²	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($) ft²	Dec. 31, 2023 GBP (£)	Dec. 31, 2022 USD ($)
Finance Lease, Liability									$ 23,000		$ 0
Operating Lease, Impairment Loss						$ 132,000		$ 0	$ 0		$ 0
Annual Rent	$ 186,000
Office Space in Florida [Member]
Lessee, Operating Lease, Term of Contract (Month)	62 months
Area of Real Estate Property (Square Foot) | ft²	4,141
Annual Rent	$ 186,345
Annual Lease Increase, Percentage	3%
Facilities in Poole, England [Member]
Area of Real Estate Property (Square Foot) | ft²						2,660	2,660		2,660
Annual Rent						$ 37,107	£ 30,000		$ 37,100	£ 30,000
Foreign Currency Exchange Rate, Translation						1.24	1.24		1.24
Lessee, Operating Lease, Renewal Term (Month)						12 months	12 months		12 months
Progressive Care [Member] | Finance Obligation for Pharmacy Equipment [Member]
Finance Lease, Liability		$ 115,000			$ 115,000
Finance Lease, Monthly Payment		$ 1,678			$ 1,700
Lessee, Finance Lease, Term of Contract (Month)		84 months			84 months
Lessee, Finance Lease, Interest Rate		6%			6%
Progressive Care [Member] | Orlando Pharmacy [Member]
Lessee, Operating Lease, Term of Contract (Month)				66 months
Operating Lease, Monthly Payment				$ 4,310
Progressive Care [Member] | North Miami Beach Pharmacy [Member]
Lessee, Operating Lease, Term of Contract (Month)			60 months
Operating Lease, Monthly Payment			$ 5,237

Note 19 - Reportable Segments_2

Note 19 - Reportable Segments (Details Textual)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Number of Reportable Segments	2	2

Note 19 - Reportable Segments -

Note 19 - Reportable Segments - Schedule of Reportable Segments (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Revenue	$ 17,493	$ 2,876	$ 37,756	$ 11,710
Cost of revenue	12,683	2,255	26,445	9,221
Selling, general and administrative	2,005	788	9,910	5,085
Salaries, wages and payroll taxes	2,624	588	6,643	2,565
Impairment loss	132	0	28	0
Professional fees	985	321	1,981	1,552
Depreciation and amortization	906	162	2,110	490
Expenses, Including Cost of Revenue	19,335	4,114	60,984	18,913
Loss before other (income) expense	(1,842)	(1,238)	(23,228)	(7,203)
Other (expense) income	(168)	(83)	(937)	132
Loss before income taxes	(1,674)	(1,155)	(22,291)	(7,335)
Income taxes	(27)	0	(28)	(87)
Net loss	(1,701)	(1,187)	(12,407)	(9,161)
Loss before equity method investment	(1,701)	(1,155)	(22,319)	(7,422)
Equity in net loss of affiliate	0	(32)	(1,440)	(1,739)
Segment Expense [Member]
Selling, general and administrative	2,005	788	9,910
Professional fees	985	321	1,981
Depreciation and amortization	906	162	2,110
Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue	11,324	0	21,412	0
E-Commerce Revenue [Member]
Revenue	2,865	2,876	10,977	11,710
Pharmacy 340B Contract [Member]
Revenue	3,304	0	5,367	0
Consolidation, Eliminations [Member]
Revenue	0	0	0	0
Cost of revenue	0	0	0	0
Selling, general and administrative				0
Salaries, wages and payroll taxes	0	0	0	0
Impairment loss	0
Professional fees				0
Depreciation and amortization				0
Expenses, Including Cost of Revenue	(60)	0	(120)	0
Loss before other (income) expense	60	0	120	0
Other (expense) income	(60)	0
Loss before income taxes	0	0
Income taxes	0	0
Net loss	0	0
Loss before equity method investment		0
Equity in net loss of affiliate		0
Consolidation, Eliminations [Member] | Segment Expense [Member]
Selling, general and administrative	(60)	0	0
Professional fees	0	0	(120)
Depreciation and amortization	0	0	0
Consolidation, Eliminations [Member] | Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue	0	0	0	0
Consolidation, Eliminations [Member] | E-Commerce Revenue [Member]
Revenue	0	0	0	0
Consolidation, Eliminations [Member] | Pharmacy 340B Contract [Member]
Revenue	0	0	0	0
E-Commerce [Member] | Operating Segments [Member]
Revenue	2,865	2,876	10,977	11,710
Cost of revenue	2,060	2,255	8,122	9,221
Selling, general and administrative				5,085
Salaries, wages and payroll taxes	508	588	2,670	2,565
Impairment loss	0
Professional fees				1,552
Depreciation and amortization				490
Expenses, Including Cost of Revenue	4,371	4,114	19,667	18,913
Loss before other (income) expense	(1,506)	(1,238)	(8,690)	(7,203)
Other (expense) income	(203)	(83)
Loss before income taxes	(1,303)	(1,155)
Income taxes	(27)	0
Net loss	(1,330)	(1,187)
Loss before equity method investment		(1,155)
Equity in net loss of affiliate		(32)
E-Commerce [Member] | Operating Segments [Member] | Segment Expense [Member]
Selling, general and administrative	1,166	788	6,633
Professional fees	507	321	1,595
Depreciation and amortization	130	162	647
E-Commerce [Member] | Operating Segments [Member] | Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue	0	0	0	0
E-Commerce [Member] | Operating Segments [Member] | E-Commerce Revenue [Member]
Revenue	2,865	2,876	10,977	11,710
E-Commerce [Member] | Operating Segments [Member] | Pharmacy 340B Contract [Member]
Revenue	0	0	0	0
Healthcare Operations [Member]
Revenue		2,876	26,779	0
Healthcare Operations [Member] | Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue		0	21,412	0
Healthcare Operations [Member] | Pharmacy 340B Contract [Member]
Revenue		0	5,367	0
Healthcare Operations [Member] | Operating Segments [Member]
Revenue	14,628	0	26,779	0
Cost of revenue	10,623	0	18,323	0
Selling, general and administrative				0
Salaries, wages and payroll taxes	2,116	0	3,973	0
Impairment loss	132
Professional fees				0
Depreciation and amortization				0
Expenses, Including Cost of Revenue	15,024	0	41,437	0
Loss before other (income) expense	(396)	0	(14,658)	0
Other (expense) income	(25)	0
Loss before income taxes	(371)	0
Income taxes	0	0
Net loss	(371)	0
Loss before equity method investment		0
Equity in net loss of affiliate		0
Healthcare Operations [Member] | Operating Segments [Member] | Segment Expense [Member]
Selling, general and administrative	899	0	3,277
Professional fees	478	0	506
Depreciation and amortization	776	0	1,463
Healthcare Operations [Member] | Operating Segments [Member] | Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue	11,324	0	21,412	0
Healthcare Operations [Member] | Operating Segments [Member] | E-Commerce Revenue [Member]
Revenue	0	0	0	0
Healthcare Operations [Member] | Operating Segments [Member] | Pharmacy 340B Contract [Member]
Revenue	$ 3,304	$ 0	$ 5,367	$ 0

Note 19 - Reportable Segments_3

Note 19 - Reportable Segments - Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Total Assets	$ 65,061	$ 64,469	$ 28,644
Operating Segments [Member] | E-Commerce [Member]
Total Assets	40,342	40,764	28,644
Operating Segments [Member] | Healthcare Operations [Member]
Total Assets	41,398	40,384	0
Consolidation, Eliminations [Member]
Total Assets	$ (16,679)	$ (16,679)	$ 0

Note 20 - Concentrations (Detai

Note 20 - Concentrations (Details Textual)	3 Months Ended		6 Months Ended	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Amazon [Member]
Concentration Risk, Percentage	39.90%	57.20%		51.60%	54.30%
Purchases [Member] | Supplier Concentration Risk [Member]
Number of Major Vendors	1		1
Purchases [Member] | Supplier Concentration Risk [Member] | One Vendor [Member]
Concentration Risk, Percentage	98%		99%

Note 20 - Concentrations - Sche

Note 20 - Concentrations - Schedules of Concentration of Risk (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Revenue	$ 17,493	$ 2,876		$ 37,756	$ 11,710
Purchases [Member] | Supplier Concentration Risk [Member] | Globalstar Europe [Member]
Purchases	$ 213	$ 0		$ 958	$ 635
Percentage	10.20%	0%		11.20%	7.30%
Purchases [Member] | Supplier Concentration Risk [Member] | Garmin [Member]
Purchases	$ 301	$ 594		$ 1,921	$ 1,821
Percentage	14.30%	20.90%		22.40%	20.90%
Purchases [Member] | Supplier Concentration Risk [Member] | Iridium Satellite [Member]
Purchases	$ 270	$ 0		$ 913	$ 0
Percentage	27.20%	0%		10.90%	0%
Revenue Benchmark [Member] | Geographic Concentration Risk [Member]
Percentage				100%	100%
Revenue				$ 10,977	$ 11,710
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | Europe [Member]
Percentage	49.90%	71.70%		60.90%	73.70%
Revenue	$ 1,430	$ 2,063		$ 6,687	$ 8,617
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | North America [Member]
Percentage	18.30%	20.40%		23.40%	18.30%
Revenue	$ 523	$ 586		$ 2,575	$ 2,152
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | South America [Member]
Percentage	0.80%	0.30%		0.60%	0.40%
Revenue	$ 23	$ 9		$ 62	$ 45
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | Asia Pacific [Member]
Percentage	14.40%	5.50%		13.80%	6.50%
Revenue	$ 413	$ 159		$ 1,510	$ 760
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | Africa [Member]
Percentage	16.60%	2.10%		1.30%	1.10%
Revenue	$ 476	$ 59		$ 143	$ 136
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | All Countries [Member]
Percentage	100%	100%
Revenue	$ 2,865	$ 2,876
Reimbursements [Member] | Customer Concentration Risk [Member] | PBM A [Member]
Percentage	33%		31%
Reimbursements [Member] | Customer Concentration Risk [Member] | PBM B [Member]
Percentage	21%		29%
Reimbursements [Member] | Customer Concentration Risk [Member] | PBM C [Member]
Percentage	16%		14%

Note 21 - Subsequent Events (De

Note 21 - Subsequent Events (Details Textual) - Subsequent Event [Member] - Outfitter Satellite, Inc. [Member] - USD ($)	Apr. 01, 2024	Mar. 25, 2024
Business Combination, Consideration Transferred	$ 760,000	$ 760,000
Payments to Acquire Businesses, Gross	660,000
Business Combination, Contingent Consideration, Liability	$ 100,000

Note 1 - Organization and Nat_4

Note 1 - Organization and Nature of Operations. (Details Textual)	Mar. 31, 2024	Dec. 31, 2023
Progressive Care [Member] | Pharmco 901 [Member]
Subsidiary, Ownership Percentage, Parent	100%	100%

Note 2 - Basis of Presentatio_4

Note 2 - Basis of Presentation and Principles of Consolidation (Details Textual)	Jul. 01, 2023
Progressive Care [Member]
Business Acquisition, Percentage of Voting Interests Acquired	53%

Note 3 - Summary of Significa_5

Note 3 - Summary of Significant Accounting Policies (Details Textual)							3 Months Ended		12 Months Ended
	Apr. 11, 2023 $ / shares shares	Apr. 05, 2023 USD ($) $ / shares shares	Dec. 14, 2022 USD ($) $ / shares shares	Dec. 09, 2022 USD ($) $ / shares shares	Jan. 05, 2022 USD ($)	Jan. 02, 2022 USD ($) $ / shares shares	Mar. 31, 2024 USD ($) $ / shares	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($) $ / shares	Dec. 31, 2022 USD ($) $ / shares
Placement Agent Fee, Percentage of Gross Proceeds				6%
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares							$ 0.0001		$ 0.0001	$ 0.0001
Proceeds from Issuance of Common Stock									$ 6,000,000	$ 13,832,000
Cash, FDIC Insured Amount							$ 250,000		250,000
Cash, Uninsured Amount							1,000,000		3,100,000
Prepaid Expense, Current							404,000		640,000	46,000
Prepaid Expense, Noncurrent							61,000		61,000	49,000
Contract with Customer, Liability							140,000		42,000	36,000
Advertising Expense									188,000	93,000
Depreciation							$ 203,000	$ 155,000	$ 758,000	$ 465,000
Pharmacy Records and Developed Software [Member]
Finite-Lived Intangible Asset, Useful Life (Year)									5 years
Trade Names and Customer Contracts [Member]
Finite-Lived Intangible Asset, Useful Life (Year)									10 years
Closing Rate [Member]
Foreign Currency Exchange Rate, Translation							1.28	1.23	1.27	1.21
Yearly Average Rate [Member]
Foreign Currency Exchange Rate, Translation							1.27	1.22	1.24	1.24
Maximum [Member]
Cash, FDIC Insured Amount							$ 250,000		$ 250,000
Officer [Member]
Placement Agent Fee, Percentage of Gross Proceeds				3%
December 2022 Private Placement [Member]
Number of Warrants Per Unit (in shares) | shares			1	1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares			1	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 1.75	$ 1.75
Warrants and Rights Outstanding, Term (Year)			3 years	3 years
December 2022 Private Placement [Member] | Dawson James [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 1.75
Warrants and Rights Outstanding, Term (Year)				3 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares				549,051
Legal Fees				$ 100,000
January 2022 Private Placement [Member]
Sale of Stock, Number of Shares Issued in Transaction (in shares) | shares						2,229,950
Sale of Stock, Price Per Share (in dollars per share) | $ / shares						$ 3.24
Stock Issued During Period, Value, New Issues					$ 7,200,000	$ 7,225,038				$ 7,005,000
Shares Issued, Price Per Share (in dollars per share) | $ / shares						$ 3.24
Stock Issued During Period, Shares, New Issues (in shares) | shares						2,229,950
Proceeds from Issuance of Common Stock						$ 7,000,000
December 2022 Private Placement [Member]
Stock Issued During Period, Value, New Issues										$ 7,472,000
Equity Offering, Units Issued (in shares) | shares			4,575,429	4,575,429
Number of Shares Per Unit Issued (in shares) | shares			1	1
Shares Issued, Price Per Share (in dollars per share) | $ / shares			$ 1.75	$ 1.75
Proceeds From Equity Offering			$ 8,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares			$ 0.0001
April 2023 Private Placement [Member]
Stock Issued During Period, Value, New Issues									$ 6,000,000
Shares Issued, Price Per Share (in dollars per share) | $ / shares	$ 1.75	$ 1.75
Stock Issued During Period, Shares, New Issues (in shares) | shares	3,428,571	3,428,571
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares	$ 0.0001	$ 0.0001
Proceeds from Issuance of Common Stock		$ 6,000,000

Note 3 - Summary of Significa_6

Note 3 - Summary of Significant Accounting Policies - Summary of Carrying Amounts of Major Classes of Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Assets of discontinued operations	$ 0	$ 0
Accounts payables and accrued expenses	0	(112)
Liabilities from discontinued operations	$ 0	$ (112)

Note 3 - Summary of Significa_7

Note 3 - Summary of Significant Accounting Policies - Schedule of Estimated Useful Life of Property and Equipment (Details)	Dec. 31, 2023
Building [Member]
Useful life (Year)	40 years
Furniture and Fixtures [Member] | Minimum [Member]
Useful life (Year)	4 years
Furniture and Fixtures [Member] | Maximum [Member]
Useful life (Year)	5 years
Computer Equipment [Member] | Minimum [Member]
Useful life (Year)	3 years
Computer Equipment [Member] | Maximum [Member]
Useful life (Year)	4 years
Rental Equipment [Member]
Useful life (Year)	4 years
Vehicles [Member] | Minimum [Member]
Useful life (Year)	3 years
Vehicles [Member] | Maximum [Member]
Useful life (Year)	5 years
Appliques [Member]
Useful life (Year)	10 years
Website Development [Member]
Useful life (Year)	2 years

Note 4 - Acquisition (Details T

Note 4 - Acquisition (Details Textual) - USD ($)			6 Months Ended	12 Months Ended
		Jul. 01, 2023	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2024	May 05, 2023	Aug. 30, 2022
Proceeds from Warrant Exercises				$ 184,000	$ 0
Common Stock, Shares, Outstanding (in shares)			18,724,596	18,724,596	14,402,025	18,724,596
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain				$ 11,352,000	$ 0
Progressive Care [Member]
Business Acquisition, Percentage of Voting Interests Acquired		53%
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual			$ 26,800,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual			(14,700,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities	[1]	$ 0
Common Stock, Shares, Outstanding (in shares)		7,662,343
Share Price (in dollars per share)		$ 4.45
Business Combination, Warrants and Options Acquired		$ 5,800,000
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain		11,400,000
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value		23,180,000
Equity Method Investments, Fair Value Disclosure		16,700,000
Finite-Lived Intangible Assets Acquired		$ 15,700,000
Progressive Care [Member] | Measurement Input, Discount Rate [Member] | Minimum [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Measurement Input		0.10
Progressive Care [Member] | Measurement Input, Discount Rate [Member] | Maximum [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Measurement Input		0.11
Progressive Care [Member] | Measurement Input, Long-Term Revenue Growth Rate [Member] | Minimum [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Measurement Input		0.03
Progressive Care [Member] | Series B Preferred Stock [Member]
Business Acquisition, Shares Acquired (in shares)		1,500,000
Progressive Care [Member] | Common Stock [Member]
Business Acquisition, Shares Acquired (in shares)		6,162,343
Progressive Care [Member] | Scenario, Adjustment [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities			$ 4,000,000	4,000,000
Progressive Care [Member]
Investment Owned, Balance, Shares (in shares)		402,269					455,000	3,000
Proceeds from Warrant Exercises		$ 506,000
Investment Owned, Balance, Shares From Warrants Exercised (in shares)		230,000
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain				$ 11,352,000
Progressive Care [Member] | Chief Executive Officer [Member]
Investment Owned, Balance, Shares From Warrants Exercised (in shares)		211,470
Progressive Care [Member] | Board Member [Member]
Investment Owned, Balance, Shares From Warrants Exercised (in shares)		130,571
[1]Under federal tax law, previously unidentified finite lived intangible assets recognized from a business combination have no tax basis and therefore are not amortized for tax purposes. This tax position created a book/tax basis difference that was previously not recognized at July 1, 2023, the date of the business combination transaction. Therefore, an approximate $4.0 million deferred tax liability measurement period adjustment was recorded at December 31, 2023 as a result of the book/tax basis difference for the finite lived intangible assets. In addition the Company determined that the acquired deferred tax liability could be utilized to offset preexisting deferred tax assets. Therefore, in accordance with ASC 805-740-45-2, the Company released the deferred tax asset valuation allowance as a reduction to goodwill in the amount of approximately $4.0 million during the measurement period.

Note 4 - Acquisition - Pro Form

Note 4 - Acquisition - Pro Forma Summary (Details) - Progressive Care [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue	$ 60,704	$ 52,312
Earnings	$ (15,854)	$ (13,867)

Note 4 - Acquisition - Summary

Note 4 - Acquisition - Summary of Consideration Transferred in Business Acquisition (Details) - USD ($) $ in Thousands		Jul. 01, 2023	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Goodwill			$ 731	$ 731	$ 0	$ 0
Progressive Care [Member]
Total purchase consideration		$ 16,679
Fair value of non-controlling interest		23,180
Total consideration		39,859
Cash		7,352
Accounts receivable, net		6,478
Accounts receivable, other		506
Inventory		1,631
Prepaid expenses		220
Property and equipment, net		2,883
Right of use assets, net		405
Deposits		39
Accounts payable and accrued expenses		(8,231)
Notes payable and accrued interest - current portion		(149)
Lease liabilities - current portion		(208)
Notes payable - long term		(1,173)
Lease liabilities - long term		(230)
Deferred tax liability (1)	[1]	0
Net assets acquired		25,233
Goodwill		14,626
Progressive Care [Member] | Trade Names [Member]
Finite-Lived Intangibles		4,700
Progressive Care [Member] | Developed Technology Rights [Member]
Finite-Lived Intangibles		2,880
Progressive Care [Member] | Pharmacy Records [Member]
Finite-Lived Intangibles		$ 8,130
[1]Under federal tax law, previously unidentified finite lived intangible assets recognized from a business combination have no tax basis and therefore are not amortized for tax purposes. This tax position created a book/tax basis difference that was previously not recognized at July 1, 2023, the date of the business combination transaction. Therefore, an approximate $4.0 million deferred tax liability measurement period adjustment was recorded at December 31, 2023 as a result of the book/tax basis difference for the finite lived intangible assets. In addition the Company determined that the acquired deferred tax liability could be utilized to offset preexisting deferred tax assets. Therefore, in accordance with ASC 805-740-45-2, the Company released the deferred tax asset valuation allowance as a reduction to goodwill in the amount of approximately $4.0 million during the measurement period.

Note 6 - Revenue - Disaggregati

Note 6 - Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Revenue	$ 17,493	$ 2,876	$ 37,756	$ 11,710
E-Commerce Revenue [Member]
Revenue	17,493		10,977	11,710
Healthcare Operations [Member]
Revenue		2,876	26,779	0
Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue	11,324	0	21,412	0
Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member] | E-Commerce Revenue [Member]
Revenue	11,324		0	0
Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member] | Healthcare Operations [Member]
Revenue		0	21,412	0
E-Commerce [Member]
Revenue			10,977	11,710
E-Commerce [Member] | E-Commerce Revenue [Member]
Revenue	2,865		10,977	11,710
E-Commerce [Member] | Healthcare Operations [Member]
Revenue		2,876	0	0
Pharmacy Prescription, Other Revenue and E-Commerce [Member]
Revenue			32,389	11,710
Pharmacy Prescription, Other Revenue and E-Commerce [Member] | E-Commerce Revenue [Member]
Revenue	14,189		10,977	11,710
Pharmacy Prescription, Other Revenue and E-Commerce [Member] | Healthcare Operations [Member]
Revenue		2,876	21,412	0
Pharmacy 340B Contract [Member]
Revenue	3,304	0	5,367	0
Pharmacy 340B Contract [Member] | E-Commerce Revenue [Member]
Revenue	$ 3,304		0	0
Pharmacy 340B Contract [Member] | Healthcare Operations [Member]
Revenue		$ 0	$ 5,367	$ 0

Note 7 - Earnings (Loss) Per _3

Note 7 - Earnings (Loss) Per Share - Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Net loss attributable to NextPlat Corp common shareholders	$ (1,481)	$ (1,187)	$ (3,778)	$ (9,161)
Basic weighted average common shares outstanding (in shares)	18,725	14,415	17,494	9,592
Potentially dilutive common shares (in shares)	0	0	0	0
Diluted weighted average common shares outstanding (in shares)	18,725	14,415	17,494	9,592
Weighted average loss per common share - basic and diluted (in dollars per share)	$ (0.08)	$ (0.08)	$ (0.22)	$ (0.96)
Diluted weighted average earnings (loss) per common share (in dollars per share)			$ (0.22)	$ (0.96)
Antidilutive securities (in shares)	105	100	811	1,668
Share-Based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	105	100	136	265
Warrant [Member]
Antidilutive securities (in shares)			675	1,403

Note 8 - Accounts Receivable (D

Note 8 - Accounts Receivable (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Accounts Receivable, Credit Loss Expense (Reversal)	$ 2,000	$ 0	$ 47,000	$ 0

Note 8 - Accounts Receivable -

Note 8 - Accounts Receivable - Summary of Accounts Receivable (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Jan. 01, 2023	Dec. 31, 2022
Gross accounts receivable – trade	$ 13,202	$ 9,195			$ 384
Less: allowance for doubtful accounts	(274)	(272)			0
Accounts receivable – trade, net	$ 12,928	$ 8,923	$ 1,000	$ 400	$ 384

Note 9 - Accounts Receivable _3

Note 9 - Accounts Receivable - Other, net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Accounts Receivables, Other	$ 1,846	$ 0
Performance Bonuses [Member]
Accounts Receivables, Other	1,602	0
Customers [Member]
Accounts Receivables, Other	192	0
Other [Member]
Accounts Receivables, Other	$ 52	$ 0

Note 10 - Inventory - Summary o

Note 10 - Inventory - Summary of Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Finished goods	$ 5,670	$ 5,195	$ 1,287
Less reserve for obsolete inventory	(60)	(60)	0
Total	$ 5,610	$ 5,135	$ 1,287

Note 11 - VAT Receivable (Detai

Note 11 - VAT Receivable (Details Textual) - USD ($)	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Value Added Tax Receivable, Current	$ 357,000	$ 342,000	$ 433,000

Note 12 - Prepaid Expenses (Det

Note 12 - Prepaid Expenses (Details Textual) - USD ($)	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Prepaid Expense, Current	$ 404,000	$ 640,000	$ 46,000
Prepaid Expense, Noncurrent	$ 61,000	$ 61,000	$ 49,000

Note 13 - Property and Equipm_3

Note 13 - Property and Equipment, Net (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Depreciation	$ 203,000	$ 155,000	$ 758,000	$ 465,000

Note 13 - Property and Equipm_4

Note 13 - Property and Equipment, Net - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Property and equipment gross	$ 6,546	$ 6,492	$ 3,111
Less: accumulated depreciation	(2,700)	(2,503)	(1,865)
Property and equipment, net	3,846	3,989	1,246
Building [Member]
Property and equipment gross	2,116	2,116	0
Vehicles [Member]
Property and equipment gross	585	595	0
Furniture and Fixtures [Member]
Property and equipment gross	543	527	128
Land [Member]
Property and equipment gross	184	184	0
Leasehold Improvements [Member]
Property and equipment gross	167	124	48
Computer Equipment [Member]
Property and equipment gross	117	117	72
Rental Equipment [Member]
Property and equipment gross	63	60	38
Appliques [Member]
Property and equipment gross	2,160	2,160	2,160
Website Development [Member]
Property and equipment gross	611	587	665
Construction in Progress [Member]
Property and equipment gross	$ 0	$ 22	$ 0

Note 14 - Goodwill and Intang_3

Note 14 - Goodwill and Intangible Assets, Net (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Goodwill, Impairment Loss			$ 13,895,000	$ 0
Amortization of Intangible Assets	$ 698,000	$ 6,000	1,337,000	$ 25,000
Pharmacy Operations [Member]
Goodwill, Impairment Loss			$ 13,900,000

Note 14 - Goodwill and Intang_4

Note 14 - Goodwill and Intangible Assets, Net - Schedule of Goodwill Reportable Segments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2024	Dec. 31, 2021
Goodwill	$ 14,626	$ 0		$ 0
Accumulated impairment losses	(13,895)	0		0
Goodwill, net as of December 31, 2021	731	0	$ 731	0
Goodwill acquired	14,626	0
Impairment losses	(13,895)	0
Goodwill Impairment [Member]
Impairment losses	(13,895)
E-Commerce Operations [Member]
Goodwill	0	0		0
Accumulated impairment losses	0	0		0
Goodwill, net as of December 31, 2021	0	0		0
Goodwill acquired	0	0
Impairment losses		0
E-Commerce Operations [Member] | Goodwill Impairment [Member]
Impairment losses	0
Healthcare Operations [Member]
Goodwill	14,626	0		0
Accumulated impairment losses	(13,895)	0		0
Goodwill, net as of December 31, 2021	731	0		$ 0
Goodwill acquired	14,626	0
Impairment losses		$ 0
Healthcare Operations [Member] | Goodwill Impairment [Member]
Impairment losses	$ (13,895)

Note 14 - Goodwill and Intang_5

Note 14 - Goodwill and Intangible Assets, Net - Summary of Finite-lived Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets, Gross	$ 15,960	$ 15,960	$ 250
Finite Lived Intangible Assets, Accumulated Amortization	(2,235)	(1,537)	(200)
Finite Lived Intangible Assets, Net	13,725	14,423	50
Pharmacy Records [Member]
Finite-Lived Intangible Assets, Gross	8,130	8,130	0
Finite Lived Intangible Assets, Accumulated Amortization	(1,219)	(807)	0
Finite Lived Intangible Assets, Net	6,911	7,323	0
Trade Names [Member]
Finite-Lived Intangible Assets, Gross	4,700	4,700	0
Finite Lived Intangible Assets, Accumulated Amortization	(353)	(224)	0
Finite Lived Intangible Assets, Net	4,347	4,476	0
Computer Software, Intangible Asset [Member]
Finite-Lived Intangible Assets, Gross	2,880	2,880	0
Finite Lived Intangible Assets, Accumulated Amortization	(432)	(281)	0
Finite Lived Intangible Assets, Net	2,448	2,599	0
Customer Contracts [Member]
Finite-Lived Intangible Assets, Gross	250	250	250
Finite Lived Intangible Assets, Accumulated Amortization	(231)	(225)	(200)
Finite Lived Intangible Assets, Net	$ 19	$ 25	$ 50

Note 14 - Goodwill and Intang_6

Note 14 - Goodwill and Intangible Assets, Net - Future Amortization of Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
2024	$ 2,672	$ 2,721
2025	2,672	2,672
2026	2,672	2,672
2027	1,571	2,672
2028		1,571
Thereafter		2,115
Total	$ 13,725	$ 14,423	$ 50

Note 15 - Equity Method Inves_3

Note 15 - Equity Method Investment (Details Textual) $ / shares in Units, $ in Thousands	May 09, 2023 shares	May 05, 2023 USD ($) $ / shares shares	Dec. 29, 2022 shares	May 28, 2021	Mar. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	Jul. 01, 2023 shares	Dec. 31, 2022 $ / shares shares	Sep. 02, 2022 USD ($)	Aug. 30, 2022 USD ($) $ / shares shares
Preferred Stock, Par or Stated Value Per Share (in dollars per share)					$ 0.0001	$ 0.0001		$ 0.0001
Common Stock, Par or Stated Value Per Share (in dollars per share)					$ 0.0001	$ 0.0001		$ 0.0001
Common Stock, Shares Authorized (in shares) | shares					50,000,000	50,000,000		50,000,000
Long-Term Debt | $					$ 1,398	$ 1,523
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio				5
Progressive Care [Member]
Common Stock, Shares Authorized (in shares) | shares			100,000,000
Progressive Care [Member] | Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio			200
NextPlat Corp [Member] | Progressive Care [Member] | Debt Converted to Common Stock [Member]
Debt Conversion, Original Debt, Amount | $		$ 2,900
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 2.2
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares	570,599	570,599
NextPlat Corp [Member] | Debt Conversion Agreement [Member] | Progressive Care [Member]
Debt Instrument, Face Amount | $									$ 2,800
NextPlat Corp [Member] | Amendment [Member] | Progressive Care [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 2.2
Debt Instrument, Term (Year)		3 years
Maximum Secured Convertible Debentures Purchased According to Agreement | $		$ 10,000
Long-Term Debt | $						$ 0
Progressive Care [Member]
Investment Owned, Cost | $		$ 1,000								$ 8,300
Investment Owned, Balance, Shares (in shares) | shares		455,000					402,269			3,000
Investment Owned, Fair Value | $										$ 6,000
Unit, Number of Preferred Stock										1
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.0001
Investment Owned, Price Per Share (in dollars per share)		2.2
Progressive Care [Member] | Confidential Purchase And Release Agreement [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share)										$ 4
Progressive Care [Member] | NextPlat Corp [Member] | Debt Conversion Agreement [Member]
Debt Instrument, Face Amount | $										$ 2,800
Progressive Care [Member] | RXMD Warrants [Member]
Unit, Number of Warrants										1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)										$ 2,000
Progressive Care [Member] | PIPE Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 2.2
Warrants and Rights Outstanding, Term (Year)		3 years
Progressive Care [Member] | Conversion Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 2.2
Warrants and Rights Outstanding, Term (Year)		3 years
Progressive Care [Member] | Series B Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)										0.001
Convertible Preferred Stock, Stated Value (in dollars per share)										$ 2,000
Preferred Stock, Votes Per Share										500
Preferred Stock, Convertible, Conversion Price (in dollars per share)										$ 4

Note 15 - Equity Method Inves_4

Note 15 - Equity Method Investment - Summary of Equity Method Investment (Details) - USD ($) $ in Thousands		3 Months Ended		12 Months Ended
		Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain				$ 11,352	$ 0
Equity in net loss of affiliate		$ (220)	$ 0	(8,629)	0
Progressive Care [Member]
December 31, 2022, beginning balance		$ 0	$ 5,261	5,261
Investment in Progressive Care Inc. and Subsidiaries				1,506
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain				11,352
Portion of loss from Progressive Care, Inc. and Subsidiaries				(1,604)
Depreciation expense due to cost basis difference (1)	[1]			(49)
Interest earned from convertible note receivable				21
Interest earned from amortization of premium on convertible note receivable				199
Elimination of intercompany interest earned				(7)
Change in accounting method as of July 1, 2023				(16,679)
December 31, 2023, carrying amount				0	$ 5,261
Equity in net loss of affiliate				$ (1,440)
[1]NextPlat records depreciation expense on its estimated cost basis difference which is subject to change.

Note 16 - Accounts Payable an_3

Note 16 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expense (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Accounts payable	$ 13,978	$ 12,142	$ 1,200
Accrued wages and payroll liabilities	378	200	23
Accrued PBM fees	366	571	0
Customer deposits payable	54	76	86
Accrued legal fees		0	85
Pre-merger accrued other liabilities		0	88
Accrued other liabilities	117	187	41
Total	$ 14,893	$ 13,176	$ 1,523

Note 17 - Notes Payable (Detail

Note 17 - Notes Payable (Details Textual)		1 Months Ended			12 Months Ended
	Jul. 16, 2020 GBP (£)	Sep. 30, 2022 USD ($)	Jul. 31, 2022 USD ($)	Apr. 30, 2021 USD ($)	Dec. 31, 2018 USD ($)	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Jul. 16, 2020 USD ($)	Jul. 16, 2020 GBP (£)
Long-Term Debt						$ 1,398,000	$ 1,523,000
Collateralized Promissory Note [Member] | Progressive Care [Member]
Debt Instrument, Face Amount					$ 1,530,000
Debt Instrument, Interest Rate, Stated Percentage					4.75%
Debt Instrument, Number of Payments					119
Debt Instrument, Periodic Payment					$ 11,901
Coronavirus Loans [Member] | HSBC UK Bank PLC [Member]
Debt Instrument, Face Amount								$ 338,343	£ 250,000
Foreign Currency Exchange Rate, Translation								1.353372	1.353372
Debt Instrument, Basis Spread on Variable Rate	4%
Debt Instrument, Interest Rate, Effective Percentage								0.10%	0.10%
Debt Instrument, Term (Year)	6 years
Debt Instrument, Periodic Payment, Principal | £	£ 4,166.67
Debt Instrument, Prepayment Limit, Percentage of Balance of Debenture								10%	10%
Long-Term Debt							165,000
Coronavirus Loans [Member] | HSBC UK Bank PLC [Member] | Base Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	4%
Note Obligation for Pharmacy Equipment [Member] | Progressive Care [Member]
Debt Instrument, Face Amount				$ 30,000
Debt Instrument, Interest Rate, Stated Percentage				6.90%
Debt Instrument, Number of Payments				46
Debt Instrument, Periodic Payment				$ 331
Long-Term Debt						5,000	6,500
Amended Note Obligation to Purchase Pharmacy Equipment [Member] | Progressive Care [Member]
Long-Term Debt							6,000
Note Obligation to Purchase Pharmacy Equipment [Member] | Progressive Care [Member]
Debt Instrument, Face Amount			$ 90,000
Debt Instrument, Interest Rate, Stated Percentage			8.78%
Debt Instrument, Number of Payments			60
Debt Instrument, Periodic Payment			$ 1,859
Long-Term Debt						70,000	74,000
Note Obligation for Vehicles [Member] | Progressive Care [Member]
Debt Instrument, Face Amount		$ 25,000
Debt Instrument, Interest Rate, Stated Percentage		8.29%
Debt Instrument, Number of Payments		24
Debt Instrument, Periodic Payment		$ 1,143
Long-Term Debt						$ 7,000	$ 10,000

Note 17 - Notes Payable - Sched

Note 17 - Notes Payable - Schedule of Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Note payable	$ 1,398	$ 1,523	$ 216
Less: current portion of notes payable	(233)	(312)	(60)
Long-term portion of notes payable	1,165	1,211	156
Mortgage Note Payable Commercial Bank Collateralized [Member]
Note payable	1,118	1,140	0
Note Payable Uncollateralized [Member]
Note payable	25	25	0
Note Payable Collateralized [Member]
Note payable	229	255	216
Insurance Premium Financing [Member]
Note payable	$ 26	$ 103	$ 0

Note 17 - Notes Payable - Sch_2

Note 17 - Notes Payable - Schedule of Future Maturities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
2025	$ 215	$ 312
2026	119	215
2027	124	119
2028	753	124
2028		753
Thereafter		0
Total	$ 1,398	$ 1,523

Note 18 - Equity (Details Textu

Note 18 - Equity (Details Textual)								12 Months Ended
	Apr. 11, 2023 USD ($) $ / shares shares	Apr. 05, 2023 USD ($) $ / shares shares	Dec. 14, 2022 USD ($) $ / shares shares	Dec. 09, 2022 $ / shares shares	Jan. 05, 2022 USD ($)	Jan. 02, 2022 USD ($) $ / shares shares	May 28, 2021	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Mar. 31, 2024 $ / shares shares	Dec. 31, 2021 USD ($)
Preferred Stock, Shares Authorized (in shares) | shares								3,333,333	3,333,333	3,333,333
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares								$ 0.0001	$ 0.0001	$ 0.0001
Preferred Stock, Shares Outstanding (in shares) | shares								0		0
Common Stock, Shares Authorized (in shares) | shares								50,000,000	50,000,000	50,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares								$ 0.0001	$ 0.0001	$ 0.0001
Common Stock, Shares, Issued (in shares) | shares								18,724,596	14,402,025	18,724,596
Payments of Stock Issuance Costs | $								$ 0	$ 754,000
Proceeds from Issuance of Common Stock | $								6,000,000	13,832,000
December 2022 Private Placement [Member]
Number of Warrants Per Unit (in shares) | shares			1	1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares			1	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 1.75	$ 1.75
Warrants and Rights Outstanding, Term (Year)			3 years	3 years
December 2022 Private Placement [Member] | Dawson James [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 1.75
Warrants and Rights Outstanding, Term (Year)				3 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares				549,051
April 2023 Private Placement [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares	$ 0.0001	$ 0.0001
Stock Issued During Period, Shares, New Issues (in shares) | shares	3,428,571	3,428,571
Shares Issued, Price Per Share (in dollars per share) | $ / shares	$ 1.75	$ 1.75
Proceeds from Issuance of Private Placement | $	$ 6,000,000
Stock Issued During Period, Value, New Issues | $								$ 6,000,000
Proceeds from Issuance of Common Stock | $		$ 6,000,000
December 2022 Private Placement [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares			$ 0.0001
Shares Issued, Price Per Share (in dollars per share) | $ / shares			$ 1.75	$ 1.75
Equity Offering, Units Issued (in shares) | shares			4,575,429	4,575,429
Number of Shares Per Unit Issued (in shares) | shares			1	1
Proceeds From Equity Offering | $			$ 8,000,000
Stock Issued During Period, Value, New Issues | $									7,472,000
December 2022 Private Placement [Member] | Dawson James [Member]
Placement Agent Fee, Percent				6%
December 2022 Private Placement [Member] | Placement Agency Agreement [Member]
Placement Agent Fee, Percent				3%
January 2022 Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares						2,229,950
Shares Issued, Price Per Share (in dollars per share) | $ / shares						$ 3.24
Stock Issued During Period, Value, New Issues | $					$ 7,200,000	$ 7,225,038			$ 7,005,000
Payments of Stock Issuance Costs | $						220,000
Proceeds from Issuance of Common Stock | $						$ 7,000,000
Stock Subscription Payable, Current | $											$ 1,400,000
Percentage of Funds Raised on Offering						73%
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio							5

Note 19 - Warrants (Details Tex

Note 19 - Warrants (Details Textual) - $ / shares		12 Months Ended
	Dec. 09, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 14, 2022	Dec. 31, 2021
Class of Warrant or Right, Outstanding (in shares)		7,569,572	7,654,572		2,530,092
The Underwriter Warrants [Member]
Class of Warrant or Right, Outstanding (in shares)		144,000	144,000
The Underwriter Warrants [Member] | Maxim Group LLC [Member]
Class of Warrant or Right, Issued During Period (in shares)		144,000
Warrants and Rights Outstanding, Term (Year)		5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 5.5
Public Offering Price Percentage		110%
December Offering Warrants [Member]
Class of Warrant or Right, Issued During Period (in shares)	4,575,429
Warrants and Rights Outstanding, Term (Year)	3 years
Class of Warrant or Right, Issued During Period, Price Per Warrant (in dollars per share)	$ 1.75
December 2022 Private Placement [Member]
Warrants and Rights Outstanding, Term (Year)	3 years			3 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 1.75			$ 1.75
December 2022 Private Placement [Member] | Dawson James [Member]
Warrants and Rights Outstanding, Term (Year)	3 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 1.75
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	549,051
Placement Agent Warrants [Member]
Class of Warrant or Right, Outstanding (in shares)		549,051	549,051
Stock Based Compensation Warrants [Member]
Class of Warrant or Right, Issued During Period (in shares)		20,000	0
Class of Warrant or Right, Issued During Period, Price Per Warrant (in dollars per share)		$ 1.6
Share Price (in dollars per share)		$ 1.6
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate		507%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year)		3 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		4.47%
Registered Warrants [Member]
Class of Warrant or Right, Outstanding (in shares)		2,386,092	2,386,092

Note 19 - Warrants - Schedule o

Note 19 - Warrants - Schedule of Outstanding Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Balance, number of warrants (in shares)	7,654,572	2,530,092
Granted, number of warrants (in shares)	20,000	5,124,480
Granted, weighted average exercise price (in dollars per share)		$ 1.75
Granted, weighted average remaining term (Year)		3 years 18 days
Exercised, number of warrants (in shares)	(105,000)	0
Cancelled, number of warrants (in shares)		0
Exercised (in dollars per share)	$ 1.75
Balance, number of warrants (in shares)	7,569,572	7,654,572
Weighted Average [Member]
Balance, weighted average exercise price (in dollars per share)	$ 2.83	$ 5
Balance, weighted average remaining term (Year)	3 years 1 month 24 days	4 years 5 months 1 day
Granted, weighted average exercise price (in dollars per share)	$ 1.65
Granted, weighted average remaining term (Year)	3 years
Balance, weighted average exercise price (in dollars per share)	$ 2.85	$ 2.83
Balance, weighted average remaining term (Year)	2 years 1 month 24 days	3 years 1 month 24 days

Note 20 - Stock-based Compens_3

Note 20 - Stock-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement, Expense	$ 0.6	$ 0.2	$ 5.4	$ 3
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount			$ 1.1	$ 2.3
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)			1 year 6 months 29 days	1 year 4 months 24 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value			$ 4.4	$ 6.1
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)			395,000	190,000
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount			$ 1.4	$ 1.4
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)			2 years 10 months 17 days	3 years 8 months 23 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum				2.66%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum				4.39%
Minimum [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price (in dollars per share)			$ 1.98	$ 1.1
Share Price (in dollars per share)			$ 1.98	$ 1.71
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate			502%	75%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year)			2 years	5 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum			3.31%
Maximum [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price (in dollars per share)			$ 2.64	$ 1.92
Share Price (in dollars per share)			$ 2.64	$ 2.2
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate			504%	100%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year)			5 years	10 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum			3.71%

Note 20 - Stock-based Compens_4

Note 20 - Stock-based Compensation - Restricted Stock (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Outstanding (in shares)	460,000	867,500
Outstanding, weighted average grant date fair value (in dollars per share)	$ 4.33	$ 4.32	$ 4.2
Granted (in shares)	559,000	136,000
Granted, weighted average grant date fair value (in dollars per share)	$ 1.65	$ 2.72
Vested (in shares)	(794,000)	(543,500)
Vested, weighted average grant date fair value (in dollars per share)	$ 2.42	$ 3.78
Forfeited (in shares)	0	0
Forfeited, weighted average grant date fair value (in dollars per share)	$ 0	$ 0
Outstanding (in shares)	225,000	460,000

Note 20 - Stock-based Compens_5

Note 20 - Stock-based Compensation - Stock Options (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Balance (in shares)	2,119,701	2,179,892
Balance, weighted average exercise price (in dollars per share)	$ 4.16	$ 4.54
Balance at January 1, 2022 (in dollars per share)	$ 2.25	$ 2.44
Balance at January 1, 2022 (Year)	4 years 3 months 3 days	5 years 2 months 23 days	5 years 11 months 4 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	395,000	190,000
Granted, weighted average exercise price (in dollars per share)	$ 2.37	$ 1.92
Granted (in dollars per share)	$ 2.37	$ 1.43
Granted (Year)	4 years 21 days	6 years 10 months 6 days
Exercised (in shares)	0	0
Exercised, weighted average exercise price (in dollars per share)	$ 0	$ 0
Cancelled (in shares)	(266,284)	(250,000)
Cancelled, weighted average exercise price (in dollars per share)	$ 5.88	$ 5.35
Expired (in shares)	(3,084)	(191)
Expired, weighted average exercise price (in dollars per share)	$ 0	$ 0
Balance (in shares)	2,245,333	2,119,701	2,179,892
Balance, weighted average exercise price (in dollars per share)	$ 3.63	$ 4.16	$ 4.54
Balance outstanding at December 31, 2022 (in dollars per share)	2.88	$ 2.25	$ 2.44
Options exercisable (in shares)		1,259,701
Options exercisable at December 31, 2022 (in dollars per share)	3.31	$ 3.51
Options exercisable at December 31, 2022 (in dollars per share)	$ 2.86	$ 1.68
Options exercisable at December 31, 2022 (Year)	4 years 7 months 17 days	6 years 3 months
Exercised (in shares)	0	0
Options exercisable at December 31, 2023 (in shares)	1,771,997

Note 21 - Income Taxes (Details

Note 21 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating Loss Carryforwards	$ 17,800,000	$ 14,800,000
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	2,200,000
Operating Loss Carryforwards, Subject to Expiration	2,900,000
Operating Loss Carryforwards, Not Subject to Expiration	14,900,000
Unrecognized Tax Benefits	0	0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense	$ 0	0
Domestic Tax Jurisdiction [Member]
Open Tax Year	2020 2021 2022 2023
Foreign Tax Jurisdiction [Member]
Open Tax Year	2019 2020 2021 2022 2023
Progressive Care [Member]
Deferred Taxes, Business Combination, Valuation Allowance, Available to Reduce Goodwill	$ 4,000,000
Progressive Care [Member]
Estimated Tax Liability	0
Operating Loss Carryforwards	14,100,000	14,400,000
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	1,700,000
Operating Loss Carryforwards, Subject to Expiration	2,800,000
Operating Loss Carryforwards, Not Subject to Expiration	11,000,000
G T C [Member]
Estimated Tax Liability	$ 60,000	$ 87,000

Note 21 - Income Taxes - Summar

Note 21 - Income Taxes - Summary of Components of Earnings Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Domestic	$ (12,672)	$ (9,436)
Foreign	293	362
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$ (12,379)	$ (9,074)

Note 21 - Income Taxes - Summ_2

Note 21 - Income Taxes - Summary of Components of Income Tax Provision (Benefit) (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Federal			$ (11)	$ 0
State			0	0
Foreign			39	87
Total current			28	87
Federal			0	0
State			0	0
Foreign			0	0
Total deferred			0	0
Income tax (benefit) provision	$ 27	$ 0	$ 28	$ 87

Note 21 - Income Taxes - Summ_3

Note 21 - Income Taxes - Summary of Effective Tax Rate and Statutory Federal Rate (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Federal income tax (benefit) provision at statutory rate			$ (2,655)	$ (1,984)
State tax expense net of federal tax benefit			0	(411)
State tax expense federal impact			0	45
Provision true-up adjustments			(488)	0
State rate change adjustment			0	(214)
Foreign taxes at rate different than US Taxes			60	87
Net operating loss deduction			(310)	0
Permanent differences			(22)	0
Other true-ups			99	106
Change in valuation allowance			3,344	2,458
Income tax (benefit) provision	$ 27	$ 0	$ 28	$ 87

Note 21 - Income Taxes - Schedu

Note 21 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Net operating loss carryforward	$ 8,016	$ 3,658
Property plant and equipment and intangibles asset	327	130
Equity method investment loss	806	441
Other tax carry-overs	613	0
Reserves and allowances	85	0
Stock-based compensation	3,861	1,949
Total deferred tax assets	13,708	6,178
Book basis of intangible assets in excess of tax basis	3,650	0
Total deferred tax liabilities	3,650	0
Net deferred tax asset before valuation allowance	10,058	6,178
Less: valuation allowance	(10,058)	(6,178)
Net deferred tax asset	$ 0	$ 0

Note 22 - Leases (Details Textu

Note 22 - Leases (Details Textual)

1 Months Ended

3 Months Ended

12 Months Ended

Dec. 02, 2021 USD ($) ft²

May 31, 2018 USD ($)

Jun. 30, 2023 USD ($)

Sep. 30, 2021 USD ($)

Dec. 31, 2020 USD ($)

Aug. 31, 2020 USD ($)

May 31, 2018 USD ($)

Mar. 31, 2024 USD ($) ft²

Mar. 31, 2024 GBP (£) ft²

Mar. 31, 2023 USD ($)

Dec. 31, 2023 USD ($) ft²

Dec. 31, 2023 GBP (£)

Dec. 31, 2022 USD ($)

Finance Lease, Liability

$ 23,000

$ 0

Annual Rent

$ 186,000

Operating Lease, Impairment Loss

$ 132,000

$ 0

$ 0

$ 0

Office Space in Florida [Member]

Lessee, Operating Lease, Term of Contract (Month)

62 months

Area of Real Estate Property (Square Foot) | ft²

4,141

Annual Rent

$ 186,345

Annual Lease Increase, Percentage

3%

Facilities in Poole, England [Member]

Area of Real Estate Property (Square Foot) | ft²

2,660

2,660

2,660

Annual Rent

$ 37,107

£ 30,000

$ 37,100

£ 30,000

Foreign Currency Exchange Rate, Translation

1.24

1.24

1.24

Lessee, Operating Lease, Renewal Term (Month)

12 months

12 months

12 months

Aircraft Lease [Member]

Lessee, Operating Lease, Term of Contract (Month)

36 months

Annual Lease Increase, Percentage

3%

Operating Lease, Monthly Payment

$ 200,650

Progressive Care [Member] | Finance Obligation for Pharmacy Equipment [Member]

Finance Lease, Liability

$ 115,000

$ 115,000

Finance Lease, Monthly Payment

$ 1,678

$ 1,700

Lessee, Finance Lease, Term of Contract (Month)

84 months

84 months

Lessee, Finance Lease, Interest Rate

6%

6%

Progressive Care [Member] | Computer Servers [Member]

Finance Lease, Liability

$ 51,000

Finance Lease, Monthly Payment

$ 1,400

Lessee, Finance Lease, Term of Contract (Month)

36 months

Progressive Care [Member] | Orlando Pharmacy [Member]

Lessee, Operating Lease, Term of Contract (Month)

66 months

Operating Lease, Monthly Payment

$ 4,310

Progressive Care [Member] | North Miami Beach Pharmacy [Member]

Lessee, Operating Lease, Term of Contract (Month)

60 months

Operating Lease, Monthly Payment

$ 5,237

Note 22 - Leases - Schedule of

Note 22 - Leases - Schedule of Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Fixed rent expense			$ 427	$ 101
Variable rent expense			111	0
Amortization of right-of-use assets - finance leases	$ 5	$ 0	15	0
Finance Lease, Interest Expense			1	0
Total Lease Costs			$ 554	$ 101

Note 22 - Leases - Schedule o_2

Note 22 - Leases - Schedule of Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Operating cash flows from operating leases			$ 464	$ 101
Financing cash flows from finance leases	$ 5	$ 0	15	0
Total cash paid for lease liabilities			$ 479	$ 101

Note 22 - Leases - Schedule o_3

Note 22 - Leases - Schedule of Balance Sheet Information Related to Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Operating lease right-of-use assets, net	$ 1,303	$ 1,566	$ 855
Current portion, operating lease liability	532	532	209
Long-term portion, operating lease liability	853	929	650
Operating Lease, Liability		$ 1,461	$ 859
Weighted average remaining lease term (years), operating lease (Year)		2 years 11 months 15 days	5 years 6 months
Weighted average discount rate, operating lease		4.65%	3.75%
Finance lease right-of-use assets, net	18	$ 22	$ 0
Current portion, Finance Lease Liability	20	18	0
Long-term portion of lease liabilities, finance lease	$ 0	5	0
Finance Lease, Liability		$ 23	$ 0
Weighted average remaining lease term (years), Finance Leases (Year)		1 year 3 months
Weighted average discount rate, Finance Leases		6%	0%
Operating Lease Right-of-use Assets, Net [Member]
Operating lease right-of-use assets, net		$ 1,566	$ 855

Note 22 - Leases - Schedule o_4

Note 22 - Leases - Schedule of Future Minimum Lease Payments (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
2024, finance lease		$ 19
2024, operating lease		582
2024, total leases		601
2025, finance lease		5
2025, operating lease		580
2025, total leases		585
2026, finance lease		0
2026, operating lease		262
2026, total leases		262
2027, finance lease		0
2027, operating lease		121
2027, total leases		121
Total lease payments to be paid, finance lease		24
Total lease payments to be paid, operating lease		1,545
Total lease payments to be paid, total leases		1,569
Less: future interest expense		(1)
Less: future interest expense		(84)
Less: future interest expense, total leases		(85)
Lease liabilities, finance lease		23	$ 0
Lease liabilities, operating lease		1,461	859
Lease liabilities, total leases		1,484
Less: current maturities, finance lease	$ (20)	(18)	0
Less: current maturities, operating lease	(532)	(532)	(209)
Less: current maturities, total leases		(550)
Long-term portion of lease liabilities, finance lease	0	5	0
Long-term portion of lease liabilities, operating lease	$ 853	929	$ 650
Long-term portion of lease liabilities, total leases		$ 934

Note 23 - Reportable Segments_2

Note 23 - Reportable Segments (Details Textual)	3 Months Ended		12 Months Ended
	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Number of Reportable Segments	2		2
Payments to Acquire Property, Plant, and Equipment	$ 64,000	$ 69,000	$ 647,000	$ 716,000
E-Commerce Operations [Member]
Payments to Acquire Property, Plant, and Equipment			109,000
Healthcare Operations [Member]
Payments to Acquire Property, Plant, and Equipment			$ 538,000

Note 23 - Reportable Segments -

Note 23 - Reportable Segments - Schedule of Reportable Segments (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Revenue	$ 17,493	$ 2,876	$ 37,756	$ 11,710
Cost of revenue	12,683	2,255	26,445	9,221
Selling, general and administrative	2,005	788	9,910	5,085
Salaries, wages and payroll taxes	2,624	588	6,643	2,565
Goodwill impairment			13,895	0
Professional fees	985	321	1,981	1,552
Depreciation and amortization	906	162	2,110	490
Total expenses	19,335	4,114	60,984	18,913
Loss before other (income) expense	(1,842)	(1,238)	(23,228)	(7,203)
Segment Expense [Member]
Selling, general and administrative	2,005	788	9,910
Professional fees	985	321	1,981
Depreciation and amortization	906	162	2,110
Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue	11,324	0	21,412	0
E-Commerce Revenue [Member]
Revenue	2,865	2,876	10,977	11,710
Pharmacy 340B Contract [Member]
Revenue	3,304	0	5,367	0
Consolidation, Eliminations [Member]
Revenue	0	0	0	0
Cost of revenue	0	0	0	0
Selling, general and administrative				0
Salaries, wages and payroll taxes	0	0	0	0
Goodwill impairment			0
Professional fees				0
Depreciation and amortization				0
Total expenses	(60)	0	(120)	0
Loss before other (income) expense	60	0	120	0
Consolidation, Eliminations [Member] | Segment Expense [Member]
Selling, general and administrative	(60)	0	0
Professional fees	0	0	(120)
Depreciation and amortization	0	0	0
Consolidation, Eliminations [Member] | Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue	0	0	0	0
Consolidation, Eliminations [Member] | E-Commerce Revenue [Member]
Revenue	0	0	0	0
Consolidation, Eliminations [Member] | Pharmacy 340B Contract [Member]
Revenue	0	0	0	0
E-Commerce [Member] | Operating Segments [Member]
Revenue	2,865	2,876	10,977	11,710
Cost of revenue	2,060	2,255	8,122	9,221
Selling, general and administrative				5,085
Salaries, wages and payroll taxes	508	588	2,670	2,565
Goodwill impairment			0
Professional fees				1,552
Depreciation and amortization				490
Total expenses	4,371	4,114	19,667	18,913
Loss before other (income) expense	(1,506)	(1,238)	(8,690)	(7,203)
E-Commerce [Member] | Operating Segments [Member] | Segment Expense [Member]
Selling, general and administrative	1,166	788	6,633
Professional fees	507	321	1,595
Depreciation and amortization	130	162	647
E-Commerce [Member] | Operating Segments [Member] | Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue	0	0	0	0
E-Commerce [Member] | Operating Segments [Member] | E-Commerce Revenue [Member]
Revenue	2,865	2,876	10,977	11,710
E-Commerce [Member] | Operating Segments [Member] | Pharmacy 340B Contract [Member]
Revenue	0	0	0	0
Healthcare Operations [Member]
Revenue		2,876	26,779	0
Healthcare Operations [Member] | Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue		0	21,412	0
Healthcare Operations [Member] | Pharmacy 340B Contract [Member]
Revenue		0	5,367	0
Healthcare Operations [Member] | Operating Segments [Member]
Revenue	14,628	0	26,779	0
Cost of revenue	10,623	0	18,323	0
Selling, general and administrative				0
Salaries, wages and payroll taxes	2,116	0	3,973	0
Goodwill impairment			13,895
Professional fees				0
Depreciation and amortization				0
Total expenses	15,024	0	41,437	0
Loss before other (income) expense	(396)	0	(14,658)	0
Healthcare Operations [Member] | Operating Segments [Member] | Segment Expense [Member]
Selling, general and administrative	899	0	3,277
Professional fees	478	0	506
Depreciation and amortization	776	0	1,463
Healthcare Operations [Member] | Operating Segments [Member] | Pharmacy Prescription and Other Revenue, Net of PBM Fees [Member]
Revenue	11,324	0	21,412	0
Healthcare Operations [Member] | Operating Segments [Member] | E-Commerce Revenue [Member]
Revenue	0	0	0	0
Healthcare Operations [Member] | Operating Segments [Member] | Pharmacy 340B Contract [Member]
Revenue	$ 3,304	$ 0	$ 5,367	$ 0

Note 23 - Reportable Segments_3

Note 23 - Reportable Segments - Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Total Assets	$ 65,061	$ 64,469	$ 28,644
Operating Segments [Member] | E-Commerce [Member]
Total Assets	40,342	40,764	28,644
Operating Segments [Member] | Healthcare Operations [Member]
Total Assets	41,398	40,384	0
Consolidation, Eliminations [Member]
Total Assets	$ (16,679)	$ (16,679)	$ 0

Note 25 - Related Party Trans_3

Note 25 - Related Party Transactions (Details Textual)															1 Months Ended	3 Months Ended		6 Months Ended	12 Months Ended
	Jul. 07, 2023 USD ($)	Jul. 01, 2023 USD ($) shares	May 09, 2023 shares	May 05, 2023 USD ($) $ / shares shares	May 01, 2023 USD ($)	Feb. 01, 2023 USD ($)	Dec. 30, 2022	Dec. 14, 2022 USD ($) $ / shares shares	Dec. 09, 2022 $ / shares shares	Sep. 02, 2022 USD ($)	Jul. 12, 2022 USD ($)	Jan. 20, 2022 USD ($) $ / shares shares	Jan. 05, 2022 USD ($)	Jan. 02, 2022 USD ($) $ / shares shares	Apr. 30, 2023 USD ($)	Mar. 31, 2024 USD ($) $ / shares	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($) $ / shares	Dec. 31, 2023 USD ($) $ / shares	Dec. 31, 2022 USD ($) $ / shares	Aug. 30, 2022 USD ($) shares
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares																$ 0.0001		$ 0.0001	$ 0.0001	$ 0.0001
Proceeds from Warrant Exercises																			$ 184,000	$ 0
December 2022 Private Placement [Member]
Number of Warrants Per Unit (in shares) | shares								1	1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares								1	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares								$ 1.75	$ 1.75
Warrants and Rights Outstanding, Term (Year)								3 years	3 years
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio							200
Predecessor Company [Member]
Investment Owned, Balance, Shares (in shares) | shares																					105,000
Progressive Care [Member]
Investment Owned, Balance, Shares (in shares) | shares		402,269		455,000																	3,000
Investment Owned, Price Per Share (in dollars per share) | $ / shares				$ 2.2
Investment Owned, Cost				$ 1,000,000																	$ 8,300,000
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares				$ 0.0001
Proceeds from Warrant Exercises		$ 506,000
Investment Owned, Balance, Shares From Warrants Exercised (in shares) | shares		230,000
Iliad [Member] | Secured Convertible Promissory Note [Member]
Payments to Acquire Notes Receivable										$ 1,000,000
Debt Conversion Agreement [Member] | Predecessor Company [Member]
Long-Term Debt, Gross																					$ 2,800,000
January 2022 Private Placement [Member]
Stock Issued During Period, Value, New Issues													$ 7,200,000	$ 7,225,038						7,005,000
Percentage of Funds Raised on Offering														73%
Stock Issued During Period, Shares, New Issues (in shares) | shares														2,229,950
Shares Issued, Price Per Share (in dollars per share) | $ / shares														$ 3.24
December 2022 Private Placement [Member]
Stock Issued During Period, Value, New Issues																				7,472,000
Shares Issued, Price Per Share (in dollars per share) | $ / shares								$ 1.75	$ 1.75
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares								$ 0.0001
Equity Offering, Units Issued (in shares) | shares								4,575,429	4,575,429
Number of Shares Per Unit Issued (in shares) | shares								1	1
Proceeds From Equity Offering								$ 8,000,000
David Phipps [Member]
Accounts Payable																		$ 8,000	8,000	720
Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold																			78,000	56,000
Lauren Sturges Fernandez [Member]
Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold																	$ 10,995			$ 10,995
Annual Salary											$ 95,000				$ 125,000
Mr Barreto [Member]
Stock Issued During Period, Value, New Issues												$ 1,200,000
Percentage of Funds Raised on Offering												17%
Stock Issued During Period, Shares, New Issues (in shares) | shares												370,701
Shares Issued, Price Per Share (in dollars per share) | $ / shares												$ 3.24
CEO and Board Member [Member] | Iliad [Member] | Secured Convertible Promissory Note [Member]
Payments to Acquire Notes Receivable, Including Contributions by Related Parties										2,300,000
Chief Operating Officer [Member] | Iliad [Member] | Secured Convertible Promissory Note [Member]
Payments to Acquire Notes Receivable										$ 400,000
NextPlat Corp [Member] | Progressive Care [Member] | Debt Converted to Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares			570,599	570,599
NextPlat Corp [Member] | Predecessor Company [Member]
Investment Owned, Balance, Shares (in shares) | shares																					45,653
Chief Executive Officer [Member] | Progressive Care [Member] | Inducement Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares			190,000
Chief Executive Officer [Member] | Progressive Care [Member] | Debt Converted to Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares			228,240
Chief Executive Officer [Member] | Predecessor Company [Member]
Investment Owned, Balance, Shares (in shares) | shares																					18,261
Chief Executive Officer [Member] | Progressive Care [Member]
Investment Owned, Balance, Shares From Warrants Exercised (in shares) | shares		211,470
Board Member [Member] | Progressive Care [Member] | Inducement Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares			30,000
Board Member [Member] | Progressive Care [Member] | Debt Converted to Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares			228,240
Board Member [Member] | Predecessor Company [Member]
Investment Owned, Balance, Shares (in shares) | shares																					18,261
Board Member [Member] | Progressive Care [Member]
Investment Owned, Balance, Shares From Warrants Exercised (in shares) | shares		130,571
Progressive Care [Member]
Management and Administrative Service Revenue, Per Month					$ 20,000	$ 25,000
Proceeds From Management and Administrative Service																$ 60,000	$ 50,000		235,000
Management Fees Eliminated																		120,000
Fernandez And Barreto [Member] | Progressive Care [Member]
Related Party, Ownership Percentage		53%
Related Party [Member]
Notes Receivable, Principal	$ 250,000
Notes Receivable, Interest Rate	7%
Financing Receivable, before Allowance for Credit Loss																$ 260,000		$ 256,000	$ 256,000
Related Party [Member] | December 2022 Private Placement [Member]
Percentage of Funds Raised on Offering								48%
Proceeds From Equity Offering								$ 8,000,000

Note 25 - Related Party Trans_4

Note 25 - Related Party Transactions - Schedule of Related Party Transaction Investments (Details) - USD ($)			12 Months Ended
	Jan. 05, 2022	Jan. 02, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Class of Warrant or Right, Outstanding (in shares)			7,569,572	7,654,572	2,530,092
January 2022 Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)		2,229,950
Stock issued, value	$ 7,200,000	$ 7,225,038		$ 7,005,000
Stock Issued During Period, Value, New Issues	$ 7,200,000	$ 7,225,038		7,005,000
December 2022 Private Placement [Member]
Stock issued, value				7,472,000
Stock Issued During Period, Value, New Issues				$ 7,472,000
Executive Chairman and Chief Executive Officer [Member] | December 2022 Private Placement [Member]
Class of Warrant or Right, Outstanding (in shares)			1,085,714
Executive Chairman and Chief Executive Officer [Member] | January 2022 Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)			679,013
Stock issued, value			$ 2,200,002
Stock Issued During Period, Value, New Issues			$ 2,200,002
Executive Chairman and Chief Executive Officer [Member] | December 2022 Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)			1,085,714
Stock issued, value			$ 1,900,000
Stock Issued During Period, Value, New Issues			$ 1,900,000
Director and President of Orbsat Chief Executive Officer of Global Operations [Member] | January 2022 Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)			46,297
Stock issued, value			$ 150,002
Stock Issued During Period, Value, New Issues			$ 150,002
Director and President of Next Plat Chief Executive Officer of Global Operations [Member] | December 2022 Private Placement [Member]
Class of Warrant or Right, Outstanding (in shares)			28,500
Director and President of Next Plat Chief Executive Officer of Global Operations [Member] | December 2022 Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)			28,500
Stock issued, value			$ 49,875
Stock Issued During Period, Value, New Issues			$ 49,875
Vice Chairman and Chief Business Development Strategist [Member] | January 2022 Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)			46,297
Stock issued, value			$ 150,002
Stock Issued During Period, Value, New Issues			$ 150,002
Director [Member] | December 2022 Private Placement [Member]
Class of Warrant or Right, Outstanding (in shares)			1,085,714
Director [Member] | January 2022 Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)			15,433
Stock issued, value			$ 50,003
Stock Issued During Period, Value, New Issues			$ 50,003
Director [Member] | December 2022 Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)			1,085,714
Stock issued, value			$ 1,900,000
Stock Issued During Period, Value, New Issues			$ 1,900,000
Senior Vice President Mergers Acquisitions and Special Projects [Member] | January 2022 Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)			15,433
Stock issued, value			$ 50,003
Stock Issued During Period, Value, New Issues			$ 50,003

Note 26 - Concentrations (Detai

Note 26 - Concentrations (Details Textual)	3 Months Ended		6 Months Ended	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Amazon [Member]
Concentration Risk, Percentage	39.90%	57.20%		51.60%	54.30%
Purchases [Member] | Supplier Concentration Risk [Member]
Number of Major Vendors	1		1
Purchases [Member] | Supplier Concentration Risk [Member] | One Vendor [Member]
Concentration Risk, Percentage	98%		99%

Note 26 - Concentrations - Sche

Note 26 - Concentrations - Schedules of Concentration of Risk (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Revenue	$ 17,493	$ 2,876		$ 37,756	$ 11,710
Supplier Concentration Risk [Member] | Purchases [Member] | Garmin [Member]
Purchases	$ 301	$ 594		$ 1,921	$ 1,821
Percentage	14.30%	20.90%		22.40%	20.90%
Concentration Risk, Percentage	14.30%	20.90%		22.40%	20.90%
Supplier Concentration Risk [Member] | Purchases [Member] | Globalstar Europe [Member]
Purchases	$ 213	$ 0		$ 958	$ 635
Percentage	10.20%	0%		11.20%	7.30%
Concentration Risk, Percentage	10.20%	0%		11.20%	7.30%
Supplier Concentration Risk [Member] | Purchases [Member] | Network Innovations [Member]
Purchases				$ 935	$ 980
Percentage				10.70%	11.20%
Concentration Risk, Percentage				10.70%	11.20%
Supplier Concentration Risk [Member] | Purchases [Member] | Iridium Satellite [Member]
Purchases	$ 270	$ 0		$ 913	$ 0
Percentage	27.20%	0%		10.90%	0%
Concentration Risk, Percentage	27.20%	0%		10.90%	0%
Supplier Concentration Risk [Member] | Purchases [Member] | Satcom Global [Member]
Purchases				$ 761	$ 744
Percentage				8.90%	8.50%
Concentration Risk, Percentage				8.90%	8.50%
Customer Concentration Risk [Member] | Reimbursements [Member] | PBM A [Member]
Percentage	33%		31%
Concentration Risk, Percentage	33%		31%
Customer Concentration Risk [Member] | Reimbursements [Member] | PBM B [Member]
Percentage	21%		29%
Concentration Risk, Percentage	21%		29%
Customer Concentration Risk [Member] | Reimbursements [Member] | PBM C [Member]
Percentage	16%		14%
Concentration Risk, Percentage	16%		14%
Geographic Concentration Risk [Member] | Revenue Benchmark [Member]
Percentage				100%	100%
Revenue				$ 10,977	$ 11,710
Concentration Risk, Percentage				100%	100%
Geographic Concentration Risk [Member] | Revenue Benchmark [Member] | Europe [Member]
Percentage	49.90%	71.70%		60.90%	73.70%
Revenue	$ 1,430	$ 2,063		$ 6,687	$ 8,617
Concentration Risk, Percentage	49.90%	71.70%		60.90%	73.70%
Geographic Concentration Risk [Member] | Revenue Benchmark [Member] | North America [Member]
Percentage	18.30%	20.40%		23.40%	18.30%
Revenue	$ 523	$ 586		$ 2,575	$ 2,152
Concentration Risk, Percentage	18.30%	20.40%		23.40%	18.30%
Geographic Concentration Risk [Member] | Revenue Benchmark [Member] | South America [Member]
Percentage	0.80%	0.30%		0.60%	0.40%
Revenue	$ 23	$ 9		$ 62	$ 45
Concentration Risk, Percentage	0.80%	0.30%		0.60%	0.40%
Geographic Concentration Risk [Member] | Revenue Benchmark [Member] | Asia Pacific [Member]
Percentage	14.40%	5.50%		13.80%	6.50%
Revenue	$ 413	$ 159		$ 1,510	$ 760
Concentration Risk, Percentage	14.40%	5.50%		13.80%	6.50%
Geographic Concentration Risk [Member] | Revenue Benchmark [Member] | Africa [Member]
Percentage	16.60%	2.10%		1.30%	1.10%
Revenue	$ 476	$ 59		$ 143	$ 136
Concentration Risk, Percentage	16.60%	2.10%		1.30%	1.10%

Note 27 - Subsequent Events (De

Note 27 - Subsequent Events (Details Textual) - USD ($)	Apr. 01, 2024	Mar. 25, 2024
Outfitter Satellite, Inc. [Member] | Subsequent Event [Member]
Business Combination, Consideration Transferred	$ 760,000	$ 760,000